WO2007006101A1 - Surface proteins of pasteurella multocida - Google Patents
Surface proteins of pasteurella multocida Download PDFInfo
- Publication number
- WO2007006101A1 WO2007006101A1 PCT/AU2006/000990 AU2006000990W WO2007006101A1 WO 2007006101 A1 WO2007006101 A1 WO 2007006101A1 AU 2006000990 W AU2006000990 W AU 2006000990W WO 2007006101 A1 WO2007006101 A1 WO 2007006101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multocida
- polypeptide
- nucleic acid
- proteins
- protein
- Prior art date
Links
- 241000606856 Pasteurella multocida Species 0.000 title claims abstract description 191
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 12
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 10
- 229940051027 pasteurella multocida Drugs 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 242
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 220
- 229960005486 vaccine Drugs 0.000 claims abstract description 38
- 230000002163 immunogen Effects 0.000 claims abstract description 24
- 230000001681 protective effect Effects 0.000 claims abstract description 21
- 230000036039 immunity Effects 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 269
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 222
- 229920001184 polypeptide Polymers 0.000 claims description 193
- 150000007523 nucleic acids Chemical class 0.000 claims description 99
- 239000012528 membrane Substances 0.000 claims description 98
- 102000039446 nucleic acids Human genes 0.000 claims description 89
- 108020004707 nucleic acids Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 81
- 108020004414 DNA Proteins 0.000 claims description 66
- 239000012634 fragment Substances 0.000 claims description 48
- 101710116435 Outer membrane protein Proteins 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 39
- 241000287828 Gallus gallus Species 0.000 claims description 39
- 235000013330 chicken meat Nutrition 0.000 claims description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 34
- 108091034117 Oligonucleotide Proteins 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 208000015181 infectious disease Diseases 0.000 claims description 32
- 241000271566 Aves Species 0.000 claims description 29
- 238000001727 in vivo Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 230000004224 protection Effects 0.000 claims description 23
- 108700026244 Open Reading Frames Proteins 0.000 claims description 22
- -1 ompH_2 Proteins 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 229910052742 iron Inorganic materials 0.000 claims description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 14
- 238000010367 cloning Methods 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 101150099542 tuf gene Proteins 0.000 claims description 8
- 101150071165 tuf1 gene Proteins 0.000 claims description 8
- 101150010742 tuf2 gene Proteins 0.000 claims description 8
- 101100419062 Caenorhabditis elegans rps-2 gene Proteins 0.000 claims description 7
- 241000282898 Sus scrofa Species 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000030570 cellular localization Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims description 5
- 238000011331 genomic analysis Methods 0.000 claims description 5
- 101001113040 Pasteurella multocida (strain Pm70) Peptidoglycan-associated lipoprotein Proteins 0.000 claims description 4
- 101150056072 TUFB gene Proteins 0.000 claims description 4
- 101150061352 tufA gene Proteins 0.000 claims description 4
- 108010041052 DNA Topoisomerase IV Proteins 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 101150057202 ompW gene Proteins 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 claims description 2
- 101150015794 mglC gene Proteins 0.000 claims description 2
- 101150067790 mlaA gene Proteins 0.000 claims description 2
- 101150074180 pepP gene Proteins 0.000 claims description 2
- 101150095786 pepPI gene Proteins 0.000 claims description 2
- 101150083416 torD gene Proteins 0.000 claims description 2
- 101150081616 trpB gene Proteins 0.000 claims description 2
- 101150111232 trpB-1 gene Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 47
- 108091007433 antigens Proteins 0.000 abstract description 47
- 102000036639 antigens Human genes 0.000 abstract description 47
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 108010077805 Bacterial Proteins Proteins 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 190
- 210000004027 cell Anatomy 0.000 description 58
- 239000000499 gel Substances 0.000 description 41
- 230000012010 growth Effects 0.000 description 30
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 206010008631 Cholera Diseases 0.000 description 18
- 108090001030 Lipoproteins Proteins 0.000 description 18
- 102000004895 Lipoproteins Human genes 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 241000894007 species Species 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 230000032258 transport Effects 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 102000017033 Porins Human genes 0.000 description 12
- 108010013381 Porins Proteins 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000286209 Phasianidae Species 0.000 description 8
- 108010026552 Proteome Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 244000144977 poultry Species 0.000 description 8
- 235000013594 poultry meat Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 7
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 239000001099 ammonium carbonate Substances 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000004960 subcellular localization Effects 0.000 description 6
- 238000004885 tandem mass spectrometry Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000272517 Anseriformes Species 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 208000032969 Hemorrhagic Septicemia Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000000955 peptide mass fingerprinting Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 101800000263 Acidic protein Proteins 0.000 description 4
- 208000030090 Acute Disease Diseases 0.000 description 4
- 206010002515 Animal bite Diseases 0.000 description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 4
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002170 nanoflow liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 229940043230 sarcosine Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- BUTXNGJCCCGNMV-REOHCLBHSA-N (2s)-2-amino-3-sulfanylpropanethioic s-acid Chemical group SC[C@H](N)C(S)=O BUTXNGJCCCGNMV-REOHCLBHSA-N 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 108091027305 Heteroduplex Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000283953 Lagomorpha Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 3
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241001559589 Cullen Species 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 241001195348 Nusa Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101150078442 RPL5 gene Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108010084754 Tuftsin Proteins 0.000 description 2
- 108010073429 Type V Secretion Systems Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000010436 membrane biogenesis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- 238000007243 oxidative cyclization reaction Methods 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 2
- 229940035670 tuftsin Drugs 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- UTSXERRKRAEDOV-UHFFFAOYSA-N 3-[dimethyl-[3-(tetradecanoylamino)propyl]azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O UTSXERRKRAEDOV-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108050001144 ABC transporter, permeases Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000001921 Aminopeptidase P Human genes 0.000 description 1
- 102100033899 Ankyrin repeat and SOCS box protein 14 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101000798396 Bacillus licheniformis Phenylalanine racemase [ATP hydrolyzing] Proteins 0.000 description 1
- 101001022844 Bacillus subtilis ATP-dependent proline adenylase Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101001016210 Bos taurus Dynein axonemal heavy chain 12 Proteins 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101000644385 Brevibacillus parabrevis ATP-dependent leucine adenylase Proteins 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 101100437498 Escherichia coli (strain K12) uidA gene Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N Hippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000925508 Homo sapiens Ankyrin repeat and SOCS box protein 14 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- 101710137186 LPS-assembly protein LptD Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000283960 Leporidae Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000254058 Photinus Species 0.000 description 1
- 241000801593 Pida Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000904 Ribosomal protein S2 Proteins 0.000 description 1
- 102000004339 Ribosomal protein S2 Human genes 0.000 description 1
- 241000272171 Scolopacidae Species 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000623377 Terminalia elliptica Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101710187777 Tryptophan synthase beta chain Proteins 0.000 description 1
- 108010038900 X-Pro aminopeptidase Proteins 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229940087827 biolon Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010048607 glycerophosphodiester phosphodiesterase Proteins 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VBPVZDFRUFVPDV-UHFFFAOYSA-N o-pentylhydroxylamine Chemical compound CCCCCON VBPVZDFRUFVPDV-UHFFFAOYSA-N 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 108010032563 oligopeptidase Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 101150015988 rpl14 gene Proteins 0.000 description 1
- 101150060482 rps2 gene Proteins 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 208000012331 ruffled feather Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000034005 thiol-disulfide exchange Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000000051 wattle Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000003032 wing Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- FIELD This invention relates to bacterial proteins, and in particular to the identification of surface proteins of the bacterial pathogen Pasteurella multocida which are useful as antigens for vaccines.
- Pasteurella multocida is a Gram-negative bacterial pathogen which is the causative agent of numerous diseases in animals, including fowl cholera in avian species, hemorrhagic septicaemia in ungulates, shipping fever and pneumonia in cattle, atrophic rhinitis in swine, and snuffles in rabbits.
- the bacterium also causes infections in humans, primarily through dog and cat bites.
- P. multocida strains can be differentiated serologically into 5 distinct capsular groups, respectively designated A, B, D, E and F, and 16 lipopolysaccharide (LPS) types, respectively designated 1 to 16.
- capsular groups respectively designated A, B, D, E and F
- LPS lipopolysaccharide
- Fowl cholera which is generally caused by serotypes A:l, A:3 or A:4, is a severe respiratory disease which occurs in domestic poultry and wild birds. This disease occurs throughout the year, and results in significant economic losses to poultry industries worldwide. For example, fowl cholera costs the turkey industry millions of dollars annually due to deaths, condemnation losses, and vaccination and medication costs. Regular outbreaks also occur in wild bird populations, resulting in high mortality.
- Fowl cholera has two clinical forms: acute disease and chronic disease.
- the acute disease is a septicaemia with high morbidity and mortality.
- Clinical signs of the acute disease include fever, anorexia, ruffled feathers, mucous discharge from the mouth, diarrhoea, increased respiratory rate and cyanosis. Death may be the first evidence of acute disease.
- the chronic form of fowl cholera is characterized by localized infections, including swelling in wattles, sinuses, periorbital subcutaneous tissues, leg or wing joints, sternal bursae and foot pads, exudative conjunctivitis, pharyngitis, emaciation and lethargy. Almost all types of birds, including chickens, turkeys, ducks and geese, are susceptible to P. multocida infection.
- Haemorrhagic septicaemia is a fatal systemic disease of cattle and buffalos.
- P. multocida is the major cause of pasteurellosis in dairy calves, and is the second most common bacterium isolated from fibrinous pneumonia in beef cattle.
- P. multocida A: 3 is the second most common bacterium isolated from' shipping fever in beef cattle and the major cause of fibrinopurulent bronchopneumonia in dairy calves .
- South Asia haemorrhagic septicaemia is caused by infection with P. multocida serotype B:2.
- P. multocida is a well-known cause of morbidity and mortality in rabbits. The predominant syndrome is upper respiratory disease or "snuffles" . P. multocida is often endemic in laboratory and other rabbit colonies, and the acquisition of infection in young rabbits is correlated to the prevalence in adult rabbits .
- the Australian chicken industry produces products with a retail value of more than $2.5 billion.
- Vaccines are also available for use in cattle; however, these vaccines too are of questionable efficacy, and in particular the efficacy of current P. multocida vaccines in bovine pneumonia has not been critically evaluated. There is therefore a need for the identification of suitable antigens which can form the basis of vaccines suitable for use in a variety of species .
- P. multocida OMP is able to induce protective immunity in poultry and other animals. Moreover, it has been reported that OMPs expressed by in vivo-grown bacteria induced heterologous protection (cross- protection) in poultry. However, the OMP antigens used in these studies were not purified proteins; crude chromatographic fractions were used in one study, and the other found that adsorbed antisera reacted with a number of proteins with various molecular masses. Nonetheless, these findings are consistent with the hypothesis that OMPs are important for protective immunity, and that those OMPs expressed exclusively in vivo are critical for protection against heterologous LPS serotypes . International patent application No.
- PCT/US98/25990 discloses the isolation of nucleic acids encoding the major outer membrane protein, OmpH, of the virulent P. multocida strains X-73 and P-1059, and proposes the use of these OMPs in vaccines for fowl cholera. Fragments of OmpH and synthetic cyclic peptides designed to mimic the native conformation of the largest loop, loop 2, of OmpH are also disclosed. However, only a few antigens were examined, and only limited homologous protection was obtained.
- P. multocida We therefore sought to characterise some of the constituents of the surface of P. multocida. We also investigated whether the expression of the P. multocida sub-proteome changed in response to environmental conditions, firstly in vitro during culture in medium with low iron concentration, which partially mimics the conditions found in host tissues, and secondly during infection of a major natural host, the chicken. In particular we sought to identify surface proteins of P. multocida which are able to elicit protective antibodies.
- the invention provides an isolated immunogenic P. multocida surface polypeptide, or a fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH_l, P6-like protein (also known as 0mpl6 or PmO966) , PIpB, GIpQ, Lpp, OmpA (also known as PmO786) , or Oma87 (also known as Pml992) .
- the invention also encompasses biologically-active fragments, variants and derivatives of the polypeptides of the invention.
- a fragment according to the invention corresponds to one or more extracellular domains of a nucleotide surface polypeptide.
- the polypeptide of the invention is an outer membrane protein, and may comprise an extracellular domain, for example from loop 2.
- the polypeptide may be a recombinant or synthetic polypeptide.
- the polypeptide elicits an immune response which is protective against infection with P. multocida.
- the polypeptide provides heterologous protection, i.e. protection against at least two different serotypes of. P. multocida.
- polypeptide elicits antibodies which bind specifically to a P. multocida surface polypeptide, and which may or may not be protective. Such antibodies are useful in immunoassays . In either of these embodiments the antibody may be a neutralizing antibody.
- polypeptide is from P. multocida serotype A, A:l, A: 1,4, A:2, A: 3, A:3,4, A: 4, A:5, A:7, A:10, A:12, B, B : 2 , B:2,5, E:2, E:2,5, D, E or F.
- polypeptide is from serotype A:l, A: 3, A: 4, or B:2,
- the polypeptide is selected from one or more of the group consisting of : a) a protein involved in transport of molecules across a P. multocida outer membrane; b) a protein involved in iron uptake; c) a protein involved in transport of nutrients; d) a protein involved in resistance of P. multocida to heavy metals,- and e) a protein involved in synthesis or structural stability of the outer membrane.
- the polypeptide is expressed more strongly when the bacterium is grown in vitro under iron- depleted, anaerobic or amino acid-depleted conditions, or when it is grown in vivo. In one embodiment the polypeptide is exclusively expressed in vivo.
- the polypeptide is one or more selected from the group consisting of est, mglC, ompH_2, ompW, parC, pepP, pfhR, PM0300, PM0336, PM0337, PM0442, PM0527, PM0612', PM0803, PM0979, PM0998, PM1021, PM1064, PM1069, PM1426, PM1578, PM1600, PM1720, PM1809, rpS2, torD, trpB, tufA, tufB and vacJ.
- the polypeptide is selected from the group consisting of PM0388, PM0442, PM0554, PM0659, PM0741, _ ⁇ _
- polypeptide is selected from the group consisting of PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730.
- the polypeptide may be fused to a heterologous polypeptide, such as a solubility tag, an affinity tag, or an immunogenic carrier protein.
- a heterologous polypeptide such as a solubility tag, an affinity tag, or an immunogenic carrier protein.
- a polypeptide of the invention is useful in immunogenic compositions to prepare antisera or vaccines.
- a fragment of a polypeptide of the invention such as a peptide, or variant or derivative thereof, is also useful in assays to detect antibodies specific for the peptide or for a polypeptide of which a portion has an amino acid sequence corresponding to an epitope within the peptide.
- Peptides of the invention may be modified, for example by cyclization as a result of disulphide bond formation.
- the invention provides an antibody which specifically binds to a polypeptide of the invention, or to a biologically active fragment, derivative, or variant thereof.
- the antibodies of the invention are useful inter alia in providing passive immunity to a subject to which the preparation is administered, and in immunoassays for detection of polypeptides of the invention.
- the present invention provides a composition
- a composition comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, together with a physiologically-acceptable carrier.
- the invention further provides a vector comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, and a host cell comprising the vector.
- the vector is an expression cassette, and may comprise a preselected DNA sequence which is operably linked to a promoter which is functional in the host cell, in which the DNA sequence encodes one or more P. multocida surface polypeptides of the invention.
- the host cell may be prokaryotic or eukaryotic in origin.
- the present invention provides a method of treating or preventing a disease or condition caused by P. multocida, comprising the step of administering a polypeptide and/or antibody of the invention, or a biologically active fragment, derivative, or variant thereof, to a subject suffering from, suspected to be suffering from, or at risk of such a condition.
- the present invention provides a method of diagnosing a disease or condition caused by P. multocida, comprising the step of detecting a polypeptide, antibody, and/or nucleic acid molecule of the invention, or a fragment, derivative, or variant thereof, in a biological sample from a subject suffering from, suspected to be suffering from, or at risk of such a condition.
- Detection of the nucleic acid molecule, or fragment, variant or derivative thereof may for example be achieved by nucleic acid amplification.
- the method of diagnosis may comprise contacting a sample of DNA obtained from a biological sample from a subject at risk of or suffering from P. multocida infection with at least two oligonucleotides which bind to complementary strands of said DNA at preselected regions under conditions effective to amplify the DNA, so as to yield amplified DNA.
- the amplification may be effected by conventional methods, such as polymerase chain reaction.
- the DNA may be obtained by reverse transcription of RNA from the cells.
- At least one of the oligonucleotides may be specific for DNA encoding an OMP of P. multocida.
- the presence of amplified DNA is then detected or determined by conventional methods.
- the presence of amplified DNA is - S -
- any convenient biological sample from the subject may be used, including but not limited to blood and other biological fluids, sputum, and tissue samples.
- the present invention provides the use of a polypeptide, antibody and/or nucleic acid molecule of the invention or a biologically active fragment, derivative, or variant thereof, in the treatment or prevention of a disease or condition caused by P. multocida.
- the present invention provides the use of a polypeptide, antibody and/or nucleic acid molecule of the invention, or a biologically active fragment, derivative, or variant thereof, in the diagnosis of a disease or condition caused by P. multocida.
- the disease or condition may be diagnosed following nucleic acid amplification.
- the subject may be suspected of having the disease or condition, or may have been, or may be suspected to have been, exposed to a subject known or suspected to be infected with P. multocida.
- the invention provides a composition comprising a polypeptide or nucleic acid molecule of the invention, or a biologically active fragment, derivative, or variant thereof, together with a pharmaceutically or veterinarily acceptable carrier.
- the composition may be a vaccine, and may further comprise an adjuvant.
- the vaccine elicits an immune response which is protective against infection with P. multocida.
- the vaccine provides heterologous protection, i.e. protection against at least two different serotypes of P. multocida.
- the vaccine elicits antibodies which bind specifically to a P. multocida surface polypeptide, and which may or may not be protective. Such antibodies are useful in immunoassays.
- the antibody may be a neutralizing antibody.
- the invention provides a method of preparing a plurality of nucleic acid molecules encoding candidate P. multocida surface proteins, comprising: a) identifying specific P. multocida nucleic acid sequences, and b) cloning the nucleic acid sequences of a) .
- the identification is on the basis of one or more of : a) the predicted cellular location of the encoded protein; b) the similarity of the encoded protein to a protein with a putative or confirmed role in infection and immunity; and c) subtractive hybridisation of a nucleic acid sequence specific to a virulent P. multocida strain, which is preferably from chickens, swine, cattle, or rabbits. More preferably the nucleic acid is specific to a strain from chickens, for example strain X-73, strain P-1059 or strain VP161.
- the invention provides a plurality of nucleic acid molecules prepared by the ninth aspect of the invention.
- the invention further provides a plurality of polypeptides encoded by the plurality of nucleic acid molecules of the tenth aspect of the invention.
- the invention provides a kit comprising one or more of a polypeptide, antibody, and/or nucleic acid molecule of the invention, or a fragment, derivative, or variant thereof.
- the kit may be used as a diagnostic kit, and may comprise one or more pairs of nucleic acid molecules which can be used as primers for nucleic acid amplification.
- the kit is a diagnostic kit for detecting the presence of DNA associated with P. multocida in a sample, in which the kit comprises: (a) a known amount of a first oligonucleotide which consists of at least about 7, 8, 9, 10, 11, 12, 13, 14, - ll -
- oligonucleotide has at least about 70% contiguous sequence identity to a nucleic acid molecule of the invention
- a second oligonucleotide in which the second oligonucleotide consists of at least about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 to about 50 nucleotides, and in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleotide sequence which is complementary to a nucleic acid molecule of the invention; and optionally
- the first oligonucleotide consists of at least about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 to about 40 nucleotides, and even more preferably about 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 to about 25 nucleotides.
- the second oligonucleotide consists of at least about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
- the invention provides a method for detecting a nucleic acid molecule encoding a surface polypeptide of P. multocida, comprising the step of contacting a nucleic acid obtained from a biological sample from a subject with at least two oligonucleotides, under conditions effective to amplify the nucleic acid so as to yield an amount of amplified nucleic acid, in which the biological sample comprises cells suspected of containing a nucleic acid molecule encoding an immunogenic polypeptide, and at least one of the oligonucleotides is specific for a nucleic acid encoding a surface polypeptide of the invention, i.e.
- the invention provides a method of identifying an immunogenic P. multocida outer membrane protein, comprising the steps of a) subjecting the genomic DNA sequence of P.
- multocida to genomic analysis b) selecting candidate open reading frames according to the estimated vaccine antigen potential of the corresponding proteins, on the basis of the predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing proteins encoded by the open reading frames identified in step(d); f) isolating the expressed proteins; and g) testing the isolated proteins for ability to protect a test animal from challenge with virulent P. multocida.
- the invention provides a library of candidate immunogenic P. multocida. outer membrane proteins, prepared by a method comprising the steps of a) subjecting the genomic DNA sequence of P. multocida to genomic analysis; b) selecting candidate open reading frames according to the estimated vaccine antigen potential of the corresponding proteins, on the basis of the predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing open reading frames identified in step(d); and f) isolating the expressed proteins.
- the disease or condition caused by P. multocida. is one which affects an avian, ungulate, lagomorph or human subject.
- ungulates include cattle and pigs
- lagomorphs include rabbits and hares.
- the subject is a bird.
- the invention is especially applicable to poultry, including chickens, turkeys, pheasants, ducks, geese, and guinea fowl, and to cattle, pigs and rabbits.
- the diagnostic, therapeutic and prophylactic aspects of the invention are also applicable to subjects which have been exposed to an animal or bird infected with P. multocida.
- the P. multocida strain is one isolated from chickens, swine, cattle or rabbits.
- the isolate is from chickens, for example strain X-73, strain P-1059, or strain VP IGl.
- FIGURES Figure 1 shows the results of 2-DGE of sarcosine-insoluble membrane fraction of P. multocida grown in BHI. Proteins were separated in the first dimension using a pH 3 to 10 IPG strip and in the second dimension by 12.5% polyacrylamide gel electrophoresis. All numbered protein spots were analysed by MALDI-TOF MS, and matches are reported in Table 1.
- Figure 2 shows the results of 1-DGE of the sarcosine- insoluble membrane fraction of P. multocida harvested after growth in BHI (lane 1) , or obtained from the bloodstream of terminally-infected chickens (lane 2) . Proteins were separated by 12% polyacrylamide gel electrophoresis and each lane cut into eight equal-sized sections, as shown by the marker lines at the left. The positions of standard molecular mass markers (lane 3) are shown on the right (KDa) .
- Figure 3 shows the results of 2-DGE of the sarcosine-insoluble membrane fraction of P. multocida grown in CDM (A) or in CDM supplemented with 200 ⁇ M 2,2'- dipyridyl (B) . Proteins were separated in the first dimension using a pH 3 to 10 IPG strip, and in the second dimension by 12.5% polyacrylamide gel electrophoresis. Spot numbers are as given in Table 1, except for spot 38, which remained unidentified, and spots 39-42 which correspond to Pm0803. Proteins showing statistically significant differential expression across triplicate gels are indicated by rings .
- Figure 4 shows the results of 2-DGE of the sarcosine-insoluble membrane fraction of P. multocida recovered after growth in BHI (A) or from the bloodstream of infected chickens in the terminal stages of fowl cholera (B) . Proteins were separated in the first dimension using a pH 3 to 10 IPG strip, and in the second dimension by 12.5% polyacrylamide gel electrophoresis. Spot numbers are as given in Table 1, except for spots 39, 41 and 43, which correspond to Pm0803. Proteins showing strong differential expression between the two conditions across all gels are indicated by rings.
- Figure 5 illustrates the results of Western blotting of sera from chickens immunized with recombinant surface proteins from P.
- Proteins are as follows: Lane 3 PM0442; Lane 4 PMO979; Lane 5 PMO659; Lane 6 PMl993; Lane 7 PMl614; Lane 8 PM1979; Lane 9 -; Lane 10 X-73 WC.
- the surface of Gram-negative bacteria is critical for the interaction of the bacterium with the environment. It consists primarily of lipopolysaccharide (LPS), phospholipids and proteins.
- LPS lipopolysaccharide
- phospholipids phospholipids
- proteins The LPS and phospholipids provide a significant permeability barrier to hydrophobic compounds, while the proteins known as, outer membrane proteins (OMPs) are generally involved in outer membrane stability and in transport of various molecules in and out of the cell.
- OMPs include porins, which allow non-specific diffusion of charged and neutral solutes, and high affinity transporters, which mediate transport of specific ligands in and out of the cell.
- the expression of the various OMPs is influenced by the extracellular environment.
- P. multocida The surface of P. multocida has not previously been well characterized. Only seven P. multocida proteins have been experimentally shown to be present in the outer membrane; OmpH_l (Luo et al, 1997) , P6-like protein (0mpl6, PmO966) (Kasten et al, 1995) , PIpB
- OmpW and Omp47 there is no evidence of either their expression in P. multocida or of their sub-cellular localization in this species.
- OMPs may be involved in protective immunity in P. multocida infections, and OMPs expressed exclusively in vivo may be involved in stimulating immunity to serotypes expressing different LPS types.
- P. multocida virulence factors may be located on the cell surface, and these may include factors which are critical for colonisation and invasion; these are important steps in pathogenesis which are at present poorly understood. However, specific factors have not yet been identified.
- Haemorrhagic septicaemia of ungulates B: 2; B: 2, 5; E: 2;
- Fowl cholera of birds A:l, A:l,4, A:3, A:3,4, A:5, A:10, A: 12, F; rarely D and B (Snipes et al, 1989; Takahashi et al, 1996; Waltman and Home, 1993)
- Pneumonic pasteurellosis A, [A: 3], F, D (Blanco-Viera et al, 1995)
- a polypeptide includes a plurality of such polypeptides
- a reference to “an amino acid” is a reference to one or more amino acids.
- the present invention employs conventional chemistry, protein chemistry, molecular biological and enzymological techniques within the capacity of those skilled in the art. Such techniques are well known to the skilled worker, and are explained fully in the literature. See, for example, Coligan, Dunn, Ploegh, Speicher and Wingfield: "Current protocols in Protein Science” (1999) Volumes I and II (John Wiley & Sons Inc.); Sambrook,
- isolated and/or purified refer to an in vitro preparation of a molecule of the invention, or fragment, variant, or derivative thereof, so that the molecule is not substantially associated with molecules with which it normally occurs in vivo, and is substantially free of infectious agents .
- polypeptide and protein are herein used interchangeably. Where they are used to refer to an amino acid sequence of a naturally-occurring polypeptide, these terms are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited polypeptide, but instead are meant also to encompass biologically active fragments, derivatives, or variants, including polypeptides having sequence similarity or sequence identity relative to the amino acid sequences provided herein.
- surface polypeptide means a polypeptide naturally located on the outer surface of P. multocida, so that in vivo it is accessible to an immune response of a subject.
- an "outer membrane protein” or “OMP” is a polypeptide isolated from the outer membrane of P. multocida. Typically a portion of the OMP will be anchored in the outer membrane of a P. multocida bacterium, while another portion will be exposed on the surface of the bacterium.
- OMP is used generically herein to encompass native OMPs, as well as variants, derivatives and fragments thereof.
- extracellular domain or ⁇ ⁇ CD refers to a form of a surface polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily an ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains or cytoplasmic domains identified for the surface polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of domain.
- An ECD of a surface polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary, with or without the associated signal peptide.
- an "immunogenic" surface polypeptide is one which is able to induce a specific immune response.
- the immunological response is an antibody response against the surface polypeptide, and may be directed to a particular epitope on the surface polypeptide.
- the presence of antibodies specific for that epitope in a biological sample from a subject correlates with the P. multocida infection status of the subject.
- the antibody is able to protect against infection with P. multocida, or reduces the severity of such infection.
- the antibody may be a neutralizing antibody, i.e. one which is able to inhibit a biological activity of the corresponding polypeptide or of P. multocida organisms.
- a recombinant surface polypeptide of the invention may be purified from other cellular components to obtain a preparation which is substantially homogenous for the recombinant surface polypeptide.
- the culture medium or lysate can be centrifuged to remove particulate cell debris.
- the membrane and soluble protein fractions are then separated.
- the surface polypeptide may then be purified from the soluble protein fraction.
- the surface polypeptide may be purified from the insoluble fraction, i.e. refractile bodies or inclusion bodies; see, for example, U.S. Patent No. 4,518,526.
- the surface polypeptide may be purified from contaminant soluble or membrane polypeptides by conventional protein purification methods, such as fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocussing,- SDS-PAGE; ammonium sulphate precipitation; and gel filtration or ligand affinity chromatography. Sarcosine solubilization as described herein may also be used.
- the recombinant surface polypeptide may be recovered from cell lysates in a soluble fraction, i.e. a fraction in which the recombinant polypeptide is not associated with membranes, in the insoluble fraction, in inclusion bodies or from supernatants .
- the recombinant protein may optionally be expressed as a fusion protein, for example in Escherichia coli.
- a "biologically active" molecule according to the invention has at least about 1%, preferably at least about 10%, 11%, 12%, 13%, 14%, 15%, 1 6%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%%, 31%, 32%, 33%, 34%, 35%, 6%, 37%, 38%, 39% or 40%, more preferably at least about 50%, 51%, 52%, 53%, 34%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 9%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79% or 80%, and even more preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the activity of the corresponding native
- the activity of the molecule of the invention can be measured by methods well known to the art, including, but not limited to, measuring the ability of a polypeptide of the invention to bind to antibodies specific for the relevant polypeptide or peptide, the ability of the polypeptide to elicit a sequence-specific immunological response when the polypeptide is administered to a subject, the correlation of P. multocida infection with the presence of amino acid sequences in the affected host corresponding to at least a portion of the polypeptide, or measuring the known normal function of the protein, e.g. ion transport .
- polypeptides within the scope of the invention may comprise moieties other than the amino acid sequences which are derived from the surface polypeptides of P. multocida, provided that these moieties do not substantially reduce the biological activity of the peptide.
- the polypeptide may be directly linked to a sequence of amino acids which is not present in the native OMP of P. multocida, in order to form a fusion protein.
- a substantial reduction in activity means a reduction in activity of greater than about 99%.
- a "fragment" is defined as a portion or domain of a full length molecule of the present invention, which maintains a biological activity of the full length molecule.
- the molecule may be either a polypeptide or nucleic acid molecule.
- the fragment may be a peptide of a P. multocida surface polypeptide.
- a "peptide” comprises no more than 75, preferably about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 to about 50, and more preferably about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 to about 40, peptidyl residues which have 100% contiguous amino acid sequence homology or identity to the amino acid sequence of a particular surface polypeptide of an isolate of P. multocida.
- the peptides of the invention are homologous to regions which have variations in both sequence and length, e.g. loop 2 or loop 5, and which are immunogenic.
- the peptide corresponds to a region which comprises subtype-specific, or non-subtype specific, epitopes useful for homologous or heterologous protection respectively.
- the epitopes may be B-cell or T-cell epitopes .
- a derivative of a polypeptide of the invention may have been modified in a manner that increases its stability in vivo, or which presents immunogenic epitopes in a more native configuration.
- Methods for preparing such derivatives are well known in the art.
- a modification known to improve the immunogenicity, stability and/or bioavailability of peptides in vivo is the cyclization of the peptide, for example by formation of one or more disulphide bonds, as described in PCT/US98/25990 (WO99/29724) .
- CCD cyclic reverse sequence derivative
- a linear peptide is synthesized with all D-form amino acids using the reverse (i.e. C-terminal to N- terminal) sequence of the peptide.
- the term "CRD” also includes cyclization by other mechanisms, e.g. via a peptidyl bond. Cyclized peptides with different kinds of linkages are known in the art; see EP 471,453 (amide bonds); EP 467,701 (disulphide bonds); EP 467,699 (thioether bonds) . Other modifications are disclosed in Jameson et al . 1994; U.S. Patent No. 4,992,463; and U.S. Patent No. 5,091,396.
- the peptide (0.1 mg/ml) is reacted for 1 hour at O 0 C with iodine (1 mM in methanol) and the oxidation is then quenched with sodium thiosulphate .
- the mixture is subjected to reverse-phase HPLC on a semi-preparative Zorbax C8 column, followed by gel filtration on a Zorbax GF250 column. Two peaks which are separated, by the gel filtration step are further analysed by mass spectroscopy, for example using an Applied Biosysterns Biolon 20 Biopolymer plasma desorption time-of-flight Mass Analyzer.
- the first peak is resolved by mass analysis into two species, a partially protected monomer peptide and a dimeric peptide.
- the material is tested for free cysteine thiol groups with Ellman' s reagent [5, 5-dithio-bis (2-nitrobenzoic acid); Sigma] at the highest concentration of peptide before saturation (20 mg/ml) .
- This peak represents the cyclic peptide, and is stored at pH 4.0 at -20 0 C until used.
- One preferred embodiment of the invention is an OMP peptide, or variant thereof, which has been cyclized by addition of one or more cysteine residues to the N and/or C terminus of the peptide with subsequent oxidation of the free cysteinyl thiol groups .
- Linear reverse D (LRD) and cyclized forward L (CFL) derivatives are also within the scope of the invention.
- LRD derivatives have the reverse (i.e., C-terminal to N-terminal) sequence of the peptide with all D-form amino acids, but are not cyclized, are also included within the scope of the term "derivative" .
- CFL derivatives have the forward (i.e., N- terminal to C- terminal) sequence of the peptide with all L-form amino acids.), followed by oxidative cyclization, or cyclization by an alternative method.
- cysteine residues may be added to the N and C termini, thereby allowing oxidative cyclization.
- amides of the surface polypeptide may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor, to an amide.
- a preferred method for amide formation at the C-terminal carboxyl group is to cleave a peptide from a solid support with an appropriate amine, or to cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine.
- Salts of carboxyl groups of a polypeptide of the invention may be prepared in the usual manner by contacting the polypeptide with one or more equivalents of a desired base, such as a metallic hydroxide base; a metal carbonate or bicarbonate base; or an amine base.
- a desired base such as a metallic hydroxide base; a metal carbonate or bicarbonate base; or an amine base.
- N-acyl derivatives of an amino group of a surface polypeptide of the invention may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected polypeptide.
- 0-acyl derivatives may be prepared by acylation of a free hydroxy peptide or peptide resin.
- Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. If desired, both N-and O- acylation may be carried out together.
- Formyl-methionine, pyroglutamine and trimethyl- alanine may be substituted at the N-terminal residue of the polypeptide, peptide or variant thereof.
- Other amino-terminal modifications include aminooxypentane modifications (see Simmons et al . , Science, 21Z, 276 (1997) ) .
- amino acid sequence of a polypeptide of the invention may be also modified so as to result in a variant.
- a "variant" may be a peptide comprising no more than 75 , p Preferably about 10, 11, 12, 13, 14, 15, 16, 17, 1 188,, 1 199,, 2 200, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
- amino acid residues which has at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% or 70%, preferably at least about 80%, 81%, 82%, 83%, 84% or 85%, and more preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100%, contiguous amino acid sequence homology or identity to the amino acid sequence of the corresponding native surface peptide of P. multocida. Similarly a "variant" has at least 50%, 51%,
- a variant polypeptide of the invention may include amino acid residues not present in the corresponding native surface polypeptide, and internal deletions relative to the corresponding native surface polypeptide.
- polypeptide variants of the invention include polypeptides and peptides in which at least one L- amino acid is replaced by the corresponding D-amino acid.
- Possible modifications include the substitution of at least one amino acid residue in the polypeptide or peptide for another amino acid residue, including substitutions which utilize the D- rather than the L- form, as well as other well-known amino acid analogues.
- These analogues include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, ⁇ -carboxyglutamate,- hippuric acid, octahydroindole-2-carboxylic acid, statine, 1, 2, 3 , 4, -tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citrulline, ⁇ -methyl- alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine.
- One or more of the residues of the polypeptide or peptide may be altered, provided that the peptide variant is still biologically active.
- the variant has at least about 10% of the biological activity of the corresponding non-variant protein .
- amino acid substitutions are preferred, e.g. aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids,- leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids.
- substitutions may be introduced, the variants may be screened for biological activity.
- Amino acid substitutions falling within the scope of the invention are, in general, accomplished by selecting substitutions which do not differ significantly in their effect on maintaining
- hydrophobic norleucine, met, ala, val, leu, ile
- Acid addition salts of amino residues of a polypeptide of the invention may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic acid, such as hydrochloric acid.
- Esters of carboxyl groups of the polypeptides may also be prepared by any of the usual methods known in the art.
- fusion protein is a polypeptide comprising two or more polypeptides that have been joined together, for example after transcription and translation of two or more fused nucleic acid molecules.
- the two or more polypeptides may be the same or different. That is, the fusion protein may comprise two or more copies of a surface polypeptide of the invention, copies of more than one different surface polypeptide of the invention, or at least one surface polypeptide of the invention fused to any other polypeptide.
- the fusion protein comprises at least an immunogenic or antigenic portion of a plurality of P. multocida outer membrane polypeptides.
- the fusion protein may be purified by methods specific for the surface polypeptide or non-surface polypeptide portion of the fusion polypeptide. For example, if the fusion polypeptide is a histidine-tagged fusion polypeptide, Ni-NTA resin may be employed to purify the fusion polypeptide. Epitope tags such as FLAGTM may also be used.
- Fusion proteins can be prepared by in vitro transcription and translation reactions .
- An expression cassette can be employed to generate surface polypeptide gene-specific transcripts which are subsequently translated in vitro.
- the construction of vectors for use in in vitro transcription/translation reactions, and methods for such reactions, are well known in the art.
- the polypeptides or fusion proteins of the invention may also be prepared by solid phase peptide synthesis, which is an established and widely used method, described in the following references: Stewart et al. 1969; Merrifield, 1963; Meienhofer in "Hormonal ' Proteins and Peptides," ed. ; C. H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267; and Bavaay and Merrifield, "The Peptides,” eds . E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp.3-285.
- a heterologous molecule is a molecule not occurring naturally in the form used in the present invention.
- a heterologous nucleic acid molecule may not occur naturally in a P. multocida cell. If it does naturally occur in a P. multocida cell, it is integrated at other genetic positions as exogenous nucleic acid and is therefore situated within another genetic environment.
- the heterologous molecule may be any molecule which it is desired to provide as a surface polypeptide fusion protein, such as a molecule from a different serotype of P. multocida.
- polypeptides of the invention may be conjugated or linked to an immunogenic protein, such as keyhole limpet haemocyanin (KLH) or albumin, to enhance their immunogenicity .
- an immunogenic protein such as keyhole limpet haemocyanin (KLH) or albumin
- KLH keyhole limpet haemocyanin
- synthetic peptides are coupled to KLH through the C-terminal cysteine of the peptide using the heterobifunctional reagent N- ⁇ - maleimidobutyric acid
- GMBS N-hydroxysuccinimide ester
- vaccine antigen potential means an estimate of the likely ability of a protein to elicit at least some degree of protective immunity. Any protein which confers some or total protection against a challenge with infective organisms can also be referred to as a potential vaccine candidate. In the case of P. multocida, OMPs are considered to be the proteins most likely to have this ability.
- antibody is used in the broadest sense, and specifically includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies), and antibody fragments, provided that they maintain their antigen-binding specificity.
- maternal antibodies which are obtained from a female subject exposed to a recombinant bacterial cell, a nucleic acid molecule, or a polypeptide of the invention.
- a hen may be vaccinated with at least one of the vaccine compositions of the invention. The hen then provides passive immunity to its progeny through the transfer of maternal antibody to the embryo.
- an egg-laying animal e.g. a chicken, may be immunized and the eggs from that animal collected.
- Antibody is recovered from the eggs, and then administered to susceptible subjects, e.g. turkeys, to provide passive protection. Preferably the turkeys are subsequently exposed to live or killed P. multocida, or with polypeptides of the invention, to provide active protection.
- susceptible subjects e.g. turkeys
- the turkeys are subsequently exposed to live or killed P. multocida, or with polypeptides of the invention, to provide active protection.
- a "monoclonal antibody” is an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.
- each monoclonal antibody is directed against a single determinant on the antigen.
- the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., 1975, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
- the person skilled in the art will be aware of numerous other references, such as Goding, J. W. Monoclonal Antibodies: principles and practice (Academic Press, New York: 3 rd ed. 1996) .
- Nucleic acid molecule refers to an oligonucleotide, polynucleotide, nucleotide, and fragments, variants, derivatives, and antisense molecules thereof, as well as to peptide nucleic acids (PNA) , fragments, variants, derivatives and antisense molecules thereof, and to DNA or RNA of genomic or synthetic origin which can be single- or double-stranded, and represent the sense or antisense strand.
- PNA peptide nucleic acids
- nucleic acid refers to a specific nucleic acid sequence it is meant to encompass polynucleotides that encode a polypeptide that is functionally equivalent to the recited polypeptide, e.g., polynucleotides that are degenerate variants, or polynucleotides that encode biologically active fragments, variants, or derivatives of the polypeptide, including polynucleotides having substantial sequence similarity or sequence identity relative to the sequences provided herein.
- nucleic acid molecules of the invention may be used to prepare probes, primers or expression cassettes which, in turn, are useful to detect, amplify and express other outer membrane protein genes and related genes .
- nucleotide sequence and “nucleic acid sequence” are used herein interchangeably.
- antisense nucleic acid molecule as described herein defines a sequence which is complementary to a nucleic acid molecule of interest or fragment, variant, or derivative thereof.
- Nucleic acid molecules encoding a surface polypeptide of the invention, or a fragment, variant, or derivative thereof, may be obtained from any isolate of P. multocida or from physiological fluid or tissue of eukaryotic organisms infected with P. multocida.
- Other sources of the DNA molecules of the invention include genomic libraries derived from any P. multocida-infected eukaryotic cellular source.
- DNA molecules which encode a subunit of a full-length surface polypeptide may be prepared in vitro, e.g.
- nucleic acid molecule encoding a surface polypeptide of the invention can be identified and isolated using standard methods, for example as described by Sambrook et al . , Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY (1989) .
- a “variant" nucleic acid molecule of the invention is a nucleic acid molecule which has at least 80%, 81%, 82%, 83%, 84% or 85%, preferably at least about 90%, 91%, 92%, 93% or 94%, and more preferably at least about 95%, 96%, 97%, 98%, 99% but less than 100%, contiguous nucleotide sequence homology or identity to the nucleotide sequence of the corresponding wild type nucleic acid molecule, which encodes a surface polypeptide of P. multocida.
- a variant nucleic acid molecule of the invention may also include nucleotide bases not present in the corresponding wild type nucleic acid molecule, and/or internal deletions relative to the corresponding wild type nucleic acid molecule.
- Nucleic acid molecules encoding amino acid sequence variants of surface polypeptides of the invention may be prepared by a variety of methods known in the art. These include, but are not limited to, isolation from a natural source (in the case of naturally-occurring amino acid sequence variants or serotypes) or preparation by site-directed mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a native surface polypeptide.
- Site-mediated mutagenesis is a preferred method for preparing amino acid substitution variants of a polypeptide of the invention. This technique is well known in the art (Adelman et al . , 1983). Briefly, DNA encoding a surface polypeptide is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, in which the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence encoding the surface polypeptide. Alternatively, the plasmid or phage can be detnatured, e.g. with NaOH.
- a DNA polymerase is used to synthesize an entire second complementary strand of the template which will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the DNA encoding the surface polypeptide. Oligonucleotides of at least 25 nucleotides in length are generally used.
- An optimal oligonucleotide will have 12, 13, 14 or 15 nucleotides which are completely complementary to the template on either side of the nucleotide (s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule.
- the oligonucleotides are readily synthesized using techniques known in the art, such as that described by Crea et al . , 1978.
- the DNA template can be generated by vectors which are either derived from bacteriophage M13 vectors such as the commercially-available M13mpl8 and M13mpl9 vectors, or which contain a single-stranded phage origin of replication, as described by Viera et al . , 1987.
- the DNA which is to be mutated may be inserted into one of these vectors to generate single-stranded template.
- Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al . , Molecular Cloning. A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York, 1989).
- single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.
- the oligonucleotide may be hybridized to the single-stranded template under suitable hybridization conditions.
- a DNA polymerizing enzyme usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis.
- a heteroduplex molecule is thus formed, such that one strand of DNA encodes the mutated form of the surface polypeptide, and the other strand (the original template) encodes the native, unaltered sequence of the surface polypeptide.
- This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as E.
- coli JMlOl or a mut S strain to allow for heteroduplex replication without repair.
- the cells are grown, they are plated on to agarose plates and screened, using the oligonucleotide primer radiolabeled with 32 -phosphate to identify the bacterial colonies which contain the mutated DNA.
- the mutated region is then removed and placed in an appropriate vector for polypeptide production, generally an expression vector of the type typically employed for transformation of an appropriate host.
- an appropriate vector for polypeptide production generally an expression vector of the type typically employed for transformation of an appropriate host.
- nucleic acid molecules encoding at least a portion of a surface polypeptide, or the complement thereto may be modified so as to yield nucleic acid molecules of the invention having silent nucleotide substitutions, or to yield nucleic acid molecules having nucleotide substitutions which result in amino acid substitutions .
- Codoning of DNA also known as gene cloning or molecular cloning, refers to the use of recombinant DNA technology to insert a desired DNA fragment into a cloning vector, which is then introduced into a host cell in which it can replicate, and culturing the host cell.
- the DNA may be isolated from its natural source, or may be cDNA or synthetic DNA.
- a "vector” or “cloning vector” is a DNA molecule originating from a virus, a plasmid, or the cell of a higher organism into which another DNA fragment of appropriate size can be integrated without loss of the vector's capacity for self-replication; vectors are routinely used to introduce foreign DNA into host cells, in which the DNA can be reproduced in large quantities . Examples include plasmids, cosmids, and yeast artificial chromosomes; vectors are often recombinant molecules containing DNA sequences from several sources.
- a vector may include one or more nucleic acid sequences, such as an origin of replication, which permit the vector to replicate in a host cell.
- a vector also may include one or more selectable marker genes and other genetic elements known in the art .
- the term "vector” as used herein is intended to encompass any carrier for nucleic acid, including plasmids, cosmids and phage.
- the vector is an expression cassette.
- a recombinant or preselected nucleic acid sequence or segment may be circular or linear, double-stranded or single-stranded.
- a preselected DNA sequence which encodes an RNA sequence which is substantially complementary to a RNA sequence encoding surface polypeptide is typically a "sense" DNA sequence cloned into a cassette in the opposite orientation (i.e. 3' to 5' rather than 5 1 to 3 ⁇ ) .
- the preselected DNA sequence or segment is in the form of chimeric DNA, such as plasmid DNA, which can also contain coding regions flanked by control sequences which promote the expression of the preselected DNA present in the resultant cell line.
- “Chimeric” means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or associated in a manner which does not occur in the "native" or wild type of the species.
- a portion of the preselected DNA may be untranscribed, serving a regulatory or a structural function.
- the preselected DNA may itself comprise a promoter which is active in the host cell, or may utilize a promoter already present in the genome that is the transformation target. Many promoter elements well known to the art may be employed in the practice of the invention.
- Control sequences are nucleic acid sequences necessary for the expression of an operably-linked coding sequence in a particular host organism.
- Control sequences which are suitable for prokaryotic cells include a promoter, and optionally an operator sequence, and a ribosome binding site.
- Such elements may or may not be necessary for the function of the nucleic acid molecule, but may provide improved expression of the nucleic acid molecule by affecting factors such as transcription or stability of mRNA, and may be included in the nucleic acid molecule to obtain optimal performance of the transforming DNA in the cell.
- operably linked means that a nucleic acid molecule is placed in a functional relationship with another nucleic acid molecule.
- “operably linked” means that the nucleic acid molecules being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites.
- the preselected nucleic acid molecule to be introduced into the cells further will generally contain a selectable marker gene and/or a reporter gene, to facilitate identification and selection of transformed cells from the population of cells sought to be transformed.
- the selectable marker may be carried on a separate piece of DNA and used in a co- transformation procedure.
- Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells .
- Useful selectable markers are well known in the art, and include antibiotic genes, such as those listed in Table 1 of Lundquist et al . (U.S. Patent No. 5,848,956).
- Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (cat) from Tn9 of E. coli, the ⁇ -glucuronidase gene (gus) of the uidA locus of E. coli, and the luciferase gene from the firefly
- nucleic acid molecule refers to a nucleic acid molecule which has been derived or isolated from any appropriate cellular source, and which may subsequently be chemically altered in vitro, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences which are not positioned as they would be positioned in a genome which has not been transformed with exogenous DNA.
- a recombinant nucleic acid "derived” from a source may be a DNA sequence which is identified as a useful fragment within a given organism, and which is then chemically synthesized in essentially pure form.
- RNA DNA sequences isolated from biological sources
- DNA sequences derived from RNA DNA sequences isolated from RNA, and mixtures thereof.
- derived with respect to a RNA molecule means that the RNA molecule has complementary- sequence identity to a particular DNA molecule.
- a DNA "isolated” from a source may be a DNA sequence which is excised or removed from the source by chemical means, e.g. by the use of restriction endonucleases, so that it can be further manipulated for use in the invention, by genetic engineering methodology.
- the term "host cell” is intended to refer to well-characterized homogenous, biologically pure populations of cells.
- the cell line or host cell is preferably of bacterial origin, and most conveniently is Escherichia coli.
- the preselected DNA sequence is related to a DNA sequence which is either resident in the genome of the host cell but not expressed, or not highly expressed, or, alternatively, is overexpressed.
- Transfected or “transformed” is used herein to include any host cell or cell line, the genome of which has been altered or augmented by the presence of at least one preselected DNA sequence, which DNA is also referred to in the art of genetic engineering as “heterologous DNA” “recombinant DNA” , “exogenous DNA” , “genetically engineered”, “non-native” or “foreign DNA”, in which the DNA was isolated and introduced into the genome of the host cell or cell line by the process of genetic engineering.
- the host cells are typically produced by transfeetion with a DNA sequence in a plasmid expression vector, a viral expression vector, or as an isolated linear DNA sequence.
- the transfected DNA is a chromosomalIy-integrated recombinant DNA sequence, which comprises a gene encoding an OMP or its complement, which host cell may or may not express significant levels of autologous or "native" OMP.
- the recombinant DNA can be readily introduced into the host cells by transfection with an expression vector comprising DNA encoding an OMP or its complement, by any procedure useful for the introduction into a particular cell, e.g., physical or biological methods (e.g., recombinant phage or viruses), to yield a transformed cell having the recombinant DNA stably integrated into its genome, so that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell .
- Physical methods for introducing a recombinant nucleic acid molecule into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like.
- the main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses in eukaryotic hosts. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression.
- a variety of assays may be performed.
- Such assays include molecular biological assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; biochemical assays, such as detecting the presence or absence of a particular OMP, e.g. by immunological means such as ELISA assays and Western blots, or by functional assays to identify specific proteins falling within the scope of the invention.
- RNA produced from introduced preselected DNA segments may be employed.
- RT-PCR reverse transcription PCR
- PCR techniques will not demonstrate integrity of the RNA product, but Northern blotting demonstrates the presence of an RNA species, and gives information about the integrity of that RNA.
- the presence or absence of an RNA species can also be determined using dot or slot blot Northern hybridizations. These techniques are modifications of Northern blotting, and only demonstrate the presence or absence of an RNA species.
- Southern blotting and PCR may be used to detect the preselected DNA segment in question, they do not provide information as to whether the preselected DNA segment is being expressed. Expression may be evaluated by specifically identifying the products of the introduced preselected DNA sequences or evaluating the phenotypic changes brought about by the expression of the introduced preselected DNA segment in the host cell.
- Recovery or isolation of a given fragment of DNA from a restriction digest employs methods well known in the art, such as separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al . , 1981, and Goeddel et al . , 1980.
- PCR Polymerase chain reaction
- Primer oligonucleotide sequences are synthesized so as to correspond to highly-conserved regions of proteins or nucleotide sequences which were identified and compared to generate the primers, e.g., by a sequence comparison of other bacterial OMP genes.
- One primer is predicted to anneal to the antisense strand, and another primer is predicted to anneal to the sense strand, of a DNA molecule which encodes an OMP.
- the products of each PCR reaction are separated, for example by agarose gel electrophoresis, and all consistently amplified products are gel-purified and cloned directly into a suitable vector, such as a known plasmid vector.
- the resultant plasmids are subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs.
- the gel-purified fragment can be directly sequenced.
- the terms “treating” , “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiological effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or condition, or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure of a disease or condition.
- Treating covers any treatment of, or prevention of, disease in the subject, and includes preventing the disease from occurring in a subject who may be predisposed to the disease, but has not yet been diagnosed as having it; inhibiting the disease, i.e., arresting its development; or relieving or ameliorating the effects of the disease, i.e., cause regression of the effects of the disease.
- disease means an impairment of health.
- the disease may be any disease caused by P. multocida, which causes numerous diseases in animals, including fowl cholera in avian species, hemorrhagic septicaemia in ungulates, shipping fever and pneumonia in cattle, atrophic rhinitis in swine, and snuffles in rabbits.
- the bacterium also causes infections in humans, primarily through dog and cat bites.
- condition means abnormal functioning, and may be any condition caused by P. multocida.
- diagnosis means identifying the nature or cause of a disease or condition, such as the diagnosis of P. multocida infection.
- the invention further relates to diagnostic assays, particularly but not solely for use in veterinary medicine.
- diagnostic assays For diagnosis of P. multocida infection status, the presence of antibodies to the OMP of P. multocida in animal serum is determined.
- Many types of test formats may be used. Such tests include, but are not limited to, immunofluorescence assay, radioimmunoassy, radioimmunosorbent test, enzyme-linked immunosorbent assay, agglutination and hemagglutination.
- the diagnostic assays can be performed using standard protocols.
- a diagnostic assay of the invention can be constructed by coating all or a unique portion of the OMP polypeptide or peptide, or an isolated P. multocida preparation (the antigen) on a solid support, for example a plastic bead, a test tube, a fibre strip, a microtitration plate or a membrane, and contacting it with the serum or other physiological fluid taken from a subject suspected of having a P. multocida infection. Following removal of the physiological fluid, any antibody bound to the immobilized antigen can be detected, preferably by reacting the binary antibody- antigen complexes with a "detection antibody" , which comprises a detectable label or a binding site for a detectable label .
- Suitable detectable labels are enzymes, fluorescent labels or radiolabels. Binding sites for detectable labels include avidin, biotin, streptavidin and the like.
- all or a unique portion of the antigen is bound to an inert particle, for example a bentonite, polystyrene, or latex particle.
- the particles are mixed with serum from a subject in a well of a plastic agglutination tray. The presence or absence of antibodies in the subject's serum is determined by observing the settling pattern of the particles in the well .
- Isolated surface polypeptides, nucleic acids, and/or antibodies of the invention may be administered to a subject in an amount effective to elicit an immune response specific for P. multocida.
- Methods and pharmaceutical carriers for preparation of pharmaceutical and veterinary compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 20th Edition, Williams & Wilkins, Pennsylvania, USA.
- the compounds and compositions of the invention may be administered by any suitable route, and the person skilled in the art will readily be able to determine the most suitable route and dose for the condition to be treated.
- Dosage will be at the discretion of the attendant physician or veterinarian, and will depend on the nature and state of the disease or condition to be treated, the age and general state of health of the subject to be treated, the route of administration, and any previous treatment which may have been administered.
- Two or more antigens of the invention may be administered simultaneously or at different times.
- the subject is a bird, and immunization results in an immune response which inhibits or prevents fowl cholera, or in the production of antibodies to the OMP employed as an immunogen. Both local and systemic administration is contemplated. Systemic administration is preferred.
- dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of the cytotoxic side effects.
- the carrier or diluent, and other excipients will depend on the route of administration, and again the person skilled in the art will readily be able to determine the most suitable formulation and dosage for each particular case.
- the dosage of recombinant bacteria required for efficacy will range from about 10 4 to about 10 12 , preferably about 10 5 to about 10 10 , and more preferably about 10 6 to about 10 9 , colony-forming units (CFU), although other amounts may prove efficacious.
- CFU colony-forming units
- the dosage required is about 1 pg to about 10 mg, preferably about 10 pg to about 1 mg, and more preferably about 100 pg to about 500 ⁇ g, although other dosages may be employed.
- the amount administered may be at dosages of at least about 1 pg to about 10 mg, preferably about 10 ⁇ g to about 1 mg, and more preferably about 100 ⁇ g to about 500 ⁇ g, although other dosages may provide beneficial results. Dosages within these ranges can be administered via bolus doses or via a plurality of unit dosage forms, until the desired effects have been obtained.
- the amount administered will vary depending on various factors, including, but not limited to, the specific immunogen chosen, the weight, physical condition and age of the subject, and the route of inoculation.
- the absolute weight of polypeptide or peptide in a given unit dosage form of vaccine can vary widely, and depends upon factors such as the species, age, weight and physical condition of the subject to be vaccinated, as well as the method of administration. Such factors can be readily determined by the veterinarian employing animal models or other test systems which are well known to the art.
- Vaccination schedules and efficacy testing for birds are well known to the art; e.g. see Rimler et al . , 1979; Schlink et al . , 1987; Wang et al . , 1994a,- Wang et al., 1994b; Zhang et al . , 1994; and Rimler et al . , 1981.
- Methods of purification of egg immunoglobulins are described in US patents No. 5367054, No. 5420253, and No. 4550019. Immunization in ovo is described in Australian patents No. 681189, No, 681697 and 727378 by Embrex, Inc.
- a unit dose of a protein or peptide vaccine is preferably administered parenterally, e.g. by subcutaneous or intramuscular injection.
- the proteins or peptides of the invention may also be conjugated or linked to an immunogenic protein, such as keyhole limpet haemocyanin (KLH) or albumin, to enhance their immunogenicity.
- an immunogenic protein such as keyhole limpet haemocyanin (KLH) or albumin
- KLH keyhole limpet haemocyanin
- synthetic peptides are coupled to KLH through the C-terminal cysteine of the peptide using the heterobifunctional reagent N- ⁇ -maleimidobutyric acid N-hydroxysuccinimide ester (GMBS; Sigma) according to the manufacturer's directions.
- GMBS heterobifunctional reagent N- ⁇ -maleimidobutyric acid N-hydroxysuccinimide ester
- the carrier-conjugated peptides are stored at-20°C until used. Two or more antigens of the invention may be administered simultaneously or at different times.
- the subject is a bird, and immunization results in an immune response which inhibits or prevents fowl cholera, or in the production of antibodies to the OMP employed as an immunogen.
- Both local and systemic administration is contemplated. Systemic administration is preferred.
- the invention also contemplates the production of maternal antibody, which is obtained from a female subject exposed to a recombinant bacterial preparation, a nucleic acid molecule, protein or peptide of the invention.
- a hen is vaccinated with at least one of the vaccine compositions of the invention. The hen then provides passive immunity to its progeny through the transfer of maternal antibody to the embryo.
- an egg-laying animal e.g. a chicken
- an egg-laying animal e.g. a chicken
- Antibody is recovered from the eggs, and then administered to susceptible subjects, e.g. turkeys, to provide passive protection.
- susceptible subjects e.g. turkeys
- the turkeys are subsequently exposed to live or killed P. multocida, or other compositions of the invention, to provide active protection.
- the compositions of recombinant bacteria which express the polypeptides of the invention may be administered as live, modified-live (attenuated) or inactivated bacteria, or as a combination of attenuated, inactivated, and/or live bacteria, or in combination with a protein or peptide of the invention, or any combination thereof .
- the bacteria may be inactivated by agents including, but not limited to, formalin, phenol, ultraviolet radiation, and ⁇ -propiolactone.
- Immunogenic compositions are typically prepared for injection or infusion, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection or infusion may also be prepared. The preparation may also be emulsified.
- the active ingredient may be mixed with diluents, carriers or excipients which are physiologically acceptable and compatible with the active ingredient (s) .
- Suitable carriers can be positively or negatively-charged or neutral avridine-containing liposomes, oil emulsions, such as live-in-oil; killed-in- oil, or water-in-oil emulsions; aluminium hydroxide; oil emulsion with terpene oils or squalene; or aqueous.
- Suitable diluents and excipients include water, saline, PBS, glycerol, or the like, and combinations thereof.
- the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH- buffering agents, and the like.
- Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions .
- excipients may be suspending agents such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, which may be a naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol ; d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate
- compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as those mentioned above.
- the sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol .
- acceptable vehicles and solvents which may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed, including synthetic mono-or diglycerides .
- fatty acids such as oleic acid may be used in the preparation of injectables.
- Such compositions are conventionally administered by parenteral injection.
- parenteral injection For example in birds, administration is by intravenous injection, by intramuscular injection to breast, lung or thigh, by subcutaneous injection, wing web injection.
- administration is via the beak, by spraying the animals and their environment, e.g. their housing or yard, or may be in the drinking water or feed.
- the administration of maternal antibody or recombinant bacteria is preferably in feed or water. Protein or peptide is preferably administered via injection.
- Formulations which are suitable for other modes of administration include suppositories, cloacal formulations, insufflated powders or solutions, eye drops, nose drops, intranasal aerosols, and oral formulations, e.g. in drinking water.
- Oral formulations include such normally- employed excipients as pharmaceutical grades of alkylcelluloses, mannitol, dextrose, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
- these compositions can take the form of solutions, suspensions, powder tablets, pills, hard or soft gelatin capsules, sustained-release formulations such as liposomes, gels or hydrogels, and can contain about 10% to about 95% of active ingredient, preferably at about 25% to about 70%. The optimum proportions of active ingredient can readily be determined by those skilled in the art.
- One or more suitable unit dosage forms comprising polypeptides or peptides of the invention may optionally be formulated for sustained release.
- the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to pharmacy. Such methods may include the step of bringing the therapeutic agent into association with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.
- the polypeptide can be isolated as described above, lyophilized and stabilized. Alternatively the surface polypeptide may be modified so as to produce a derivative, as described above. The polypeptide antigen may then be adjusted to an appropriate concentration, optionally combined with a suitable carrier and/or suitable vaccine adjuvant, and preferably packaged for use as a vaccine.
- an “adjuvant” is a substance which augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level .
- An adjuvant may be added to a vaccine, or may be administered before administering an antigen, in order to improve the immune response, so that less vaccine is needed to produce the immune response.
- Widely-used adjuvants include alum, ISCOMs which comprise saponins such as Quil A, liposomes, and agents such as Freund's adjuvant, Bacillus Calmette Guerin (BCG) , Corynebacterium parvum or mycobacterial peptides which contain bacterial antigens.
- Other adjuvants include, but are not limited to, surfactants, e.g.
- polyanions e.g. pyran, dextran sulphate, poly IC, polyacrylic acid, and carbopol
- peptides e.g. muramyl dipeptide, dimethylglycine, and tuftsin
- oil emulsions and mixtures thereof.
- the immunogenic product may be incorporated into liposomes for use in a vaccine formulation, or may be conjugated to polysaccharides or other polymers.
- Some adjuvants are endogenous to the subject to be vaccinated; these include histamine, interferon, transfer factor, tuftsin and interleukin-1. Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e. affecting a restricted type of immune response to a narrow group of antigens .
- the subject may be a human, or may be a domestic, companion or zoo animal or bird.
- the compounds and compositions of the invention are suitable for use in veterinary treatment, including treatment of companion animals such as dogs, cats and rabbits, and domestic animals such as horses, cattle, buffalos, sheep, goats, pigs, rabbits and poultry, zoo animals such as non-human primates, felids, canids, bovids, lagomorphs, suids and ungulates, and zoo or other captive birds such as waterfowl, peacocks, pheasants and guinea fowl, they are also applicable to treatment of humans.
- companion animals such as dogs, cats and rabbits
- domestic animals such as horses, cattle, buffalos, sheep, goats, pigs, rabbits and poultry
- zoo animals such as non-human primates, felids, canids, bovids, lagomorphs, suids and ungulates
- zoo or other captive birds such as waterfowl, peacocks, pheasants and
- P. multocida strain x-73 was grown routinely at 37 0 C in brain-heart infusion broth (BHI) with constant aeration. Although the complete genome sequence is only available for P. multocida strain Pm70, this strain is not virulent in chickens, so we used strain X-73
- CDM chemically-defined medium
- P. multocida was harvested in stationary phase after growth for 16 h at 37°C in a modified chemically-defined medium (CDM; (Boucher et al, 2005)) containing 35mM Na 2 HPO 4 , 10 mM KH 2 PO 4 , 20 mM NaCl, 30 mM glucose, 0.1 mM orotic acid, 5 ⁇ M calcium panthothenate , 50 ⁇ M nicotinamide, 0.3 ⁇ M thiamine-HCl, 15 ⁇ M FeCl 3 , 750 ⁇ M cysteine, 20 mM L- aspartic acid, 750 ⁇ M L-tyrosine, 1.5 mM MgSO 4 , 1% (wt/vol) casamino acids (Difco) and supplemented with 200 ⁇ M 2 , 2 ' -dipyridyl where appropriate.
- CDM chemically-defined medium
- dipyridyl concentration chosen 200 ⁇ M was the highest concentration at which P. multocida grew to an A 65O > 0.7, and is very similar to concentrations used previously for iron-limited P. multocida microarray and protein expression experiments (Jacques et al, 1994; Paustian et al, 2001) .
- In vivo-grown bacteria were purified from blood obtained from infected chickens, as described previously (Boyce et al, 2002) .
- Leghorn cross chickens were infected with IxIO 4 CFU of P. multocida x-73, and the infection allowed to proceed for 16-22 h.
- Chickens were monitored closely for signs of infection, and the level of bacteraemia was assessed by blood smear.
- At the terminal stage of infection when bacteremia levels were approximately IxIO 10 CFU/ml, blood (15-40 ml) was recovered by terminal heart puncture .
- Bacteria were separated from the red blood cells by centrifugation for 1 h at 3,000 X g in the presence of 12.5% sucrose.
- Example 1 Preparation of P. multocida outer membranes by differential solubility in sarcosine
- sarcosine-insoluble outer membrane fraction of bacteria After growth in BHI .
- the sarcosine-insoluble membrane fraction is simpler to produce, and is as pure as outer membrane preparations prepared by other methods, including isopycnic sucrose gradients (Morton et al, 1996; Davies et al, 1990) .
- Triplicate samples of outer membrane material were prepared, and 2-DGE performed on each sample .
- OMPs of P. multocida were purified by sarcosine differential solubility as described previously (Zhao et al, 1995), with minor modifications.
- Unlysed cells were removed by two cycles of centrifugation at 10,000 X g, and the crude membranes collected by centrifugation at 150,000 X g for 1 h.
- Protein concentration was determined using the BCA Protein Assay reagent (Pierce) , and standardised aliquots of outer membrane material stored at -70°C until required.
- the outer membrane material was precipitated for 16 h at 4°C with acetone (10 vol) and resuspended directly in the appropriate sample buffer prior to gel electrophoresis.
- Example 2 2-DGE identification of protein spots and in-gel tryptic digests of proteins Acetone-precipitated outer membrane material from Example 1 was resuspended in ASB-14 (BioRad) and separated in the first dimension using IPG strips with a pH gradient of 3.0-10.0 and then resolved in the second dimension by 12.5% SDS-PAGE as described previously (Cullen et al, 2002) .
- 400 ⁇ g of outer membrane protein was separated on 17 cm IPG strips and resolved in the second dimension by large format (20 x 20 cm) SDS-PAGE. Because of the limited amount of outer membrane material recoverable from bacteria purified from the blood of chickens, 35 ⁇ g of membrane protein was loaded on to 7 cm IPG strips and resolved in the second dimension by small format (7 x 8 cm) SDS-PAGE.
- Proteins were visualised by sequential staining with Sypro Ruby (Molecular Probes, Eugene, Oregon) and Coomassie brilliant blue G-250 (Bio-Rad) . All 2-DGE analyses were performed on duplicate ⁇ in vivo-grown bacteria) or triplicate (in vitro-grown and iron-starved bacteria) biological repeats using different preparations of bacteria from different birds or flasks. As only duplicate biological replicates were available for in vivo-grown material, duplicate gels of each biological sample were run. Protein spots were excised, subjected to in-gel tryptic digestion, • and the tryptic peptides prepared for and analysed by MALDI-TOF MS as described previously (Cullen et al, 2002) .
- Peptide mass matches for proteins identified by 2-DGE from the sarcosine-insoluble membrane fraction of P. multocida grown in BHI.
- Protein names are as used in the Pm70 genome annotation (May et al, 2001) . In some instances the closest matching peptide was to a protein from a P. multocida strain other than Pm70, but for simplicity the orthologous Pm70 protein name has been used.
- b indicates the number of peptide masses obtained by MALDI-TOF MS which match the theoretical peptide masses derived by in sil ⁇ co tryptic digestion of the conceptual translation.
- c indicates the percentage of sequence covered by the matching peptides .
- spots 2 and 3 contained more than one protein per spot .
- Spots 2 and 3 contained both TufA and TufB, while spot 26 contained both PmO786 and Pral720.
- TufA and TufB are very similar (99.2% identity), and have nearly identical predicted pi and mass.
- PmO786 and Pml720 do not have identical predicted pi and mass, but PmO786 is the most abundant P. multocida OMP, and occurs in at least eight resolvable isoforms, one of which appears to co-migrate with Pml720.
- the outer membrane profile was analysed after harvest of the bacteria in stationary phase, exponential phase and after growth in CDM. No significant differences between these growth stages were observed in the outer membrane protein profile.
- D LC MS/MS Standard 2-DGE protocols are generally biased against very large and hydrophobic proteins, which may be difficult to solubilize, and against very basic or acidic proteins, which are not adequately resolved during the IEF step (Ong & Pandey, 2001; Bunai & Yamane, 2005) .
- modifications to the standard 2 -DGE protocols which substantially reduce these biases have been described (Bunai & Yamane, 2005; Drews et al, 2004), in order to maximise the coverage of OMPs identified we used a different identification technique.
- porcine trypsin Promega
- 5 ⁇ l of the digest were initially loaded and desalted on to the ⁇ -precolumn in buffer A at a flow rate of 30 ⁇ l/min for 5 min.
- the desalted peptides were washed from the ⁇ - precoluran and loaded onto the analytical column at a flow rate of 320 nl/min.
- the peptides were eluted directly into an esquireHCTTM ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany), using a linear gradient of 4-64% acetonitrile over 35 min at a flow rate of 320 nl/min.
- the esquireHCTTM was equipped with an online nanoElectrospray source (Bruker Daltonics, Bremen, Germany) , consisting of a PicotipTM adapter (New Objective, Woburn, MA, USA) to connect the tubing from the nanoLC system to a tip-end coated fused silica needle with 10 ⁇ m i.d. (New Objective) .
- the io ⁇ trap was operated in the positive ion mode at a MS scan speed of 8100 m/z/sec and a fast Ultra Scan of 26,000 m/z/sec for MS/MS analysis.
- the capillary voltage was set to 1500 V
- the drying gas (N 2 ) was set to 3 litres/min and 150 0 C.
- the peptides were fragmented using auto-MS/MS with the SmartFragTM option, which ramps the fragmentation energy automatically across a certain range of excitation amplitudes (0.5 to 2).
- Data analysis and MS/MS database searching was performed using DataAnalysisTM 3.1, BioToolsTM 2.2 (Bruker Daltonics) and MASCOT (Matrix Science Ltd) .
- the sarcosine-insoluble fraction was separated by 1-D SDS-PAGE and proteins visualized by Coomassie brilliant blue G-250 staining, as illustrated in Fig. 2 lane 1.
- the entire gel lane was excised into eight equal strips, and the proteins within the gel fragments were reduced, alkylated and digested with trypsin.
- the released tryptic peptides were analysed by nanoLC MS/MS, resulting in the identification of 29 unique proteins (significance of p ⁇ 0.05) by comparison with both the GenBank database and a specific P. multocida strain Pm70 database. Many proteins were identified from more than one gel slice. These results are summarised in Table 2. Of the proteins listed, the following have not previously been shown to be associated with the P.
- multocida outer membrane PM0336, PM0337, HyaD, PM0300, PM0803, PM1600, ParC, PfhR, FusA, Wst, HyaE, PM1809, AtpA, PM0527, PepP, GIyA, TrpB, TufA, OmpH_2, RecA, AsnA, MreB, MgIC, PM1578, PM1426, ThyA, PM0998, PIpB, RpS2, VacJ, PM1021, PM0442, TorD, RpL5, FIdA, PM1480 and PMO979.
- a Protein names are as used in the Pm70 genome annotation (May et al, 2001) . In some instances the closest matching peptide was to a protein sequenced from a P. multocida strain other than Pm70, but for simplicity the orthologous Pm70 protein name has been used. For HyaD the protein name from P. multocida strain X-73 (Chung et al, 1998) has been used; there is no true orthologue of this protein in Pm70, as it is of a different capsular type. Proteins are listed in order of decreasing molecular weight.
- b Lane indicates the gel lane from which the protein was identified (Fig. 2) .
- Lane A contained sarcosine- insoluble membrane material from bacteria grown in BHI while lane B contained sarcosine-insoluble membrane material from bacteria isolated from the blood of chickens .
- c The 1-D gel slice from which the protein was identified. In some instances the protein was identified from more than one gel slice. Gel slice 1 was from the highest MW region of the gel while gel slice 8 was from the lowest
- d Indicates the number of peptides obtained by nanoLC- MS/MS which match the theoretical peptides derived by in silico tryptic digestion of the conceptual translation.
- TrpB CYT NP tryptophan synthase beta chain TufA CYT CYT translation elongation factor EF-Tu TUfA CYT CYT translation elongation factor EF-Tu
- a Protein names are as used in the Pm70 genome annotation (May et al , 2001) .
- CYT cytoplasmic location;
- IM inner membrane- associated;
- PER periplasmic location;
- OM outer membrane- located, SEC, secreted;
- NP no prediction.
- the COGs functional categories are: C, Energy production and conversion; E, Amino acid transport and metabolism; G, Carbohydrate transport and metabolism; I, Lipid transport and metabolism; J, Translation; L, Replication, recombination and repair; M, Cell wall/membrane biogenesis; P, Inorganic ion transport and metabolism; S, Function unknown (which includes categories R, General function prediction only and -, not in COGs) ; e Predicted protein function or known function of the closest orthologous protein. f Proteins identified by both 2 -DGE MALDI-TOF MS and 1-D LC MS/MS methods
- Example 5 P. multocida outer membrane profile after growth in iron-depleted medium Iron is essential for growth in almost all bacterial species, but the in vivo concentration of iron in avian hosts is too low to sustain normal growth
- OMPs separated by 2-DGE were quantified by densitometric analysis using Melanie 4 (GeneBio, Geneva, Switzerland) . Protein spot quantities were calculated as a percentage of the total spot density on the gel, and log expression ratios defined as Log 2 [percentage spot density on the experimental gel (iron-limited) divided by the percentage spot density on the control gel (iron- replete) ] . All spot values of zero were "normalised” to a low positive value to allow expression values to be determined. Spots were quantified on triplicate gels (biological replicates) and the confidence value (CV) calculated as the standard deviation divided by the mean expression value. Three proteins (GIpQ, PmO527 and PmO612) were not identified consistently on the triplicate 2-DGE, so they were omitted from the analysis.
- Example 6 P. multocida OMP profile during growth in chicken blood in vivo
- the contaminating proteins were present at low levels, as they were not identified as significant spots present on the 2-DGE (Fig. 4) .
- Pm0803 and TufA were abundant constituents of these in vivo-derived ID LC MS/MS analysed samples, ' and were identified from 2 and 6 gel slices respectively, thereby corroborating the 2-DGE and MALDI-TOF MS data.
- ORFs were analysed for cellular localisation, using the PSORTB and ProteomeAnalyst web servers . Analysis was set for Gram-negative bacteria. Proteins were chosen for cloning if they met any of the following criteria: 1. Identified as outer membrane, extracellular or secreted proteins by PSORTB and Proteome Analyst;
- BLASTP analysis indicated identity to known autotransporter proteins from other species; 5. BLASTP analysis indicated identity to known OMPs from other species .
- ORFs open reading frames
- DH5 ⁇ as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. It is expected that by routine variation and optimization of conditions the remaining fusion proteins may also be expressed, provided that the encoded gene product is not toxic to the host cell.
- mice Approximately 25 ⁇ g of each of a subset of the antigens prepared in Example 7, plus aluminium hydroxide (Sigma) as an adjuvant, was injected subcutaneousIy into 5 mice, followed by a booster injection also using aluminium hydroxide.
- the following antigens were used: PM0076, PM1064, PM1451, PM1578, PMl611, PM1614, PM1717, PM1746, PM1805, PM1809, PM1826, PM1827, PM1886, PM1897, PM1905, PM1980, PM1993 and PM2008.
- Each group of mice, including an unvaccinated control group was then challenged intraperitoneally with 100 CFU of live virulent P.
- mice were monitored for clinical symptoms, and euthanised in accordance to animal ethics requirements.
- the protective capacity of the antigen was assessed by the lack of clinical symptoms or a delay in onset of clinical symptoms in the vaccinated mice compared to unvaccinated controls.
- Example 9 Protection studies in chickens Purified recombinant OMP is mixed with Alhydrogel (Sigma) 0.25 mg/ml .
- the birds are divided into groups with 4 to 10 birds per group.
- Test groups are injected intramuscularly with purified recombinant protein preparation up to 100 ⁇ g protein (0.5 ml) per bird.
- a positive control group 4 is injected intramuscularly with P. multocida X-73 bacterin prepared as described previously (Wang et al . , 1994a; Wang et al . , 1994b) .
- a negative control group is not vaccinated.
- the birds are vaccinated twice, at an interval of 2 to 3 weeks between vaccinations. Fourteen days after the second vaccination, a blood sample is taken from each bird and the birds are challenged with 100 CFU of P. multocida X-73. The birds are observed for 10-18 days after challenge, and mortalities are recorded.
- Antibody titres in the blood samples are determined by enzyme-linked immunosorbent assay (ELISA) .
- Immunoplates (Nunc, VWR Scientific, Bridgeport, New Jersey) are coated at 4 0 C overnight with 100 ng of the following antigens: recombinant OMP, and X-73 whole P. multocida cell lysate in carbonate buffer (pH 9.5). The plates are washed three times with 0.01 M PBS containing 0.05% Tween 20 (pH 7.2), followed by adding 200 ⁇ l of blocking buffer (PBS containing 1% bovine serum albumin) and incubated at room temperature for 30 minutes. After washing, 50 ⁇ l of antisera serially diluted with blocking buffer are added and incubated at room temperature for 30 minutes. After further washing, 50 ⁇ l of 1: 5000 diluted rabbit anti-chicken IgG conjugated to horseradish peroxidase (HRP) (Zymed Laboratories, Inc., San
- TMB 3,3', 5,5'- tetramethylbenzidine
- Antibody levels in chicken blood may also be assessed by western blotting.
- Antigens consisting of P. multocida whole cells, purified recombinant proteins or E. coli cells expressing the recombinant proteins are separated by ID SDS-PAGE as described above. Separated proteins are transblotted on to nitrocellulose membranes, pore size 0.45 ⁇ m (Schleicher and Scheuell, Dassel, Germany) using a BioRad transblot cell or equivalent apparatus at 75 V for 1 hour in transblot buffer consisting of 1.52 g Tris, 7.21 g glycine and 100 ml methanol made up to 1 litre with distilled water.
- Membranes are then blocked for 30 minutes at room temperature with 3% bovine serum albumin in TBS-Tween. Membranes are then incubated with dilutions of chicken serum from 1/50 to 1/10,000 for 1 hour to overnight at either room temperature or 37°C. Membranes are then washed four times for 5 minutes in TBS-Tween and then incubated at 37 0 C for 2 hours with 1/100 to 1/10,000 dilutions in TBS-Tween of peroxidase-conjugated goat or rabbit anti-chicken immunoglobulins. Membranes are then washed four times for 5 minutes in TBS-Tween and once in TBS.
- Detection is achieved by incubating the membranes in the dark at room temperature in substrate solution consisting of 25ml TBS, 15 ⁇ l of 30% (vol/vol) hydrogen peroxide added to 5 ml methanol with 30 mg 4-chloro-l- naphthol until the desired colour level is obtained. Membranes are washed several times in distilled water and stored in the dark at room temperature .
- Example 10 Identification of protective antigens This experiment was aimed at identifying vaccine antigens capable of protecting chickens from the devastating effects of P. multocida, the causative agent of fowl cholera. The objective was to identify which of the expressed recombinant proteins offers a degree of protection from the lethal effects of P. multocida. challenge. Sixty-seven candidate antigens were tested individually. Three multivalent vaccination groups were also tested, giving a total of 70 vaccinated groups.
- the trial was performed using commercial layer hens 12 weeks of age (288 birds) .
- the birds were randomly assigned to two rooms, each containing 12 pens with 12 birds in each pen. All birds were wing-tagged.
- Each treatment group consisted of four birds, so each pen housed three treatment groups, resulting in a total of 70 treatment groups (70 antigens) .
- chickens Prior to challenge, chickens were vaccinated subcutaneousIy with 0.5 ml of vaccine, containing 50 ⁇ g purified recombinant protein which was mixed with 0.5 ml Alhydrogel (Sigma) . The vaccination was repeated two weeks later. In each room each of 35 groups of birds received a unique vaccine. In each room a 36th group of birds acted as unvaccinated negative controls .
- a further trial is carried out using 10 chickens per group in order to produce statistically significant results.
- amino acid sequences of the proteins used in this example are as follows:
- PM1730 (SEQ ID NO : 6) MKLTKLFG]-ATLVSAVALAGCKDDKPAAAAAPQEPAARKLTVGVMTGAEAQVTEVAA KIAKEKYNIDVKLVEFTEYTQPNDALTKGDLDANAFQHKPYMDKEVEQRGYKLAIVG NTFVFPIAAYSKKIKNVSELQDGATVAVPNNPSNLGRALLLLEKQGLIKLKDPSNLF STS IDVI ENPKNLQ I KEVEGSLLPRMLDDVDFAI INNNYAVQQGLTAEKDGI FVEDK DSPYVNLWSREDNKDNEAIKDFVKAFQTEEVYQEALKHFQGGWKGW
- PM1614 ( SEQ ID NO : 10 ) MKKSFLLLPISVAVLAACSSNTPAPVESADGSLSPGMMQPVDASSGGTWEPQIQQQN TMPAGMDQSVYSPSTSQPSLPVSHQPTPPTSSSFDIPRKPVTGEPDYSKIARGSYQG ESYTVRKGDSMYLISYISGLSIKEIAALNNLSEPYTLATGQVLKLSNKVSTTSTMSP STAVGEVGTNVKPTTQHFEIPRNPADNRPDYSKIDKGFYKGETYTVRKGDTMYLIAY ISGLDVKELASLNNMSEPYRLSVGQTLRVSNGRVASTSSQPVTQPVTVPVSQPKSSE VTYTPGPHGTQYGSDGTIIGPIKSGVSSAPVPVQPEPWKPVESTSVPSTSSKHM VSNVTWQWPTKGNIVQGFSTADGGNKGIDIAGSRGQAVNAAAAGRWYAGNALRGYG NL
- GIpQ which was only identified by the 2-DGE MALDI-TOF MS
- 15 were predicted to be outer membrane or secreted proteins by at least one of the two subcellular localisation programs PSORTB or Proteome Analyst (Table 3) .
- Two proteins were predicted to be periplasmic, but both of these were predicted to be lipoproteins (LipoP; (Juncker et al, 2003)), and may be anchored to the outer membrane but oriented towards the periplasmic side; this is likely also to be the case for GIpQ (Lo et al, 2004) .
- the other 11 proteins were predicted to be either cytoplasmic (five) , inner membrane (four) , either cytoplasmic or inner membrane (one) , or not predicted for any location by either algorithm (one) .
- Orthologues of four of the predicted cytoplasmic proteins are well characterized in other bacterial species, and are likely to be true cytoplasmic contaminants.
- tufA and tufB which both encode elongation factor-Tu, are clearly normally located in the cytoplasm, they may be targeted to the outer membrane at certain times (Sedgwick & Bragg, 1986; Otto et al, 2001; Dallo et al, 2002; Berrier et al, 2000; and Marques et al, 1998) .
- Ef- Tu in Mycoplasma pneumoniae has been shown to be surface- located and involved in binding host fibronectin (Dallo et al, 2002) .
- TufA and TufB are legitimate components of the outer membrane .
- Two of the four predicted inner membrane proteins (RpS2 and MgIC) have well-characterised orthologues, and are likely to be inner membrane contaminants present in the sarcosine- insoluble membrane preparation, but PmO442 and PmlO21 have no well-characterised orthologues, and may be completely novel OMPs.
- PmlO21 has the following sequence:
- PmO527 is part of an efflux system involved in resistance to heavy metals.
- Pml426 has significant sequence identity with E. coli phospholipase A (Cronan & Rock, 1996) , so it is probably involved in phospholipid turnover in the P. multocida outer membrane.
- PmO786 is the major P. multocida OMP, and has significant sequence identity to E. coli OmpA, which is involved in outer membrane stability and also has porin properties (Nikaido 2003) .
- PmO998 has significant sequence identity to E. coli MipA, which is involved in the structure and synthesis of the murein sacculus (Vollmer et al, 1999) .
- Est and GIpQ may also play a role in outer membrane synthesis, as Est is predicted to be involved in lipid metabolism, while GIpQ is involved in salvage of the glycerol portion of ' phospholipids after breakdown.
- the other outer membrane proteins have no identity to characterised proteins, so their function in P. multocida is presently unknown.
- Bioinformatics analyses of the P. multocida genome sequence by either of the algorithms PSORTB or Proteome Analyst predicted that a combined set of 63 proteins was localized in the outer membrane. We identified 23 of these proteins, i.e. more than 1/3 of the predicted OMPs, in the sarcosine-insoluble membrane fraction. We also identified 10 of the 18 P. multocida porins identified in the superfamily database (Madera et al, 2004) , although two of these (PfhR and Pm0803) were identified only under in vivo or iron-limited growth conditions. Clearly some OMPs will not be expressed under the conditions which we have tested so far, but will be expressed under other conditions.
- the proteins Pm0803, TufA and TufB were identified as up-regulated in response to the in vivo host environment by the 2-DGE proteomic analysis.
- the transcriptional response of P. multocida to growth in vivo in chickens has been analysed previously using DNA microarrays (Boyce et al, 2002; Boyce et al, 2004) .
- the pm0803 gene was up-regulated during growth in the host chicken in five of six infections, again indicating agreement between the microarray and proteomics data.
- tufA and tufB were not measured as up-regulated in vivo by the DNA microarrays.
- coli TufA and TufB have been shown to be preferentially targeted to the periplasm under stress conditions (Berrier et al, 2000) , and therefore the increased levels measured in the outer membrane of P. multocida appear to be due to differential targeting and not to an increased level of transcription.
- proteins which we postulate to be components of the P. multocida outer membrane. These proteins include numerous predicted porins and specific transporters, including those predicted to be involved in the transport of iron- containing compounds, amino acids, lipids and carbohydrates .
- We also identified a putative iron- regulated porin (Pm0803) which was highly up-regulated under both in vivo and iron-limited growth conditions.
- Botzler R. G., Ann N. Y. Acad Sci 2002, 969, 224-8.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
This invention relates to bacterial proteins, and in particular to the identification of surface proteins of the bacterial pathogen Pasteurella multocida which are useful as antigens for vaccines. Immunogenic proteins which are able to elicit protective immunity are disclosed and claimed.
Description
SURFACE PROTEINS OF PASTEURELLA MULTOCIDA
PRIORITY
This application claims priority from Australian provisional application no. 2005903721 filed on 13 July 2005, the entire disclosure of which is incorporated herein by this reference .
FIELD This invention relates to bacterial proteins, and in particular to the identification of surface proteins of the bacterial pathogen Pasteurella multocida which are useful as antigens for vaccines.
BACKGROUND
All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents . It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
Pasteurella multocida is a Gram-negative bacterial pathogen which is the causative agent of numerous diseases in animals, including fowl cholera in avian species, hemorrhagic septicaemia in ungulates, shipping fever and pneumonia in cattle, atrophic rhinitis in swine, and snuffles in rabbits. The bacterium also causes infections in humans, primarily through dog and cat bites.
P. multocida strains can be differentiated serologically into 5 distinct capsular groups, respectively designated A, B, D, E and F, and 16
lipopolysaccharide (LPS) types, respectively designated 1 to 16.
Fowl cholera, which is generally caused by serotypes A:l, A:3 or A:4, is a severe respiratory disease which occurs in domestic poultry and wild birds. This disease occurs throughout the year, and results in significant economic losses to poultry industries worldwide. For example, fowl cholera costs the turkey industry millions of dollars annually due to deaths, condemnation losses, and vaccination and medication costs. Regular outbreaks also occur in wild bird populations, resulting in high mortality.
Fowl cholera has two clinical forms: acute disease and chronic disease. The acute disease is a septicaemia with high morbidity and mortality. Clinical signs of the acute disease include fever, anorexia, ruffled feathers, mucous discharge from the mouth, diarrhoea, increased respiratory rate and cyanosis. Death may be the first evidence of acute disease. The chronic form of fowl cholera is characterized by localized infections, including swelling in wattles, sinuses, periorbital subcutaneous tissues, leg or wing joints, sternal bursae and foot pads, exudative conjunctivitis, pharyngitis, emaciation and lethargy. Almost all types of birds, including chickens, turkeys, ducks and geese, are susceptible to P. multocida infection.
Haemorrhagic septicaemia is a fatal systemic disease of cattle and buffalos. P. multocida is the major cause of pasteurellosis in dairy calves, and is the second most common bacterium isolated from fibrinous pneumonia in beef cattle. In the United States, P. multocida A: 3 is the second most common bacterium isolated from' shipping fever in beef cattle and the major cause of fibrinopurulent bronchopneumonia in dairy calves . In South Asia haemorrhagic septicaemia is caused by infection with P. multocida serotype B:2.
P. multocida is a well-known cause of morbidity
and mortality in rabbits. The predominant syndrome is upper respiratory disease or "snuffles" . P. multocida is often endemic in laboratory and other rabbit colonies, and the acquisition of infection in young rabbits is correlated to the prevalence in adult rabbits .
The Australian chicken industry produces products with a retail value of more than $2.5 billion. A number of bacterial diseases, including fowl cholera, pose a threat to the industry. At present these diseases are largely kept in check by the use of antibiotics provided in animal or bird feed, but antibiotics have limited effectiveness, and there is pressure on the agricultural industry to curtail or eliminate their use. It has been estimated that fowl cholera costs the Australian poultry industry between $3 and $6 million per year in lost production (1998 figures) . There is a clear need in the art for alternative control measures which do not utilise antibiotics.
Current vaccines against fowl cholera include killed whole cells and live naturally attenuated strains. Two kinds of vaccines are used in poultry, the inactivated vaccines (bacterins) and attenuated live vaccines. However, both vaccine types have significant drawbacks. Killed whole cell (bacterin) vaccines elicit only limited protection, restricted to strains which express homologous LPS types i.e. provide serotype- specific protection. As there are currently 16 somatic serotypes, the efficacy of bacterins is very limited. Although live attenuated strains, such as those which employ the CU, PM-I and M-9 strains, can induce heterologous immunity giving long-term protection against strains expressing heterologous LPS types, they themselves can revert to virulence and induce disease .
Vaccines are also available for use in cattle; however, these vaccines too are of questionable efficacy, and in particular the efficacy of current P. multocida vaccines in bovine pneumonia has not been critically evaluated. There is therefore a need for the
identification of suitable antigens which can form the basis of vaccines suitable for use in a variety of species .
The basis of immunity in fowl cholera has not yet been defined precisely, but it is known that birds exposed to P. multocida are protected against challenge, and passive immunisation experiments have shown a major role for humoral immunity. Although most P. multocida strains express a polysaccharide capsule, strong protection can be elicited in the absence of capsule, implicating LPS and OMPs as the major protective antigens. However, birds vaccinated with killed in vitro-grown P. multocida are protected only against P. multocida strains expressing homologous LPS types. In contrast, it has been shown that birds vaccinated with either killed in vivo-grown P. multocida or live attenuated strains are protected against strains expressing heterologous LPS types.
P. multocida OMP is able to induce protective immunity in poultry and other animals. Moreover, it has been reported that OMPs expressed by in vivo-grown bacteria induced heterologous protection (cross- protection) in poultry. However, the OMP antigens used in these studies were not purified proteins; crude chromatographic fractions were used in one study, and the other found that adsorbed antisera reacted with a number of proteins with various molecular masses. Nonetheless, these findings are consistent with the hypothesis that OMPs are important for protective immunity, and that those OMPs expressed exclusively in vivo are critical for protection against heterologous LPS serotypes . International patent application No. PCT/US98/25990, the entire disclosure of which is incorporated herein by reference, discloses the isolation of nucleic acids encoding the major outer membrane protein, OmpH, of the virulent P. multocida strains X-73 and P-1059, and proposes the use of these OMPs in vaccines for fowl cholera. Fragments of OmpH and
synthetic cyclic peptides designed to mimic the native conformation of the largest loop, loop 2, of OmpH are also disclosed. However, only a few antigens were examined, and only limited homologous protection was obtained.
In order to search for protective antigens against P. multocida, it is essential to have a more complete understanding of the P. multocida OMPs and their response to the host environment .
SUMMARY
We therefore sought to characterise some of the constituents of the surface of P. multocida. We also investigated whether the expression of the P. multocida sub-proteome changed in response to environmental conditions, firstly in vitro during culture in medium with low iron concentration, which partially mimics the conditions found in host tissues, and secondly during infection of a major natural host, the chicken. In particular we sought to identify surface proteins of P. multocida which are able to elicit protective antibodies.
In a first aspect the invention provides an isolated immunogenic P. multocida surface polypeptide, or a fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH_l, P6-like protein (also known as 0mpl6 or PmO966) , PIpB, GIpQ, Lpp, OmpA (also known as PmO786) , or Oma87 (also known as Pml992) .
It will be clearly understood that the invention also encompasses biologically-active fragments, variants and derivatives of the polypeptides of the invention. Preferably a fragment according to the invention corresponds to one or more extracellular domains of a nucleotide surface polypeptide. Preferably the polypeptide of the invention is an outer membrane protein, and may comprise an extracellular domain, for example from loop 2. The polypeptide may be a recombinant or synthetic
polypeptide. In one embodiment the polypeptide elicits an immune response which is protective against infection with P. multocida. Preferably the polypeptide provides heterologous protection, i.e. protection against at least two different serotypes of. P. multocida. In another embodiment the polypeptide elicits antibodies which bind specifically to a P. multocida surface polypeptide, and which may or may not be protective. Such antibodies are useful in immunoassays . In either of these embodiments the antibody may be a neutralizing antibody.
In one embodiment the polypeptide is from P. multocida serotype A, A:l, A: 1,4, A:2, A: 3, A:3,4, A: 4, A:5, A:7, A:10, A:12, B, B : 2 , B:2,5, E:2, E:2,5, D, E or F. In a particular embodiment the polypeptide is from serotype A:l, A: 3, A: 4, or B:2,
In one embodiment the polypeptide is selected from one or more of the group consisting of : a) a protein involved in transport of molecules across a P. multocida outer membrane; b) a protein involved in iron uptake; c) a protein involved in transport of nutrients; d) a protein involved in resistance of P. multocida to heavy metals,- and e) a protein involved in synthesis or structural stability of the outer membrane.
Preferably the polypeptide is expressed more strongly when the bacterium is grown in vitro under iron- depleted, anaerobic or amino acid-depleted conditions, or when it is grown in vivo. In one embodiment the polypeptide is exclusively expressed in vivo.
In one embodiment the polypeptide is one or more selected from the group consisting of est, mglC, ompH_2, ompW, parC, pepP, pfhR, PM0300, PM0336, PM0337, PM0442, PM0527, PM0612', PM0803, PM0979, PM0998, PM1021, PM1064, PM1069, PM1426, PM1578, PM1600, PM1720, PM1809, rpS2, torD, trpB, tufA, tufB and vacJ. In particular embodiments the polypeptide is selected from the group consisting of PM0388, PM0442, PM0554, PM0659, PM0741,
_ <η _
PM0786, PM0903, PM0966, PM0979, PM1050, PMl614, PM1614, PM1730, PM1979, PM1992, and PM1993. In even more particular embodiments the polypeptide is selected from the group consisting of PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730.
The polypeptide may be fused to a heterologous polypeptide, such as a solubility tag, an affinity tag, or an immunogenic carrier protein.
A polypeptide of the invention, or a biologically fragment, derivative, or variant thereof, is useful in immunogenic compositions to prepare antisera or vaccines. A fragment of a polypeptide of the invention, such as a peptide, or variant or derivative thereof, is also useful in assays to detect antibodies specific for the peptide or for a polypeptide of which a portion has an amino acid sequence corresponding to an epitope within the peptide. Peptides of the invention may be modified, for example by cyclization as a result of disulphide bond formation. In a second aspect the invention provides an antibody which specifically binds to a polypeptide of the invention, or to a biologically active fragment, derivative, or variant thereof. The antibodies of the invention are useful inter alia in providing passive immunity to a subject to which the preparation is administered, and in immunoassays for detection of polypeptides of the invention.
In a third aspect the present invention provides a composition comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, together with a physiologically-acceptable carrier.
The invention further provides a vector comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, and a host cell comprising the vector. Preferably the vector is an
expression cassette, and may comprise a preselected DNA sequence which is operably linked to a promoter which is functional in the host cell, in which the DNA sequence encodes one or more P. multocida surface polypeptides of the invention. The host cell may be prokaryotic or eukaryotic in origin.
In a fourth aspect the present invention provides a method of treating or preventing a disease or condition caused by P. multocida, comprising the step of administering a polypeptide and/or antibody of the invention, or a biologically active fragment, derivative, or variant thereof, to a subject suffering from, suspected to be suffering from, or at risk of such a condition. In a fifth aspect the present invention provides a method of diagnosing a disease or condition caused by P. multocida, comprising the step of detecting a polypeptide, antibody, and/or nucleic acid molecule of the invention, or a fragment, derivative, or variant thereof, in a biological sample from a subject suffering from, suspected to be suffering from, or at risk of such a condition. Detection of the nucleic acid molecule, or fragment, variant or derivative thereof may for example be achieved by nucleic acid amplification. Thus the method of diagnosis may comprise contacting a sample of DNA obtained from a biological sample from a subject at risk of or suffering from P. multocida infection with at least two oligonucleotides which bind to complementary strands of said DNA at preselected regions under conditions effective to amplify the DNA, so as to yield amplified DNA. The amplification may be effected by conventional methods, such as polymerase chain reaction. Alternatively the DNA may be obtained by reverse transcription of RNA from the cells. At least one of the oligonucleotides may be specific for DNA encoding an OMP of P. multocida. The presence of amplified DNA is then detected or determined by conventional methods. The presence of amplified DNA is
- S -
indicative that the subject is infected with P. multocida. It will be appreciated that any convenient biological sample from the subject may be used, including but not limited to blood and other biological fluids, sputum, and tissue samples.
In a sixth aspect the present invention provides the use of a polypeptide, antibody and/or nucleic acid molecule of the invention or a biologically active fragment, derivative, or variant thereof, in the treatment or prevention of a disease or condition caused by P. multocida.
In a seventh aspect the present invention provides the use of a polypeptide, antibody and/or nucleic acid molecule of the invention, or a biologically active fragment, derivative, or variant thereof, in the diagnosis of a disease or condition caused by P. multocida. The disease or condition may be diagnosed following nucleic acid amplification.
The subject may be suspected of having the disease or condition, or may have been, or may be suspected to have been, exposed to a subject known or suspected to be infected with P. multocida.
In an eighth aspect the invention provides a composition comprising a polypeptide or nucleic acid molecule of the invention, or a biologically active fragment, derivative, or variant thereof, together with a pharmaceutically or veterinarily acceptable carrier. The composition may be a vaccine, and may further comprise an adjuvant. In one embodiment the vaccine elicits an immune response which is protective against infection with P. multocida. Preferably the vaccine provides heterologous protection, i.e. protection against at least two different serotypes of P. multocida. In another embodiment the vaccine elicits antibodies which bind specifically to a P. multocida surface polypeptide, and which may or may not be protective. Such antibodies are useful in immunoassays. In either of these embodiments the antibody may be a neutralizing antibody.
In a ninth aspect the invention provides a method of preparing a plurality of nucleic acid molecules encoding candidate P. multocida surface proteins, comprising: a) identifying specific P. multocida nucleic acid sequences, and b) cloning the nucleic acid sequences of a) .
Preferably the identification is on the basis of one or more of : a) the predicted cellular location of the encoded protein; b) the similarity of the encoded protein to a protein with a putative or confirmed role in infection and immunity; and c) subtractive hybridisation of a nucleic acid sequence specific to a virulent P. multocida strain, which is preferably from chickens, swine, cattle, or rabbits. More preferably the nucleic acid is specific to a strain from chickens, for example strain X-73, strain P-1059 or strain VP161.
In a tenth aspect the invention provides a plurality of nucleic acid molecules prepared by the ninth aspect of the invention. The invention further provides a plurality of polypeptides encoded by the plurality of nucleic acid molecules of the tenth aspect of the invention.
In an eleventh aspect the invention provides a kit comprising one or more of a polypeptide, antibody, and/or nucleic acid molecule of the invention, or a fragment, derivative, or variant thereof. The kit may be used as a diagnostic kit, and may comprise one or more pairs of nucleic acid molecules which can be used as primers for nucleic acid amplification.
In one embodiment the kit is a diagnostic kit for detecting the presence of DNA associated with P. multocida in a sample, in which the kit comprises: (a) a known amount of a first oligonucleotide which consists of at least about 7, 8, 9, 10, 11, 12, 13, 14,
- ll -
lS, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 to about 50 nucleotides, in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleic acid molecule of the invention;
(b) a known amount of a second oligonucleotide, in which the second oligonucleotide consists of at least about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 to about 50 nucleotides, and in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleotide sequence which is complementary to a nucleic acid molecule of the invention; and optionally
(c) reagents for nucleic acid amplification. Preferably the first oligonucleotide consists of at least about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 to about 40 nucleotides, and even more preferably about 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 to about 25 nucleotides. Also preferably the second oligonucleotide consists of at least about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 to about 40 nucleotides, and even more preferably about 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 to about 25 nucleotides. The skilled person will be able to optimize the oligonucleotides using methods known in the art.
In a twelfth aspect, the invention provides a method for detecting a nucleic acid molecule encoding a surface polypeptide of P. multocida, comprising the step of contacting a nucleic acid obtained from a biological sample from a subject with at least two oligonucleotides, under conditions effective to amplify the nucleic acid so as to yield an amount of amplified nucleic acid, in which the biological sample comprises cells suspected of
containing a nucleic acid molecule encoding an immunogenic polypeptide, and at least one of the oligonucleotides is specific for a nucleic acid encoding a surface polypeptide of the invention, i.e. is able to hybridise to the nucleic acid under stringent conditions . Suitable conditions are well known in the art. The presence of the amplified nucleic acid may be detected by conventional methods, such as ethidium bromide or silver staining. A variety of other methods is known in the art. In a thirteenth aspect the invention provides a method of identifying an immunogenic P. multocida outer membrane protein, comprising the steps of a) subjecting the genomic DNA sequence of P. multocida to genomic analysis; b) selecting candidate open reading frames according to the estimated vaccine antigen potential of the corresponding proteins, on the basis of the predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing proteins encoded by the open reading frames identified in step(d); f) isolating the expressed proteins; and g) testing the isolated proteins for ability to protect a test animal from challenge with virulent P. multocida.
In a fourteenth aspect, the invention provides a library of candidate immunogenic P. multocida. outer membrane proteins, prepared by a method comprising the steps of a) subjecting the genomic DNA sequence of P. multocida to genomic analysis;
b) selecting candidate open reading frames according to the estimated vaccine antigen potential of the corresponding proteins, on the basis of the predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing open reading frames identified in step(d); and f) isolating the expressed proteins.
Preferably the disease or condition caused by P. multocida. is one which affects an avian, ungulate, lagomorph or human subject. It will be clearly understood that ungulates include cattle and pigs, and lagomorphs include rabbits and hares. In one embodiment of the invention the subject is a bird. It will be appreciated that the invention is especially applicable to poultry, including chickens, turkeys, pheasants, ducks, geese, and guinea fowl, and to cattle, pigs and rabbits. It will be appreciated that the diagnostic, therapeutic and prophylactic aspects of the invention are also applicable to subjects which have been exposed to an animal or bird infected with P. multocida.
In one embodiment the P. multocida strain is one isolated from chickens, swine, cattle or rabbits. In a preferred form the isolate is from chickens, for example strain X-73, strain P-1059, or strain VP IGl.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows the results of 2-DGE of sarcosine-insoluble membrane fraction of P. multocida grown in BHI. Proteins were separated in the first dimension using a pH 3 to 10 IPG strip and in the second
dimension by 12.5% polyacrylamide gel electrophoresis. All numbered protein spots were analysed by MALDI-TOF MS, and matches are reported in Table 1.
Figure 2 shows the results of 1-DGE of the sarcosine- insoluble membrane fraction of P. multocida harvested after growth in BHI (lane 1) , or obtained from the bloodstream of terminally-infected chickens (lane 2) . Proteins were separated by 12% polyacrylamide gel electrophoresis and each lane cut into eight equal-sized sections, as shown by the marker lines at the left. The positions of standard molecular mass markers (lane 3) are shown on the right (KDa) .
Figure 3 shows the results of 2-DGE of the sarcosine-insoluble membrane fraction of P. multocida grown in CDM (A) or in CDM supplemented with 200 μM 2,2'- dipyridyl (B) . Proteins were separated in the first dimension using a pH 3 to 10 IPG strip, and in the second dimension by 12.5% polyacrylamide gel electrophoresis. Spot numbers are as given in Table 1, except for spot 38, which remained unidentified, and spots 39-42 which correspond to Pm0803. Proteins showing statistically significant differential expression across triplicate gels are indicated by rings .
Figure 4 shows the results of 2-DGE of the sarcosine-insoluble membrane fraction of P. multocida recovered after growth in BHI (A) or from the bloodstream of infected chickens in the terminal stages of fowl cholera (B) . Proteins were separated in the first dimension using a pH 3 to 10 IPG strip, and in the second dimension by 12.5% polyacrylamide gel electrophoresis. Spot numbers are as given in Table 1, except for spots 39, 41 and 43, which correspond to Pm0803. Proteins showing strong differential expression between the two conditions across all gels are indicated by rings. Figure 5 illustrates the results of Western blotting of sera from chickens immunized with recombinant surface proteins from P. multocida, showing that antibodies specifically recognising four of the six
putative vaccine candidates tested in this gel were elicited. Proteins are as follows: Lane 3 PM0442; Lane 4 PMO979; Lane 5 PMO659; Lane 6 PMl993; Lane 7 PMl614; Lane 8 PM1979; Lane 9 -; Lane 10 X-73 WC.
DETAILED DESCRIPTION
The surface of Gram-negative bacteria is critical for the interaction of the bacterium with the environment. It consists primarily of lipopolysaccharide (LPS), phospholipids and proteins. The LPS and phospholipids provide a significant permeability barrier to hydrophobic compounds, while the proteins known as, outer membrane proteins (OMPs) are generally involved in outer membrane stability and in transport of various molecules in and out of the cell. These OMPs include porins, which allow non-specific diffusion of charged and neutral solutes, and high affinity transporters, which mediate transport of specific ligands in and out of the cell. The expression of the various OMPs is influenced by the extracellular environment.
The surface of P. multocida has not previously been well characterized. Only seven P. multocida proteins have been experimentally shown to be present in the outer membrane; OmpH_l (Luo et al, 1997) , P6-like protein (0mpl6, PmO966) (Kasten et al, 1995) , PIpB
(Cooney & Lo, 1993), GIpQ (Lo et al, 2004), Lpp (Lo et al, 2004) , OmpA (PmO786) (Gatto et al, 2002) and Oma87 (Pml992) (Ruffolo et al, 1996) . Although there are several P. multocida. proteins which are probably orthologues of known OMPs in other species, including
OmpW and Omp47, there is no evidence of either their expression in P. multocida or of their sub-cellular localization in this species. OMPs may be involved in protective immunity in P. multocida infections, and OMPs expressed exclusively in vivo may be involved in stimulating immunity to serotypes expressing different LPS types. P. multocida virulence factors may be located on the cell surface, and these may include factors which
are critical for colonisation and invasion; these are important steps in pathogenesis which are at present poorly understood. However, specific factors have not yet been identified. Although it has been shown that PIpB protein probably gives 80-100% protection even against heterologous strains (Tabatabai and Zehr, 2004) , only affinity-purified protein was used as the immunising antigen, and this preparation may be contaminated with trace LPS or other protective antigens . Consequently the immunogenicity and protective capacity of this protein were not confirmed by these authors.
While the invention is described in detail with reference to isolates which are virulent in chickens, it will be appreciated that the methods described herein for genomic analysis and cloning are equally applicable to strains which are virulent for other species.
Known serotypes of P. multocida which are associated with major conditions include the following:
Haemorrhagic septicaemia of ungulates: B: 2; B: 2, 5; E: 2;
E:2,5 (Boyce et al, 2004)
Fowl cholera of birds: A:l, A:l,4, A:3, A:3,4, A:5, A:10, A: 12, F; rarely D and B (Snipes et al, 1989; Takahashi et al, 1996; Waltman and Home, 1993)
Snuffles of rabbits: A:l, A:2, A:3, A:4, A:5, A:7, A:12 (El Tayeb et al, 2004)
Pneumonic pasteurellosis : A, [A: 3], F, D (Blanco-Viera et al, 1995)
DEFINITIONS
In the description of the invention and in the claims which follow, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as
"comprises" or "comprising" is used in an inclusive
sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
As used herein, the singular forms "a" , "an" , and "the" include the corresponding plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a polypeptide" includes a plurality of such polypeptides, and a reference to "an amino acid" is a reference to one or more amino acids. Where a range of values is expressed, it will be clearly understood that this range encompasses the upper and lower limits of the range, and all values in between these limits.
It is to be clearly understood that this invention is not limited to the particular materials and methods described herein, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and it is not intended to limit the scope of the present invention, which will be limited only by the appended claims .
Unless otherwise indicated, the present invention employs conventional chemistry, protein chemistry, molecular biological and enzymological techniques within the capacity of those skilled in the art. Such techniques are well known to the skilled worker, and are explained fully in the literature. See, for example, Coligan, Dunn, Ploegh, Speicher and Wingfield: "Current protocols in Protein Science" (1999) Volumes I and II (John Wiley & Sons Inc.); Sambrook,
Fritsch and Maniatis: "Molecular Cloning: A Laboratory Manual" (2001); Shuler, M. L.: Bioprocess Engineering: Basic Concepts (2nd Edition, Prentice-Hall International, 1991); Glazer, A.N. , DeLange, R.J., and Sigman, D. S.: Chemical Modification of Proteins (North Holland
Publishing Company, Amsterdam, 1975); Graves, D.J., Martin, B. L., and Wang, J.H. : Co- and post-translational modification of proteins: chemical principles and
biological effects (Oxford University Press, 1994) Lundblad, R. L. (1995) Techniques in protein modification. CRC Press, Inc. Boca Raton, Fl. USA; and Goding, J. W Monoclonal Antibodies: principles and practice (Academic Press, New York: 3rd ed. 1996) .
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any materials and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred materials and methods are described.
The terms "isolated" and/or "purified" refer to an in vitro preparation of a molecule of the invention, or fragment, variant, or derivative thereof, so that the molecule is not substantially associated with molecules with which it normally occurs in vivo, and is substantially free of infectious agents . The terms "polypeptide" and "protein" are herein used interchangeably. Where they are used to refer to an amino acid sequence of a naturally-occurring polypeptide, these terms are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited polypeptide, but instead are meant also to encompass biologically active fragments, derivatives, or variants, including polypeptides having sequence similarity or sequence identity relative to the amino acid sequences provided herein. As used herein, the term "surface polypeptide" means a polypeptide naturally located on the outer surface of P. multocida, so that in vivo it is accessible to an immune response of a subject.
As used herein, an "outer membrane protein" or "OMP" is a polypeptide isolated from the outer membrane of P. multocida. Typically a portion of the OMP will be anchored in the outer membrane of a P. multocida bacterium, while another portion will be exposed on the
surface of the bacterium. The term OMP is used generically herein to encompass native OMPs, as well as variants, derivatives and fragments thereof.
As used herein, "extracellular domain" or ΛΕCD" refers to a form of a surface polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily an ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains or cytoplasmic domains identified for the surface polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of domain. An ECD of a surface polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary, with or without the associated signal peptide.
An "immunogenic" surface polypeptide is one which is able to induce a specific immune response.
Preferably the immunological response is an antibody response against the surface polypeptide, and may be directed to a particular epitope on the surface polypeptide. In one embodiment the presence of antibodies specific for that epitope in a biological sample from a subject correlates with the P. multocida infection status of the subject. In another embodiment the antibody is able to protect against infection with P. multocida, or reduces the severity of such infection. In either of these embodiments the antibody may be a neutralizing antibody, i.e. one which is able to inhibit a biological activity of the corresponding polypeptide or of P. multocida organisms.
A recombinant surface polypeptide of the invention may be purified from other cellular components to obtain a preparation which is substantially homogenous for the recombinant surface polypeptide. For example, the culture medium or lysate can be centrifuged to remove
particulate cell debris. The membrane and soluble protein fractions are then separated. The surface polypeptide may then be purified from the soluble protein fraction. Alternatively, the surface polypeptide may be purified from the insoluble fraction, i.e. refractile bodies or inclusion bodies; see, for example, U.S. Patent No. 4,518,526. The surface polypeptide may be purified from contaminant soluble or membrane polypeptides by conventional protein purification methods, such as fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocussing,- SDS-PAGE; ammonium sulphate precipitation; and gel filtration or ligand affinity chromatography. Sarcosine solubilization as described herein may also be used.
The recombinant surface polypeptide may be recovered from cell lysates in a soluble fraction, i.e. a fraction in which the recombinant polypeptide is not associated with membranes, in the insoluble fraction, in inclusion bodies or from supernatants . The recombinant protein may optionally be expressed as a fusion protein, for example in Escherichia coli.
A "biologically active" molecule according to the invention has at least about 1%, preferably at least about 10%, 11%, 12%, 13%, 14%, 15%, 1 6%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%%, 31%, 32%, 33%, 34%, 35%, 6%, 37%, 38%, 39% or 40%, more preferably at least about 50%, 51%, 52%, 53%, 34%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 9%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79% or 80%, and even more preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the activity of the corresponding native molecule. The activity of the molecule of the invention can be measured by methods well known to the art, including, but not limited to, measuring the ability of a polypeptide of the invention to bind to antibodies specific for the relevant
polypeptide or peptide, the ability of the polypeptide to elicit a sequence-specific immunological response when the polypeptide is administered to a subject, the correlation of P. multocida infection with the presence of amino acid sequences in the affected host corresponding to at least a portion of the polypeptide, or measuring the known normal function of the protein, e.g. ion transport .
It is envisioned that polypeptides within the scope of the invention may comprise moieties other than the amino acid sequences which are derived from the surface polypeptides of P. multocida, provided that these moieties do not substantially reduce the biological activity of the peptide. For example, the polypeptide may be directly linked to a sequence of amino acids which is not present in the native OMP of P. multocida, in order to form a fusion protein. A substantial reduction in activity means a reduction in activity of greater than about 99%. A "fragment" is defined as a portion or domain of a full length molecule of the present invention, which maintains a biological activity of the full length molecule. The molecule may be either a polypeptide or nucleic acid molecule. The fragment may be a peptide of a P. multocida surface polypeptide.
A "peptide" comprises no more than 75, preferably about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 to about 50, and more preferably about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 to about 40, peptidyl residues which have 100% contiguous amino acid sequence homology or identity to the amino acid sequence of a particular surface polypeptide of an isolate of P. multocida.
Preferably the peptides of the invention are homologous to regions which have variations in both sequence and length, e.g. loop 2 or loop 5, and which are immunogenic.
Also preferably the peptide corresponds to a region which comprises subtype-specific, or non-subtype specific, epitopes useful for homologous or heterologous protection respectively. The epitopes may be B-cell or T-cell epitopes .
Polypeptides which have been subjected to Chemical modifications, such as esterification, amidation, reduction, protection and the like, are referred to herein as "derivatives." In particular, it is envisioned that a derivative of a polypeptide of the invention may have been modified in a manner that increases its stability in vivo, or which presents immunogenic epitopes in a more native configuration. Methods for preparing such derivatives are well known in the art. For example, a modification known to improve the immunogenicity, stability and/or bioavailability of peptides in vivo is the cyclization of the peptide, for example by formation of one or more disulphide bonds, as described in PCT/US98/25990 (WO99/29724) . Another modification is the synthesis of a cyclic reverse sequence derivative (CRD) of a peptide of the invention, in which a linear peptide is synthesized with all D-form amino acids using the reverse (i.e. C-terminal to N- terminal) sequence of the peptide. The term "CRD" also includes cyclization by other mechanisms, e.g. via a peptidyl bond. Cyclized peptides with different kinds of linkages are known in the art; see EP 471,453 (amide bonds); EP 467,701 (disulphide bonds); EP 467,699 (thioether bonds) . Other modifications are disclosed in Jameson et al . 1994; U.S. Patent No. 4,992,463; and U.S. Patent No. 5,091,396.
For example, to cyclize peptides by oxidation of free cysteinyl thiol groups, the peptide (0.1 mg/ml) is reacted for 1 hour at O0C with iodine (1 mM in methanol) and the oxidation is then quenched with sodium thiosulphate . The mixture is subjected to reverse-phase HPLC on a semi-preparative Zorbax C8 column, followed by gel filtration on a Zorbax GF250 column. Two peaks which
are separated, by the gel filtration step are further analysed by mass spectroscopy, for example using an Applied Biosysterns Biolon 20 Biopolymer plasma desorption time-of-flight Mass Analyzer. The first peak is resolved by mass analysis into two species, a partially protected monomer peptide and a dimeric peptide. The material is tested for free cysteine thiol groups with Ellman' s reagent [5, 5-dithio-bis (2-nitrobenzoic acid); Sigma] at the highest concentration of peptide before saturation (20 mg/ml) . This peak represents the cyclic peptide, and is stored at pH 4.0 at -200C until used.
One preferred embodiment of the invention is an OMP peptide, or variant thereof, which has been cyclized by addition of one or more cysteine residues to the N and/or C terminus of the peptide with subsequent oxidation of the free cysteinyl thiol groups .
Linear reverse D (LRD) and cyclized forward L (CFL) derivatives are also within the scope of the invention. LRD derivatives have the reverse (i.e., C-terminal to N-terminal) sequence of the peptide with all D-form amino acids, but are not cyclized, are also included within the scope of the term "derivative" . CFL derivatives have the forward (i.e., N- terminal to C- terminal) sequence of the peptide with all L-form amino acids.), followed by oxidative cyclization, or cyclization by an alternative method.
For all of these cyclic variants, if the peptide sequence does not already have N and C terminal cysteine residues, additional cysteine residues may be added to the N and C termini, thereby allowing oxidative cyclization.
Once a given surface polypeptide has been isolated and characterized, derivatives of the polypeptide can be readily prepared. For example, amides of the surface polypeptide may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor, to an amide. A preferred method for amide formation at the C-terminal
carboxyl group is to cleave a peptide from a solid support with an appropriate amine, or to cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine. Salts of carboxyl groups of a polypeptide of the invention may be prepared in the usual manner by contacting the polypeptide with one or more equivalents of a desired base, such as a metallic hydroxide base; a metal carbonate or bicarbonate base; or an amine base. N-acyl derivatives of an amino group of a surface polypeptide of the invention may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected polypeptide. 0-acyl derivatives may be prepared by acylation of a free hydroxy peptide or peptide resin. Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. If desired, both N-and O- acylation may be carried out together. Formyl-methionine, pyroglutamine and trimethyl- alanine may be substituted at the N-terminal residue of the polypeptide, peptide or variant thereof. Other amino-terminal modifications include aminooxypentane modifications (see Simmons et al . , Science, 21Z, 276 (1997) ) .
The amino acid sequence of a polypeptide of the invention may be also modified so as to result in a variant. A "variant" may be a peptide comprising no more than 75 , p Preferably about 10, 11, 12, 13, 14, 15, 16, 17, 1 188,, 1 199,, 2 200, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32 , 33 , 34 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46 , 47 , 48 or 49 to about 50, and more preferably about
20 , 21 , 22 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34 , 35 , 36 37, 38, or 39 to about 40, amino acid residues, which has at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% or 70%, preferably at least about 80%, 81%, 82%, 83%, 84% or 85%, and more preferably at least
about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100%, contiguous amino acid sequence homology or identity to the amino acid sequence of the corresponding native surface peptide of P. multocida. Similarly a "variant" has at least 50%, 51%,
52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% or 70%, preferably at least about 80%, 81%, 82%, 83%, 84% or 85%, and more preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100%, contiguous amino acid sequence homology or identity to the amino acid sequence of the corresponding native surface polypeptide of a particular isolate of P. multocida. A variant polypeptide of the invention may include amino acid residues not present in the corresponding native surface polypeptide, and internal deletions relative to the corresponding native surface polypeptide.
Surface polypeptide variants of the invention include polypeptides and peptides in which at least one L- amino acid is replaced by the corresponding D-amino acid.
Possible modifications include the substitution of at least one amino acid residue in the polypeptide or peptide for another amino acid residue, including substitutions which utilize the D- rather than the L- form, as well as other well-known amino acid analogues. These analogues include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, γ-carboxyglutamate,- hippuric acid, octahydroindole-2-carboxylic acid, statine, 1, 2, 3 , 4, -tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citrulline, α-methyl- alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine.
One or more of the residues of the polypeptide or peptide may be altered, provided that the peptide variant is still biologically active. For example, it is preferred that the variant has at least about 10% of the biological activity of the corresponding non-variant
protein .
Conservative amino acid substitutions are preferred, e.g. aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids,- leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids. After the substitutions are introduced, the variants may be screened for biological activity. Amino acid substitutions falling within the scope of the invention are, in general, accomplished by selecting substitutions which do not differ significantly in their effect on maintaining
(a) the structure of the peptide backbone in the area of the substitution,
(b) the charge or hydrophobicity of the molecule at the target site, or
(c) the bulk of the side chain. Naturally-occurring amino acid residues are conventionally divided into groups on the basis of their common side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu,-
(4) basic: asn, gin, his, lys, arg,-
(5) residues which influence chain orientation: gly, pro; and
(6) aromatic; trp, tyr, phe. The invention also envisions polypeptide variants with non-conservative substitutions. Non- conservative substitutions entail exchanging a member of one of the classes described above for another.
Acid addition salts of amino residues of a polypeptide of the invention may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic acid, such as hydrochloric acid. Esters of carboxyl groups of the
polypeptides may also be prepared by any of the usual methods known in the art.
Other modifications include the reduction of cysteinyl thiol groups with 2-mercaptoethanol and carboxymethylation with iodoacetamide .
The surface polypeptides of the invention or fragments, variants or derivatives thereof can be prepared in vitro, e.g. by a solid phase peptide synthetic method or by a recombinant DNA approach. As used herein, a "fusion protein" is a polypeptide comprising two or more polypeptides that have been joined together, for example after transcription and translation of two or more fused nucleic acid molecules. The two or more polypeptides may be the same or different. That is, the fusion protein may comprise two or more copies of a surface polypeptide of the invention, copies of more than one different surface polypeptide of the invention, or at least one surface polypeptide of the invention fused to any other polypeptide. In one embodiment of the invention the fusion protein comprises at least an immunogenic or antigenic portion of a plurality of P. multocida outer membrane polypeptides.
If the surface polypeptide of the invention is expressed as a fusion protein, the fusion protein may be purified by methods specific for the surface polypeptide or non-surface polypeptide portion of the fusion polypeptide. For example, if the fusion polypeptide is a histidine-tagged fusion polypeptide, Ni-NTA resin may be employed to purify the fusion polypeptide. Epitope tags such as FLAG™ may also be used.
Fusion proteins can be prepared by in vitro transcription and translation reactions . An expression cassette can be employed to generate surface polypeptide gene-specific transcripts which are subsequently translated in vitro. The construction of vectors for use in in vitro transcription/translation reactions, and methods for such reactions, are well known in the art. The polypeptides or fusion proteins of the
invention may also be prepared by solid phase peptide synthesis, which is an established and widely used method, described in the following references: Stewart et al. 1969; Merrifield, 1963; Meienhofer in "Hormonal ' Proteins and Peptides," ed. ; C. H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267; and Bavaay and Merrifield, "The Peptides," eds . E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp.3-285.
As used herein, a "heterologous" molecule is a molecule not occurring naturally in the form used in the present invention. For example, a heterologous nucleic acid molecule may not occur naturally in a P. multocida cell. If it does naturally occur in a P. multocida cell, it is integrated at other genetic positions as exogenous nucleic acid and is therefore situated within another genetic environment. The heterologous molecule may be any molecule which it is desired to provide as a surface polypeptide fusion protein, such as a molecule from a different serotype of P. multocida. The polypeptides of the invention may be conjugated or linked to an immunogenic protein, such as keyhole limpet haemocyanin (KLH) or albumin, to enhance their immunogenicity . For example, synthetic peptides are coupled to KLH through the C-terminal cysteine of the peptide using the heterobifunctional reagent N-γ- maleimidobutyric acid
N-hydroxysuccinimide ester (GMBS; Sigma) according to the manufacturer's directions. The carrier-conjugated peptides are stored at-20°C until used.
The term "vaccine antigen potential" means an estimate of the likely ability of a protein to elicit at least some degree of protective immunity. Any protein which confers some or total protection against a challenge with infective organisms can also be referred to as a potential vaccine candidate. In the case of P. multocida, OMPs are considered to be the proteins most likely to have this ability.
The term "antibody" is used in the broadest sense, and specifically includes monoclonal antibodies,
polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies), and antibody fragments, provided that they maintain their antigen-binding specificity. Also envisioned are maternal antibodies, which are obtained from a female subject exposed to a recombinant bacterial cell, a nucleic acid molecule, or a polypeptide of the invention. For example, a hen may be vaccinated with at least one of the vaccine compositions of the invention. The hen then provides passive immunity to its progeny through the transfer of maternal antibody to the embryo. Alternatively, an egg-laying animal, e.g. a chicken, may be immunized and the eggs from that animal collected. In ovo immunization is also contemplated. Antibody is recovered from the eggs, and then administered to susceptible subjects, e.g. turkeys, to provide passive protection. Preferably the turkeys are subsequently exposed to live or killed P. multocida, or with polypeptides of the invention, to provide active protection. A "monoclonal antibody" is an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes) , each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al.,
1975, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The person skilled in the art will be aware of numerous other references, such as Goding, J. W. Monoclonal Antibodies: principles and practice (Academic Press, New York: 3rd ed. 1996) .
"Nucleic acid molecule" as used herein refers to an oligonucleotide, polynucleotide, nucleotide, and fragments, variants, derivatives, and antisense molecules thereof, as well as to peptide nucleic acids (PNA) , fragments, variants, derivatives and antisense molecules thereof, and to DNA or RNA of genomic or synthetic origin which can be single- or double-stranded, and represent the sense or antisense strand. Where "nucleic acid" is used to refer to a specific nucleic acid sequence it is meant to encompass polynucleotides that encode a polypeptide that is functionally equivalent to the recited polypeptide, e.g., polynucleotides that are degenerate variants, or polynucleotides that encode biologically active fragments, variants, or derivatives of the polypeptide, including polynucleotides having substantial sequence similarity or sequence identity relative to the sequences provided herein.
The nucleic acid molecules of the invention, or fragments, variants, or derivatives thereof, may be used to prepare probes, primers or expression cassettes which, in turn, are useful to detect, amplify and express other outer membrane protein genes and related genes .
The terms "nucleotide sequence" and "nucleic acid sequence" are used herein interchangeably. The term "antisense nucleic acid molecule" as described herein defines a sequence which is complementary to a nucleic acid molecule of interest or fragment, variant, or derivative thereof.
Nucleic acid molecules encoding a surface polypeptide of the invention, or a fragment, variant, or derivative thereof, may be obtained from any isolate of P. multocida or from physiological fluid or tissue of eukaryotic organisms infected with P. multocida. Other
sources of the DNA molecules of the invention include genomic libraries derived from any P. multocida-infected eukaryotic cellular source. Moreover, DNA molecules which encode a subunit of a full-length surface polypeptide may be prepared in vitro, e.g. by synthesizing an oligonucleotide of about 200, preferably about 100, more preferably about 75, nucleotides in length, or by subcloning a portion of a DNA segment which encodes a particular OMP. A nucleic acid molecule encoding a surface polypeptide of the invention can be identified and isolated using standard methods, for example as described by Sambrook et al . , Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY (1989) . A "variant" nucleic acid molecule of the invention is a nucleic acid molecule which has at least 80%, 81%, 82%, 83%, 84% or 85%, preferably at least about 90%, 91%, 92%, 93% or 94%, and more preferably at least about 95%, 96%, 97%, 98%, 99% but less than 100%, contiguous nucleotide sequence homology or identity to the nucleotide sequence of the corresponding wild type nucleic acid molecule, which encodes a surface polypeptide of P. multocida. A variant nucleic acid molecule of the invention may also include nucleotide bases not present in the corresponding wild type nucleic acid molecule, and/or internal deletions relative to the corresponding wild type nucleic acid molecule.
Nucleic acid molecules encoding amino acid sequence variants of surface polypeptides of the invention may be prepared by a variety of methods known in the art. These include, but are not limited to, isolation from a natural source (in the case of naturally-occurring amino acid sequence variants or serotypes) or preparation by site-directed mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a native surface polypeptide.
Site-mediated mutagenesis is a preferred method for preparing amino acid substitution variants of a
polypeptide of the invention. This technique is well known in the art (Adelman et al . , 1983). Briefly, DNA encoding a surface polypeptide is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, in which the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence encoding the surface polypeptide. Alternatively, the plasmid or phage can be detnatured, e.g. with NaOH. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template which will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the DNA encoding the surface polypeptide. Oligonucleotides of at least 25 nucleotides in length are generally used.
An optimal oligonucleotide will have 12, 13, 14 or 15 nucleotides which are completely complementary to the template on either side of the nucleotide (s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art, such as that described by Crea et al . , 1978.
The DNA template can be generated by vectors which are either derived from bacteriophage M13 vectors such as the commercially-available M13mpl8 and M13mpl9 vectors, or which contain a single-stranded phage origin of replication, as described by Viera et al . , 1987. Thus the DNA which is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al . , Molecular Cloning. A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York, 1989). Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.
For alteration of the native DNA sequence, for
example to generate amino acid sequence variants, the oligonucleotide may be hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed, such that one strand of DNA encodes the mutated form of the surface polypeptide, and the other strand (the original template) encodes the native, unaltered sequence of the surface polypeptide. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as E. coli JMlOl, or a mut S strain to allow for heteroduplex replication without repair. After the cells are grown, they are plated on to agarose plates and screened, using the oligonucleotide primer radiolabeled with 32 -phosphate to identify the bacterial colonies which contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for polypeptide production, generally an expression vector of the type typically employed for transformation of an appropriate host. A modification of this method which uses a homoduplex molecule is described in PCT/US98/25990.
Thus nucleic acid molecules encoding at least a portion of a surface polypeptide, or the complement thereto, may be modified so as to yield nucleic acid molecules of the invention having silent nucleotide substitutions, or to yield nucleic acid molecules having nucleotide substitutions which result in amino acid substitutions .
"Cloning" of DNA, also known as gene cloning or molecular cloning, refers to the use of recombinant DNA technology to insert a desired DNA fragment into a cloning vector, which is then introduced into a host cell in which it can replicate, and culturing the host cell. The DNA may be isolated from its natural source, or may
be cDNA or synthetic DNA.
A "vector" or "cloning vector" is a DNA molecule originating from a virus, a plasmid, or the cell of a higher organism into which another DNA fragment of appropriate size can be integrated without loss of the vector's capacity for self-replication; vectors are routinely used to introduce foreign DNA into host cells, in which the DNA can be reproduced in large quantities . Examples include plasmids, cosmids, and yeast artificial chromosomes; vectors are often recombinant molecules containing DNA sequences from several sources.
A vector may include one or more nucleic acid sequences, such as an origin of replication, which permit the vector to replicate in a host cell. A vector also may include one or more selectable marker genes and other genetic elements known in the art . The term "vector" as used herein is intended to encompass any carrier for nucleic acid, including plasmids, cosmids and phage. Preferably the vector is an expression cassette. To prepare expression cassettes for transformation of host organisms, a recombinant or preselected nucleic acid sequence or segment may be circular or linear, double-stranded or single-stranded. A preselected DNA sequence which encodes an RNA sequence which is substantially complementary to a RNA sequence encoding surface polypeptide is typically a "sense" DNA sequence cloned into a cassette in the opposite orientation (i.e. 3' to 5' rather than 51 to 3 ■ ) . Generally the preselected DNA sequence or segment is in the form of chimeric DNA, such as plasmid DNA, which can also contain coding regions flanked by control sequences which promote the expression of the preselected DNA present in the resultant cell line.
"Chimeric" means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or associated in a manner which does not occur in the "native" or wild type of the species.
Apart from preselected DNA sequences which serve as transcription units for surface polypeptides, or fragments, variants, or derivatives thereof, a portion of the preselected DNA may be untranscribed, serving a regulatory or a structural function. For example, the preselected DNA may itself comprise a promoter which is active in the host cell, or may utilize a promoter already present in the genome that is the transformation target. Many promoter elements well known to the art may be employed in the practice of the invention.
"Control sequences" are nucleic acid sequences necessary for the expression of an operably-linked coding sequence in a particular host organism. Control sequences which are suitable for prokaryotic cells, for example, include a promoter, and optionally an operator sequence, and a ribosome binding site. Such elements may or may not be necessary for the function of the nucleic acid molecule, but may provide improved expression of the nucleic acid molecule by affecting factors such as transcription or stability of mRNA, and may be included in the nucleic acid molecule to obtain optimal performance of the transforming DNA in the cell.
"Operably linked" means that a nucleic acid molecule is placed in a functional relationship with another nucleic acid molecule. Generally, "operably linked" means that the nucleic acid molecules being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites.
If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
The preselected nucleic acid molecule to be introduced into the cells further will generally contain a selectable marker gene and/or a reporter gene, to facilitate identification and selection of transformed cells from the population of cells sought to be
transformed. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co- transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells . Useful selectable markers are well known in the art, and include antibiotic genes, such as those listed in Table 1 of Lundquist et al . (U.S. Patent No. 5,848,956).
Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (cat) from Tn9 of E. coli, the β-glucuronidase gene (gus) of the uidA locus of E. coli, and the luciferase gene from the firefly
Photinus. Expression of the reporter gene is assayed at a suitable time after a nucleic acid molecule has been introduced into the recipient cells.
As used herein, the term "recombinant" nucleic acid molecule refers to a nucleic acid molecule which has been derived or isolated from any appropriate cellular source, and which may subsequently be chemically altered in vitro, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences which are not positioned as they would be positioned in a genome which has not been transformed with exogenous DNA. A recombinant nucleic acid "derived" from a source may be a DNA sequence which is identified as a useful fragment within a given organism, and which is then chemically synthesized in essentially pure form. Therefore the term "recombinant nucleic acid" includes completely synthetic DNA sequences, semi-synthetic DNA sequences, DNA sequences isolated from biological
sources, and DNA sequences derived from RNA, and mixtures thereof. The term "derived" with respect to a RNA molecule means that the RNA molecule has complementary- sequence identity to a particular DNA molecule. A DNA "isolated" from a source may be a DNA sequence which is excised or removed from the source by chemical means, e.g. by the use of restriction endonucleases, so that it can be further manipulated for use in the invention, by genetic engineering methodology. As used herein, the term "host cell" is intended to refer to well-characterized homogenous, biologically pure populations of cells. The cell line or host cell is preferably of bacterial origin, and most conveniently is Escherichia coli. Generally, the preselected DNA sequence is related to a DNA sequence which is either resident in the genome of the host cell but not expressed, or not highly expressed, or, alternatively, is overexpressed.
ΛλTransfected" or "transformed" is used herein to include any host cell or cell line, the genome of which has been altered or augmented by the presence of at least one preselected DNA sequence, which DNA is also referred to in the art of genetic engineering as "heterologous DNA" "recombinant DNA" , "exogenous DNA" , "genetically engineered", "non-native" or "foreign DNA", in which the DNA was isolated and introduced into the genome of the host cell or cell line by the process of genetic engineering. The host cells are typically produced by transfeetion with a DNA sequence in a plasmid expression vector, a viral expression vector, or as an isolated linear DNA sequence. Preferably the transfected DNA is a chromosomalIy-integrated recombinant DNA sequence, which comprises a gene encoding an OMP or its complement, which host cell may or may not express significant levels of autologous or "native" OMP.
General methods for constructing recombinant DNA which can transform target cells are well known to those skilled in the art, and the same compositions and
methods of construction may be utilized to produce the DNA useful herein. For example, J. Sambrook et al.°, Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press (2d ed., 1989), provides suitable methods of recombinant DNA construction.
The recombinant DNA can be readily introduced into the host cells by transfection with an expression vector comprising DNA encoding an OMP or its complement, by any procedure useful for the introduction into a particular cell, e.g., physical or biological methods (e.g., recombinant phage or viruses), to yield a transformed cell having the recombinant DNA stably integrated into its genome, so that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell .
Physical methods for introducing a recombinant nucleic acid molecule into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. The main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses in eukaryotic hosts. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression. To confirm the presence of the preselected DNA sequence in the host cell, a variety of assays may be performed. Such assays include molecular biological assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; biochemical assays, such as detecting the presence or absence of a particular OMP, e.g. by immunological means such as ELISA assays and Western blots, or by functional assays to identify specific proteins falling within the scope of the invention.
To detect and quantify RNA produced from introduced preselected DNA segments, reverse transcription PCR (RT-PCR) may be employed. In this
application of PCR, it is first necessary to reverse transcribe RNA into DNA, using enzymes such as reverse transcriptase, and then through the use of conventional PCR techniques amplify the DNA. In most instances PCR techniques will not demonstrate integrity of the RNA product, but Northern blotting demonstrates the presence of an RNA species, and gives information about the integrity of that RNA. The presence or absence of an RNA species can also be determined using dot or slot blot Northern hybridizations. These techniques are modifications of Northern blotting, and only demonstrate the presence or absence of an RNA species.
While Southern blotting and PCR may be used to detect the preselected DNA segment in question, they do not provide information as to whether the preselected DNA segment is being expressed. Expression may be evaluated by specifically identifying the products of the introduced preselected DNA sequences or evaluating the phenotypic changes brought about by the expression of the introduced preselected DNA segment in the host cell.
Recovery or isolation of a given fragment of DNA from a restriction digest employs methods well known in the art, such as separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al . , 1981, and Goeddel et al . , 1980.
"Polymerase chain reaction" (PCR) refers to a procedure in which amounts of a preselected fragment of nucleic acid, RNA and/or DNA, are amplified, such as described in U.S. Patent No. 4,683,195. Sequence information from the ends of the region of interest or beyond is generally employed to design oligonucleotide primers comprising at least 7-8 nucleotides. These primers will be identical or similar in sequence to
opposite strands of the template to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, and the like. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51, 263 (1987); Erlich, ed. , PCR Technology, (Stockton Press, New York, 1989) . Thus PCR-based cloning approaches rely upon conserved sequences deduced from alignments of related gene or polypeptide sequences.
Primer oligonucleotide sequences are synthesized so as to correspond to highly-conserved regions of proteins or nucleotide sequences which were identified and compared to generate the primers, e.g., by a sequence comparison of other bacterial OMP genes. One primer is predicted to anneal to the antisense strand, and another primer is predicted to anneal to the sense strand, of a DNA molecule which encodes an OMP. The products of each PCR reaction are separated, for example by agarose gel electrophoresis, and all consistently amplified products are gel-purified and cloned directly into a suitable vector, such as a known plasmid vector. The resultant plasmids are subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs.
Alternatively the gel-purified fragment can be directly sequenced.
"Stringent conditions" for hybridization or annealing of nucleic acid molecules are well known in the art, and include those which
(1) employ low ionic strength and high temperature for washing, for example 0.015 M NaCl/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate (SDS) at 500C, or
(2) employ during hybridization a denaturing agent such as formamide, for example 50% (vol/vol) formamide with
0.1% bovine serum albumin/O.1% Ficoll/O.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C.
Alternatively 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 raM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt ' s solution, sonicated salmon sperm DNA (50 μg/mL) , 0.1% SDS, and 10% dextran sulfate at 420C, with washes at 42°C in 0.2 x SSC and 0.1% SDS, may be used. See Maniatis et al, op. cit.
Generally, the terms "treating" , "treatment" and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a disease or condition, or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure of a disease or condition. "Treating" as used herein covers any treatment of, or prevention of, disease in the subject, and includes preventing the disease from occurring in a subject who may be predisposed to the disease, but has not yet been diagnosed as having it; inhibiting the disease, i.e., arresting its development; or relieving or ameliorating the effects of the disease, i.e., cause regression of the effects of the disease.
As used herein "disease" means an impairment of health. The disease may be any disease caused by P. multocida, which causes numerous diseases in animals, including fowl cholera in avian species, hemorrhagic septicaemia in ungulates, shipping fever and pneumonia in cattle, atrophic rhinitis in swine, and snuffles in rabbits. The bacterium also causes infections in humans, primarily through dog and cat bites. As used herein "condition" means abnormal functioning, and may be any condition caused by P. multocida.
As used herein "diagnosis" means identifying the nature or cause of a disease or condition, such as the diagnosis of P. multocida infection.
The invention further relates to diagnostic assays, particularly but not solely for use in veterinary medicine. For diagnosis of P. multocida infection
status, the presence of antibodies to the OMP of P. multocida in animal serum is determined. Many types of test formats may be used. Such tests include, but are not limited to, immunofluorescence assay, radioimmunoassy, radioimmunosorbent test, enzyme-linked immunosorbent assay, agglutination and hemagglutination. The diagnostic assays can be performed using standard protocols.
For example, a diagnostic assay of the invention can be constructed by coating all or a unique portion of the OMP polypeptide or peptide, or an isolated P. multocida preparation (the antigen) on a solid support, for example a plastic bead, a test tube, a fibre strip, a microtitration plate or a membrane, and contacting it with the serum or other physiological fluid taken from a subject suspected of having a P. multocida infection. Following removal of the physiological fluid, any antibody bound to the immobilized antigen can be detected, preferably by reacting the binary antibody- antigen complexes with a "detection antibody" , which comprises a detectable label or a binding site for a detectable label . Suitable detectable labels are enzymes, fluorescent labels or radiolabels. Binding sites for detectable labels include avidin, biotin, streptavidin and the like. In another embodiment of the diagnostic assay of the invention, all or a unique portion of the antigen is bound to an inert particle, for example a bentonite, polystyrene, or latex particle. The particles are mixed with serum from a subject in a well of a plastic agglutination tray. The presence or absence of antibodies in the subject's serum is determined by observing the settling pattern of the particles in the well .
Isolated surface polypeptides, nucleic acids, and/or antibodies of the invention may be administered to a subject in an amount effective to elicit an immune response specific for P. multocida. Methods and pharmaceutical carriers for preparation of pharmaceutical
and veterinary compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 20th Edition, Williams & Wilkins, Pennsylvania, USA. The compounds and compositions of the invention may be administered by any suitable route, and the person skilled in the art will readily be able to determine the most suitable route and dose for the condition to be treated. Dosage will be at the discretion of the attendant physician or veterinarian, and will depend on the nature and state of the disease or condition to be treated, the age and general state of health of the subject to be treated, the route of administration, and any previous treatment which may have been administered. Two or more antigens of the invention may be administered simultaneously or at different times. In one embodiment, the subject is a bird, and immunization results in an immune response which inhibits or prevents fowl cholera, or in the production of antibodies to the OMP employed as an immunogen. Both local and systemic administration is contemplated. Systemic administration is preferred.
Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of the cytotoxic side effects. Various considerations are described in references such as Langer, 1990. The carrier or diluent, and other excipients, will depend on the route of administration, and again the person skilled in the art will readily be able to determine the most suitable formulation and dosage for each particular case. In general, the dosage of recombinant bacteria required for efficacy will range from about 104 to about 1012, preferably about 105 to about 1010, and more preferably about 106 to about 109, colony-forming units
(CFU), although other amounts may prove efficacious. For proteins and peptides of the invention, the dosage required is about 1 pg to about 10 mg, preferably about 10 pg to about 1 mg, and more preferably about 100 pg to about 500 μg, although other dosages may be employed. In particular, for administration of a protein or peptide of the invention to a bird, e.g. a turkey or chicken, the amount administered may be at dosages of at least about 1 pg to about 10 mg, preferably about 10 μg to about 1 mg, and more preferably about 100 μg to about 500 μg, although other dosages may provide beneficial results. Dosages within these ranges can be administered via bolus doses or via a plurality of unit dosage forms, until the desired effects have been obtained. The amount administered will vary depending on various factors, including, but not limited to, the specific immunogen chosen, the weight, physical condition and age of the subject, and the route of inoculation. Thus for polypeptide and peptides, the absolute weight of polypeptide or peptide in a given unit dosage form of vaccine can vary widely, and depends upon factors such as the species, age, weight and physical condition of the subject to be vaccinated, as well as the method of administration. Such factors can be readily determined by the veterinarian employing animal models or other test systems which are well known to the art.
Vaccination schedules and efficacy testing for birds are well known to the art; e.g. see Rimler et al . , 1979; Schlink et al . , 1987; Wang et al . , 1994a,- Wang et al., 1994b; Zhang et al . , 1994; and Rimler et al . , 1981. Methods of purification of egg immunoglobulins are described in US patents No. 5367054, No. 5420253, and No. 4550019. Immunization in ovo is described in Australian patents No. 681189, No, 681697 and 727378 by Embrex, Inc. A unit dose of a protein or peptide vaccine is preferably administered parenterally, e.g. by subcutaneous or intramuscular injection.
The proteins or peptides of the invention may
also be conjugated or linked to an immunogenic protein, such as keyhole limpet haemocyanin (KLH) or albumin, to enhance their immunogenicity. For example, synthetic peptides are coupled to KLH through the C-terminal cysteine of the peptide using the heterobifunctional reagent N-γ-maleimidobutyric acid N-hydroxysuccinimide ester (GMBS; Sigma) according to the manufacturer's directions. The carrier-conjugated peptides are stored at-20°C until used. Two or more antigens of the invention may be administered simultaneously or at different times. In one embodiment, the subject is a bird, and immunization results in an immune response which inhibits or prevents fowl cholera, or in the production of antibodies to the OMP employed as an immunogen. Both local and systemic administration is contemplated. Systemic administration is preferred.
The invention also contemplates the production of maternal antibody, which is obtained from a female subject exposed to a recombinant bacterial preparation, a nucleic acid molecule, protein or peptide of the invention. For example, a hen is vaccinated with at least one of the vaccine compositions of the invention. The hen then provides passive immunity to its progeny through the transfer of maternal antibody to the embryo.
Alternatively, an egg-laying animal, e.g. a chicken, may be immunized and the eggs from that animal collected. In ovo immunization is also contemplated. Antibody is recovered from the eggs, and then administered to susceptible subjects, e.g. turkeys, to provide passive protection. Preferably the turkeys are subsequently exposed to live or killed P. multocida, or other compositions of the invention, to provide active protection. The compositions of recombinant bacteria which express the polypeptides of the invention may be administered as live, modified-live (attenuated) or inactivated bacteria, or as a combination of attenuated,
inactivated, and/or live bacteria, or in combination with a protein or peptide of the invention, or any combination thereof . The bacteria may be inactivated by agents including, but not limited to, formalin, phenol, ultraviolet radiation, and β-propiolactone.
Immunogenic compositions are typically prepared for injection or infusion, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection or infusion may also be prepared. The preparation may also be emulsified. The active ingredient may be mixed with diluents, carriers or excipients which are physiologically acceptable and compatible with the active ingredient (s) . Suitable carriers can be positively or negatively-charged or neutral avridine-containing liposomes, oil emulsions, such as live-in-oil; killed-in- oil, or water-in-oil emulsions; aluminium hydroxide; oil emulsion with terpene oils or squalene; or aqueous. Suitable diluents and excipients include water, saline, PBS, glycerol, or the like, and combinations thereof. In addition, if desired, the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH- buffering agents, and the like. Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions . Such excipients may be suspending agents such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, which may be a naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol ;
d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate .
The compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as those mentioned above. The sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol . Among the acceptable vehicles and solvents which may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono-or diglycerides . In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Such compositions are conventionally administered by parenteral injection. For example in birds, administration is by intravenous injection, by intramuscular injection to breast, lung or thigh, by subcutaneous injection, wing web injection. Alternatively administration is via the beak, by spraying the animals and their environment, e.g. their housing or yard, or may be in the drinking water or feed. The administration of maternal antibody or recombinant bacteria is preferably in feed or water. Protein or peptide is preferably administered via injection.
Formulations which are suitable for other modes of administration include suppositories, cloacal formulations, insufflated powders or solutions, eye
drops, nose drops, intranasal aerosols, and oral formulations, e.g. in drinking water.
Oral formulations include such normally- employed excipients as pharmaceutical grades of alkylcelluloses, mannitol, dextrose, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Thus these compositions can take the form of solutions, suspensions, powder tablets, pills, hard or soft gelatin capsules, sustained-release formulations such as liposomes, gels or hydrogels, and can contain about 10% to about 95% of active ingredient, preferably at about 25% to about 70%. The optimum proportions of active ingredient can readily be determined by those skilled in the art. One or more suitable unit dosage forms comprising polypeptides or peptides of the invention may optionally be formulated for sustained release. The formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to pharmacy. Such methods may include the step of bringing the therapeutic agent into association with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.
To prepare a vaccine composition comprising a surface polypeptide, the polypeptide can be isolated as described above, lyophilized and stabilized. Alternatively the surface polypeptide may be modified so as to produce a derivative, as described above. The polypeptide antigen may then be adjusted to an appropriate concentration, optionally combined with a suitable carrier and/or suitable vaccine adjuvant, and preferably packaged for use as a vaccine.
An "adjuvant" is a substance which augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level .
An adjuvant may be added to a vaccine, or may be administered before administering an antigen, in order to improve the immune response, so that less vaccine is needed to produce the immune response. Widely-used adjuvants include alum, ISCOMs which comprise saponins such as Quil A, liposomes, and agents such as Freund's adjuvant, Bacillus Calmette Guerin (BCG) , Corynebacterium parvum or mycobacterial peptides which contain bacterial antigens. Other adjuvants include, but are not limited to, surfactants, e.g. hexadecylamine, octadecylamine, lysolecithin, di-methyldioctadecylammonium bromide, N, N-dioctadecyl-n1 -N-bis (2- hydroxyethylpropane diamine) , methoxyhexadecyl-glycerol, and pluronic polyols; polyanions, e.g. pyran, dextran sulphate, poly IC, polyacrylic acid, and carbopol; peptides, e.g. muramyl dipeptide, dimethylglycine, and tuftsin; oil emulsions, and mixtures thereof. Only some of these are currently approved for human or veterinary use,- others are in clinical trial. The immunogenic product may be incorporated into liposomes for use in a vaccine formulation, or may be conjugated to polysaccharides or other polymers. Some adjuvants are endogenous to the subject to be vaccinated; these include histamine, interferon, transfer factor, tuftsin and interleukin-1. Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e. affecting a restricted type of immune response to a narrow group of antigens . The subject may be a human, or may be a domestic, companion or zoo animal or bird. While it is particularly contemplated that the compounds and compositions of the invention are suitable for use in veterinary treatment, including treatment of companion animals such as dogs, cats and rabbits, and domestic animals such as horses, cattle, buffalos, sheep, goats, pigs, rabbits and poultry, zoo animals such as non-human primates, felids, canids, bovids, lagomorphs, suids and
ungulates, and zoo or other captive birds such as waterfowl, peacocks, pheasants and guinea fowl, they are also applicable to treatment of humans.
ABBREVIATIONS
1-DGE one-dimensional gel electrophoresis
1-D LC MS/MS one dimensional SDS polyacrylamide gel electrophoresis nano-liquid chromatography tandem mass spectrometry
2 -DGE MALDI-TOF MS two-dimensional gel electrophoresis matrix-assisted laser desorption ionization-time-of-flight mass spectrometry
BHI brain-heart infusion broth
CDM chemically-defined medium
CFU colony-forming units
COGs clusters of orthologous groups
ELISA enzyme-linked immunosorbent assay
LPS lipopolysaccharide
MS mass spectrometry nanoLC nano liquid chromatography
OMP outer membrane protein
ORF open reading frame
PBS phosphate-buffered saline
PMF peptide mass fingerprinting
SDS sodium dodecyl sulphate
MATERIALS AND METHODS Bacterial strains and routine culture conditions
P. multocida strain x-73 was grown routinely at 370C in brain-heart infusion broth (BHI) with constant aeration. Although the complete genome sequence is only available for P. multocida strain Pm70, this strain is not virulent in chickens, so we used strain X-73
(serotype A:l) for all experiments. For the purification of membrane preparations from bacteria grown in BHI, cells were harvested in either late exponential phase
(A65O=O.8) or stationary phase.
Growth conditions for iron starvation experiments
For iron starvation experiments P. multocida was harvested in stationary phase after growth for 16 h at 37°C in a modified chemically-defined medium (CDM; (Boucher et al, 2005)) containing 35mM Na2HPO4, 10 mM KH2PO4, 20 mM NaCl, 30 mM glucose, 0.1 mM orotic acid, 5 μM calcium panthothenate , 50 μM nicotinamide, 0.3 μM thiamine-HCl, 15 μM FeCl3, 750 μM cysteine, 20 mM L- aspartic acid, 750 μM L-tyrosine, 1.5 mM MgSO4, 1% (wt/vol) casamino acids (Difco) and supplemented with 200 μM 2 , 2 ' -dipyridyl where appropriate. To ensure that growth conditions were iron-limited, bacteria were grown in modified CDM containing various concentrations of dipyridyl. The final dipyridyl concentration chosen (200 μM) was the highest concentration at which P. multocida grew to an A65O > 0.7, and is very similar to concentrations used previously for iron-limited P. multocida microarray and protein expression experiments (Jacques et al, 1994; Paustian et al, 2001) .
Growth conditions for in vivo experiments
In vivo-grown bacteria were purified from blood obtained from infected chickens, as described previously (Boyce et al, 2002) . Leghorn cross chickens were infected with IxIO4 CFU of P. multocida x-73, and the infection allowed to proceed for 16-22 h. Chickens were monitored closely for signs of infection, and the level of bacteraemia was assessed by blood smear. At the terminal stage of infection, when bacteremia levels were approximately IxIO10 CFU/ml, blood (15-40 ml) was recovered by terminal heart puncture . Bacteria were separated from the red blood cells by centrifugation for 1 h at 3,000 X g in the presence of 12.5% sucrose.
Bacteria were recovered from above the sucrose cushion and concentrated by centrifugation for 10 min at 12,000 X g. The final recovery was' approximately IxIO10CFU.
The invention will now be described in detail by way of reference only to the following non-limiting examples and drawings .
Example 1 Preparation of P. multocida outer membranes by differential solubility in sarcosine To determine the protein composition of the P. multocida outer membrane under normal growth conditions in vitro, we analyzed the sarcosine-insoluble outer membrane fraction of bacteria after growth in BHI . The sarcosine-insoluble membrane fraction from numerous bacterial species, including P. multocida, has been shown to be highly enriched in OMPs (Baik et al, 2004; Morton et al, 1996; Ravaoarinoro et al, 1994; Davies et al, 1990) . Indeed, the sarcosine-insoluble membrane fraction is simpler to produce, and is as pure as outer membrane preparations prepared by other methods, including isopycnic sucrose gradients (Morton et al, 1996; Davies et al, 1990) . Triplicate samples of outer membrane material were prepared, and 2-DGE performed on each sample .
OMPs of P. multocida were purified by sarcosine differential solubility as described previously (Zhao et al, 1995), with minor modifications. Cultures of P. multocida were harvested by centrifugation at 12,000 X g for 20 min and washed once in buffer 1 (200 mM Tris-HCl [pH=7.8] , 10 mM EDTA) . Washed cells were subjected to three freeze/thaw cycles and then disrupted by sonication at 40C (6 X 30 sec pulses at 7OW separated by 45 sec) . Unlysed cells were removed by two cycles of centrifugation at 10,000 X g, and the crude membranes collected by centrifugation at 150,000 X g for 1 h. The membrane fraction was washed once in buffer 1 and resuspended in 1 ml of 10 mM Tris-HCl (pH=7.8) . An equal volume of 1% N-lauryl sarcosine, 10 mM Tris-HCl (pH=7.8) was added, and the solution incubated for 1 h at room
temperature with intermittent mixing.
The sarcosine-insoluble fraction was recovered by centrifugation at 150,000 X g for 1 h at 40C and washed once in 10 mM Tris-HCl (pH=7.8), 10 mM EDTA. The sarcosine-insoluble outer membrane material was resuspended in 10 mM Tris-HCl (pH=7.8), 10 mM EDTA by continuous stirring for 16 h at 40C. Protein concentration was determined using the BCA Protein Assay reagent (Pierce) , and standardised aliquots of outer membrane material stored at -70°C until required. The outer membrane material was precipitated for 16 h at 4°C with acetone (10 vol) and resuspended directly in the appropriate sample buffer prior to gel electrophoresis.
Example 2 2-DGE identification of protein spots and in-gel tryptic digests of proteins Acetone-precipitated outer membrane material from Example 1 was resuspended in ASB-14 (BioRad) and separated in the first dimension using IPG strips with a pH gradient of 3.0-10.0 and then resolved in the second dimension by 12.5% SDS-PAGE as described previously (Cullen et al, 2002) . For bacteria grown in BHI or in iron-replete or iron-limited CDM, 400 μg of outer membrane protein was separated on 17 cm IPG strips and resolved in the second dimension by large format (20 x 20 cm) SDS-PAGE. Because of the limited amount of outer membrane material recoverable from bacteria purified from the blood of chickens, 35 μg of membrane protein was loaded on to 7 cm IPG strips and resolved in the second dimension by small format (7 x 8 cm) SDS-PAGE.
Proteins were visualised by sequential staining with Sypro Ruby (Molecular Probes, Eugene, Oregon) and Coomassie brilliant blue G-250 (Bio-Rad) . All 2-DGE analyses were performed on duplicate {in vivo-grown bacteria) or triplicate (in vitro-grown and iron-starved bacteria) biological repeats using different preparations of bacteria from different birds or flasks. As only duplicate biological replicates were available for in
vivo-grown material, duplicate gels of each biological sample were run. Protein spots were excised, subjected to in-gel tryptic digestion, • and the tryptic peptides prepared for and analysed by MALDI-TOF MS as described previously (Cullen et al, 2002) .
Replicate gels showed very similar protein profiles. Thirty-seven protein spots were observed, as shown in Fig. 1, and these were excised from the gel, destained and digested with trypsin to establish peptide mass fingerprints using MALDI-TOF-MS.
Monoisotopic peptide masses were used to search the Swiss-Prot/TrEMBL database using Peptldent (Wilkins & Williams, 1997) . From the 37 spots subjected to peptide mass fingerprinting (PMF) we identified 19 unique proteins, which are summarised in Table 1. Four protein spots (spots 34-37) could not be identified by PMF. However, three of these appeared on only a single gel, while the fourth (spot 36) was in an identical position to the abundant inner membrane protein RpS2 , which was identified from the sarcosine-soluble membrane fraction and also from the sarcosine-insoluble fraction by 1-D LC MS/MS (see below) .
Table 1
Peptide mass matches for proteins identified by 2-DGE from the sarcosine-insoluble membrane fraction of P. multocida grown in BHI.
Spot Protein Theoretical Theoretical Matching % sequence
ID identified Mass (KDa) pi peptides b coverage ° a
1 Pml992 87,761 6.3 16 21.5
2 TufA 43,353 5.4 22 58.6
2 TUfB 43,375 5.4 21 54.3
3 TUfA 43,353 5.4 18 48
3 TUfB 43,375 5.4 18 48
4 PmO527 50,682 9.1 12 28.4
5 PmO998 26,355 9.6 8 38.1
6 PtnO998 26,355 9.6 14 57.6
7 PmO998 26,355 9.6 11 39.8
8 GIpQ 41,162 6.6 22 69.3
9 Pml578 35,861 6.8 9 31.3
10 PIpB 28,246 5.0 15 66.8
11 PIpB 28,246 5.0 16 82.0
12 OmpH_l 37,450 8.8 16 44.7
13 OmpH_l 37,450 8.8 26 65.2
14 OmpH_l 37,450 8.8 22 68.2
15 OmpH_l 37,450 8.8 24 51.3
16 OmpH_l 37,450 8.8 11 40.8
17 PmlO69 43,654 9.0 7 25.1
18 PmlO64 30,119 9.4 9 39.7
19 PmO786 38,031 9.1 14 56.4
20 PmO786 38,031 9.1 19 69.7
21 PmO786 38,031 9.1 8 35.7
22 PmO786 38,031 9.1 8 30.6
23 PmO786 38,031 9.1 9 39.7
24 PmO786 38,031 9.1 14 61.2
25 PmO786 38,031 9.1 11 46.2
2δ PtnO786 38,031 9.1 9 40.2
26 Ptnl720 27,237 6.0 7 35.3
27 VacJ 27,528 7.7 16 63.0
28 PmO442 23,866 5.0 7 42.4
29 PmO966 14,318 5.9 7 56.5
30 PmO966 14,318 5.9 10 64.9
31 PmO612 11,490 5.6 5 46.6
32 Lpp 15,587 9.1 6 42.2
33 OmpW 21,870 9.2 5 25.2
34-37 No match a Protein names are as used in the Pm70 genome annotation (May et al, 2001) . In some instances the closest matching peptide was to a protein from a P. multocida strain other than Pm70, but for simplicity the orthologous Pm70 protein name has been used. b indicates the number of peptide masses obtained by MALDI-TOF MS which match the theoretical peptide masses derived by in sil±co tryptic digestion of the conceptual translation. c indicates the percentage of sequence covered by the matching peptides .
Three spots (2, 3 and 26) contained more than one protein per spot . Spots 2 and 3 contained both TufA and TufB, while spot 26 contained both PmO786 and Pral720. TufA and TufB are very similar (99.2% identity), and have nearly identical predicted pi and mass. PmO786 and Pml720 do not have identical predicted pi and mass, but PmO786 is the most abundant P. multocida OMP, and occurs in at least eight resolvable isoforms, one of which appears to co-migrate with Pml720. The outer membrane profile was analysed after harvest of the bacteria in stationary phase, exponential phase and after growth in CDM. No significant differences between these growth stages were observed in the outer membrane protein profile.
Example 3 Identification of P. multocida OMPs by 1-
D LC MS/MS Standard 2-DGE protocols are generally biased against very large and hydrophobic proteins, which may be difficult to solubilize, and against very basic or acidic proteins, which are not adequately resolved during the IEF step (Ong & Pandey, 2001; Bunai & Yamane, 2005) . Although modifications to the standard 2 -DGE protocols which substantially reduce these biases have been described (Bunai & Yamane, 2005; Drews et al, 2004), in order to maximise the coverage of OMPs identified we used a different identification technique. We used 1-DGE followed by nanoLC-MS/MS, as 1-D SDS-PAGE resolves both basic and acidic proteins without bias, and also shows very little bias against large hydrophobic proteins. Although 1-D SDS-PAGE does not resolve the OMP sample into individual proteins, subsequent nanoLC-MS/MS can easily identify many proteins within a single gel slice. Indeed, this method is particularly recommended for membrane proteins (Gorg et al, 2004) .
1-DGE and in-gel tryptic digests of proteins
Acetone-precipitated outer membrane material (35 μg) was resuspended in sample buffer (0.2 M Tris-HCl [pH=6.8], 20% glycerol, 10% 2-mercaptoethanol, 4% SDS, 0.1% bromophenol blue) and separated by SDS-PAGE as described previously (Laemmli, 1970) , and the proteins were visualised by staining with Coomassie brilliant blue G-250. Selected gel segments were excised and washed twice in 50 mM ammonium bicarbonate/acetonitrile (1:1) and twice in 50 mM ammonium bicarbonate/ethanol (1:1) . Gel slices were dehydrated in ethanol for 5 min and incubated in 10 mM dithiothreitol (DTT) , 50 mM ammonium bicarbonate for 1 h at 560C. The solution was removed and replaced with 54 mM iodoacetamide, 50 mM ammonium bicarbonate and incubated for a further 30 min at 240C. The gel slices were washed three times in 50 mM ammonium bicarbonate and then dehydrated in ethanol for 5 min and dried under vacuum. Dried gel slices were allowed to rehydrate for 30 min at 40C in excess sequencing grade porcine trypsin (Promega) (0.01 μg/μl trypsin in 25 mM ammonium bicarbonate, 1 mM calcium chloride [pH=7.8]), after which excess trypsin buffer was removed and 10 μl of 25 mM ammonium bicarbonate added, and the incubation was continued for 18 h at 37°C.
NanoLC-ESI Ion Trap Tandem Mass Spectrometry
Tryptic digests were acidified with TFA before online nanoLC-MS/MS analyses. An UltiMate™ NanoLC system (LC Packings, Amsterdam, Netherlands) , controlled by HyStar™ 2.3 software (Bruker Daltonics) , was used with a μ-precolumn of PepMap™ C18, 300 μm i.d. x 5 mm (LC Packings) and an analytical column of PepMap™ C18, 75 μm i.d. x 15 cm (LC Packings) . Buffer A was 0.5% (v/v) formic acid in H2O and buffer B was 80% (v/v) acetonitrile, 20% H2O, 0.5% (v/v) formic acid. 5 μl of the digest were initially loaded and desalted on to the μ-precolumn in buffer A at a flow rate of 30 μl/min for 5 min. The desalted peptides were washed from the μ-
precoluran and loaded onto the analytical column at a flow rate of 320 nl/min. The peptides were eluted directly into an esquireHCT™ ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany), using a linear gradient of 4-64% acetonitrile over 35 min at a flow rate of 320 nl/min. The esquireHCT™ was equipped with an online nanoElectrospray source (Bruker Daltonics, Bremen, Germany) , consisting of a Picotip™ adapter (New Objective, Woburn, MA, USA) to connect the tubing from the nanoLC system to a tip-end coated fused silica needle with 10 μm i.d. (New Objective) . The ioή trap was operated in the positive ion mode at a MS scan speed of 8100 m/z/sec and a fast Ultra Scan of 26,000 m/z/sec for MS/MS analysis. The capillary voltage was set to 1500 V, and the drying gas (N2) was set to 3 litres/min and 150 0C.
The peptides were fragmented using auto-MS/MS with the SmartFrag™ option, which ramps the fragmentation energy automatically across a certain range of excitation amplitudes (0.5 to 2). Data analysis and MS/MS database searching was performed using DataAnalysis™ 3.1, BioTools™ 2.2 (Bruker Daltonics) and MASCOT (Matrix Science Ltd) .
The sarcosine-insoluble fraction was separated by 1-D SDS-PAGE and proteins visualized by Coomassie brilliant blue G-250 staining, as illustrated in Fig. 2 lane 1. The entire gel lane was excised into eight equal strips, and the proteins within the gel fragments were reduced, alkylated and digested with trypsin. The released tryptic peptides were analysed by nanoLC MS/MS, resulting in the identification of 29 unique proteins (significance of p<0.05) by comparison with both the GenBank database and a specific P. multocida strain Pm70 database. Many proteins were identified from more than one gel slice. These results are summarised in Table 2. Of the proteins listed, the following have not previously been shown to be associated with the P. multocida outer membrane: PM0336, PM0337, HyaD, PM0300, PM0803, PM1600,
ParC, PfhR, FusA, Wst, HyaE, PM1809, AtpA, PM0527, PepP, GIyA, TrpB, TufA, OmpH_2, RecA, AsnA, MreB, MgIC, PM1578, PM1426, ThyA, PM0998, PIpB, RpS2, VacJ, PM1021, PM0442, TorD, RpL5, FIdA, PM1480 and PMO979.
Table 2
Proteins identified by 1-D LC MS/MS in the sarcosine- insoluble membrane fraction of P. multocida
Protein LaneD Theoretical Matching identified3 mass (KDa) Gel slice0 peptides3
PM0336 1 113843 2 4
PM0337 1 113340 2 5
2 2 11
HyaD 2 111601 2, 5 1
PM0300 1 109713 2 11
2 2 16
PM0803 2 90993 1, 2 13, 4
PM1600 1 88018 2 9
PM1992 1 87761 2 33
2 1, 2 18, 3
ParC 1 83698 3 4
PfhR 2 81332 1 7
FuSA 2 77186 2 9
ESt 1 74601 3 6
HyaE 2 72986 1 4
PM1809 1 67106 3 3
AtpA 2 55770 3 3
PM0527 1 50682 4 12
PepP 1 50316 5 4
GIyA 2 45684 3 4
PM1069 1 43654 3, 4 , 5, 6 2, 13, 8, 5
2 4 4
TrpB 1 43624 6 1
2 1, 2 , 3, 4, 12, 9, 19, 3,
TufA 43353 5, 8 6, 2
OmpH_2 1 38778 4, 5 9, 3
2 4 4
1 1, 2 , 3, 4, 1, 4, 6, 14,
PM0786 38031 5, 6 , 7, 8 16, 16, 3, 5
2 1, 3 , 4, 5 7, 7, 8, 13
RecA 2 37907 4 1
AsnA 2 37463 4 1
OmpH_l 1 37450 1, 3, 4, 5, 8 1, 3, 3, 3, 1
2 1, 3, 4, 5, 5, 6, 12, 10,
6, 7 1, 3
MreB 2 37415 4 2
MgIC 1 35886 8 1
PM1578 1 35861 5 1
PM1426 1 35581 6 3
2 5 2
ThyA 2 32577 5 2
PM0998 1 28623 2, 3, 4, 6 1, 2, 3, 6
2 5 2
PIpB 1 28246 6 2
RpS2 1 27944 6 3
VacJ 1 27528 6 1
PM1021 1 26413 6 1
PM0442 1 23866 1, 3 1, 1
TorD 1 22828 2 2
OmpW 1 21870 8 2
2 7 1
RpL5 2 20383 7 3
PIdA 2 19723 7 1
PM1480 2 18876 8 2
Lpp 1 15588 7 5
2 8 1
PM0979 1 14610 7 4
PM0966 1 14319 7 6
2 8 4
RpSIl 2 13885 8 1
RpL14 2 13501 8 2
a Protein names are as used in the Pm70 genome annotation (May et al, 2001) . In some instances the closest matching peptide was to a protein sequenced from a P. multocida strain other than Pm70, but for simplicity the orthologous Pm70 protein name has been used. For HyaD the protein name from P. multocida strain X-73 (Chung et al, 1998) has been used; there is no true orthologue of this protein in Pm70, as it is of a different capsular
type. Proteins are listed in order of decreasing molecular weight. b Lane indicates the gel lane from which the protein was identified (Fig. 2) . Lane A contained sarcosine- insoluble membrane material from bacteria grown in BHI while lane B contained sarcosine-insoluble membrane material from bacteria isolated from the blood of chickens . c The 1-D gel slice from which the protein was identified. In some instances the protein was identified from more than one gel slice. Gel slice 1 was from the highest MW region of the gel while gel slice 8 was from the lowest
MW region of the gel. d Indicates the number of peptides obtained by nanoLC- MS/MS which match the theoretical peptides derived by in silico tryptic digestion of the conceptual translation.
Multiple values refer to the number of matched peptides in each gel slice from which the protein was identified.
Example 4 Functional grouping of P. multocida OMPs
Using the combined analyses described above, a total of 35 proteins was identified in the sarcosine- insoluble membrane fraction of P. multocida grown in vitro in BHI. The predicted function of these proteins was assessed by similarity searches using the programs BLASTP and RPSBLAST, with the following settings: BLASTP settings : Matrix=Blosum62 ; Gap costs=Existence=ll, Extension=l; Low complexity filter=ON;
Expect =10 RPSBLAST settings : Low complexity filter=ON, Expect =0.01, Search mode=Multiple hits 1-Pass
Each of the proteins was also placed in its appropriate clusters of orthologous groups (COGs) functional category, as summarised in Table 3.
Table 3
Bioinformatic predictions of subcellular localization and protein function for all proteins identified in the P. multocida sarcosine-insoluble membrane fraction of in vitro-grown bacteria.
Protein Proteome PSORTB " COGs Predicted function or
Analyst b group orthologue function6
ESt SEC OM I autotransporter ; lipase
GIpQ PER 1 OM C glycerophosphodiester phosphodiesterase ; l_ lipoprotein _ __
Lpp f OM IM M peptidoglycan-assocxated lipoprotein; lipoprotein
MgIC IM IM G galactoside ABC transporter, permease protein
OmpH_l " OM OM M outer membrane porin
0mpH_2 OM OM M outer membrane_ porin _
OmpW £ OM OM M outer membrane protein
_ OmpW _ ___ ParC CYT IM L topoisomerase _IV subunit _A_
PepP CYT CYT E aminopeptidase P, xaa-pro ammopeptidase
PIpB OM NP ABC-type transport; lipoprotein
Pm0300 OM OM P Haemoglobin binding protein, TonB dependent
PmO336 OM OM P Haemoglobin binding protein, TonB dependent
PmO337 OM OM P Haemoglobin binding protejLn, TonB dep_end_ent j
PmO442 ε
IM _ IM J S unknown; lipoprotein
PmO527 ε OM OM I M TolC-like efflux protein; lipoprotein
PmO612 NP NP S unknown
PmO786 ε OM OM M OmpA-like outer membrane
protein_
PmO96δ * OM OM M OmpA-like outer membrane protein; _ lipoprotein
PmO979 PER j NP S_ unknown; lipoprotein
PmO998 f OM OM M Synthesis of murein sacculus; scaffolding protein_
PmlO21 i IM NP M D, D-carboxypeptidase related protein
PmlO64 OM NP S unknown; lipoprotein
PmlO69 OM OM I Outer membrane porin ; fatty acid transport
Pml426 ! OM OM M phospholipase A
Pml578 f PER NP S Periplasmic binding protein; lipoprotein
PmlβOO i OM OM M organic solvent tolerance protein
Pml720 SEC NP Competence associated; lipoprotein
Pml809 OM OM M unknown Pml992 OM OM M outer membrane porin; antigen OMA87 __
RpS2 IM _NP_ J ribosomal protein S2 TorD CYT CYT S trimethylamine-n-oxide oxidoreductase
TrpB CYT NP tryptophan synthase beta chain TufA CYT CYT translation elongation factor EF-Tu TUfA CYT CYT translation elongation factor EF-Tu
VacJ OM NP M intercellular spread in
Shigella flexneri ; lipoprotein
a Protein names are as used in the Pm70 genome annotation (May et al , 2001) .
b Subcellular localization as predicted by Proteome Analyst (Lu et al, 2004) ; CYT, cytoplasmic location; IM, inner membrane- associated; PER, periplasmic location; OM, outer membrane- located, SEC, secreted; NP, no prediction.
0 Subcellular localization as predicted by PSORTB (Gardy et al, 2003) ; CYT, cytoplasmic location; IM, inner membrane-associated; PER, periplasmic location; OM, outer membrane-located, SEC, secreted; NP, no prediction. d Clusters of orthologous groups (COGs) category (Tatusov et al, 1997) . The COGs functional categories are: C, Energy production and conversion; E, Amino acid transport and metabolism; G, Carbohydrate transport and metabolism; I, Lipid transport and metabolism; J, Translation; L, Replication, recombination and repair; M, Cell wall/membrane biogenesis; P, Inorganic ion transport and metabolism; S, Function unknown (which includes categories R, General function prediction only and -, not in COGs) ; e Predicted protein function or known function of the closest orthologous protein. f Proteins identified by both 2 -DGE MALDI-TOF MS and 1-D LC MS/MS methods
Fourteen of the 35 proteins were from the COGs cell wall/membrane biogenesis (M) category, while nine were from COGs categories involved in transport, including transport of amino acids (E) , carbohydrates (G) , lipids (I) and inorganic ions (P) . Seven of the 35 were from COGs categories with no defined function. The subcellular localisation of the proteins was predicted by the algorithms PSORTB (Gardy et al, 2003) and Proteome Analyst (Lu et al, 2004), and is also shown in Table 3. Twenty-one of the 35 proteins were predicted by at least one of the two prediction algorithms to be located in the outer membrane, indicating that the sarcosine-insoluble membrane fraction is indeed highly enriched in OMPs. Interestingly, nearly 1/3 of the proteins (11 of 34) were
predicted to be lipoproteins by LipoP (Juncker et al, 2003) ; this is more than double the proportion identified in the Escherichia coli outer membrane (Molloy et al, 2000) .
Example 5 P. multocida outer membrane profile after growth in iron-depleted medium Iron is essential for growth in almost all bacterial species, but the in vivo concentration of iron in avian hosts is too low to sustain normal growth
(Paustian et al, 2001) . P. multocida has been shown previously to modify its gene expression in response to low free iron concentrations (Paustian et al, 2001) . Therefore we sought to identify changes in outer membrane protein profile in response to this important environmental condition. To determine the protein composition of the P. multocida outer membrane under iron-limited growth, we analysed the sarcosine-insoluble membrane fraction of bacteria grown in chemically-defined medium in the presence or absence of the iron chelator
2,2 ■ -dipyridyl.
OMPs separated by 2-DGE were quantified by densitometric analysis using Melanie 4 (GeneBio, Geneva, Switzerland) . Protein spot quantities were calculated as a percentage of the total spot density on the gel, and log expression ratios defined as Log2 [percentage spot density on the experimental gel (iron-limited) divided by the percentage spot density on the control gel (iron- replete) ] . All spot values of zero were "normalised" to a low positive value to allow expression values to be determined. Spots were quantified on triplicate gels (biological replicates) and the confidence value (CV) calculated as the standard deviation divided by the mean expression value. Three proteins (GIpQ, PmO527 and PmO612) were not identified consistently on the triplicate 2-DGE, so they were omitted from the analysis.
The OMPs from three replicate cultures were separated by 2 -DGE, as illustrated in Figure 3, and the
proteins were identified by MALDI-TOF MS. Protein spot quantities were determined by densitometry, and two proteins were identified which showed statistically significant changes across all three replicate gels. These results are summarised in Table 4, in which the proteins not previously known to be associated with the outer membrane are PIpB, PM0442, PM0803, PM0998, PM1064, PM1069, PM1578, PM1720, TufA/B and VacJ. Pm0803, which was found to be strongly expressed during growth in iron- limited conditions, was not identified at all under standard growth conditions. Conversely, the expression of OmpW was found to be significantly down-regulated during iron-limited growth.
Table 4
Average expression ratio of all sarcosine-insoluble proteins from cells cultured under either iron-limited or iron-replete growth conditions in CDM. Expression ratios were determined by densitometric analysis of SyproRuby- stained second dimension polyacrylamide gels.
Proteina Average expression CV0 ratio"
Lpp 0.27 10
PIpB -0.42 -3.0
Pml992 -0.56 -1.8
OmpH_l 1.16 1.0
OmpW4 -1.72 -0.3
PmO966 -0.14 -5
Pm0442 -1.41 -1.7
PmO786 -0.61 -0.7
PmO803 6.63 0.5
PmO998 0.70 1.9
PmlO64 -1.17 -1.3
PmlO69 -1.12 -1.8
Pml578 -0.09 -150
Pml720 -1.89 -0.8
TufA/B -0.12 -3.3
VacJ 0.02 0.5
a Three proteins identified from Fig. 1 (GIpQ, PmO527 and PmO612) were not identified consistently from the triplicate gels, and have been omitted from the quantitative analysis. b Average expression values are expressed as the log2 of
(average density of spots from iron-limited growth/average density of spots from iron-replete growth) . Identical experimental and control expression values would be 0.0. c Confidence value is standard deviation (calculated from triplicate gels) /mean expression value. d Proteins in bold showed significant differential
expression, defined as an absolute expression ratio > 1.0 and an absolute CV <0.5.
Example 6 P. multocida OMP profile during growth in chicken blood in vivo
To determine the protein composition of the P. multocida outer membrane during growth in vivo, we analysed the sarcosine-insoluble membrane fraction of bacteria recovered from the bloodstream of infected chickens. Although bacteria were recovered from three separate chicken infections, we only obtained sufficient outer membrane material for 2-DGE analysis from two of the three infections . Therefore we compared two technical replicates of each duplicate biological sample by 2 -DGE, as illustrated in Fig. 4, and the proteins were identified by MALDI-TOF MS. Three proteins, Pm0803, TufA and TufB, were identified as significantly up-regulated across all of the 2-D gels. The in vivo-derived sarcosine-insoluble membrane fraction from one of the samples was also analysed by 1-D SDS PAGE (Figure 2, lane 1) and the proteins identified by nanoLC-MS/MS (Table 2) .
Fifteen proteins were identified in these samples which were not found in the sarcosine-insoluble membrane fraction from P. multocida grown in vitro in BHI. These included the predicted iron-regulated porins PmO803 and PfhR. However, thirteen of these proteins were predicted to be either inner membrane or cytoplasmic proteins, indicating that this in vivo-derived sample was more contaminated with low levels of non-outer membrane material than the in vitro-derived samples. Although the reason for this higher level of contamination is unclear, it was limited to the in vivo samples, and may be due either to increased fragility of the in vivo-derived organisms or to the slightly different processing required for purification of bacteria from the blood of chickens . The contaminating proteins were present at low levels, as they were not identified as significant spots present on the 2-DGE (Fig. 4) . Despite this, Pm0803 and
TufA were abundant constituents of these in vivo-derived ID LC MS/MS analysed samples,' and were identified from 2 and 6 gel slices respectively, thereby corroborating the 2-DGE and MALDI-TOF MS data.
Example 7 Candidate vaccine antigens
In order to develop protective vaccines against fowl cholera caused by P. multocida, a genomics-based approach was applied in the identification of putative vaccine candidates. This approach utilised the genome sequence of P. multocida PM70 to select candidate genes according to the vaccine antigen potential of the corresponding protein, which we predicted on the basis of the predicted cellular localisation of the protein, as discussed in Examples 4 to 6, and its similarity to other proteins with putative or confirmed experimental roles in infection and immunity. A range of bioinformatics analyses was used to predict the entire set of P. multocida outer membrane antigens. All 2015 P. multocida strain Pm70 proteins encoded by open reading frames
(ORFs) were analysed for cellular localisation, using the PSORTB and ProteomeAnalyst web servers . Analysis was set for Gram-negative bacteria. Proteins were chosen for cloning if they met any of the following criteria: 1. Identified as outer membrane, extracellular or secreted proteins by PSORTB and Proteome Analyst;
2. Predicted to be lipoproteins by LipoP;
3. Were listed as porins in the superfamily database
(Madera et al, 2004) ; 4. BLASTP analysis indicated identity to known autotransporter proteins from other species; 5. BLASTP analysis indicated identity to known OMPs from other species .
As the strain whose genome has been sequenced, PM70, is not virulent for chickens, subtractive hybridisation was used to identify genes specific to the chicken-virulent isolate P. multocida strain X-73. Any genes unique to X-73 and predicted to encode outer
membrane or secreted proteins were also chosen for cloning. Over 130 P. multocida proteins were predicted to be surface expressed and/or secreted extracellularly, thus necessitating the adoption of a high-throughput cloning strategy (Pizza et al 2000) . A very high throughput proteome microarray screening method for antigen discovery may also be used (see for example the method of Davies et al, 2005) .
So far 92 PCR-amplified open reading frames (ORFs) from P. multocida, encoding putative surface or secreted proteins, have been cloned using the Gateway cloning system. Other ORFs may be cloned in the same way. Each ORF was cloned into an entry plasmid vector (pENTR™/SD/D-TOPO<B, Invitrogen) and then transferred to a destination plasmid vector (pBAD-DEST49 or pDEST17, (Invitrogen), or pLIC-Nus (Cabrita ETAL, 2006)) for protein expression in Escherichia coli DH5α. As only the gene section encoding the mature length protein was cloned, this necessitated prediction of the signal peptide cleavage point as well as the addition of an ATG initiation sequence at the 5' end of gene. Moreover, as the genes were eventually going to be expressed in-frame with a C-terminal tag, the native stop codon was removed when designing the reverse primer. Gene amplification was carried out with primers containing the sequence 5'- CACC-3', which is required for directional cloning into the TOPO entry vector. All genes were amplified using a proofreading polymerase. Of the 92 fusion proteins which were generated in pBAD-DEST49, 80% have been shown to express measurable levels of protein in Escherichia coli
DH5α, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. It is expected that by routine variation and optimization of conditions the remaining fusion proteins may also be expressed, provided that the encoded gene product is not toxic to the host cell.
The proteins which were cloned and their expression levels are summarized in Table 5. In some
cases it was advantageous to express the protein linked to the solubility tag NusA or thioredoxin to enable enhance solubility and/or folding of the protein, and/or to express the protein linked to the affinity tag hexahistidine (His6) to facilitate assay and purification, and the destination vectors were selected accordingly. It will be appreciated that a variety of alternative solubility and affinity tags are known in the art, and the skilled person will be able to select the optimal system for a given protein.
TABLE 5
INSOLUBLE PROTEINS
Gene Vector Expression Nus A MW
Name Level
PMO040 pDEST 17 ++ No 72
PM0055 pLIC-Nus ++++ Yes 84
PM0056 pDEST 17 + NO 48
PM0076 pDEST 17 ++ No 68
PM0246 pDEST 17 ++++ No 20
PM0300 pDEST 17 + No 96
PM0331 pDEST 17 ++ No 20
PM0337 pDEST 17 + No 100
PM0355 pDEST 17 ++++ No 26
PM0388 pDEST 17 ++++ No 35
PM0389 pDEST 17 + No 35
PM0519 pDEST 17 + No 71
PMO527 pDEST 17 ++++ No 46
PMO542 pLIC-Nus + Yes 126
PM0554 pLIC-Nus +++ yes 75
PM0586 pDEST 17 ++++ No 28
PM0612 pLIC-Nus +++ Yes 70
PM0618 pLIC-Nus + Yes 146
PM0680 pLIC-Nus + yes 128
PM0708 pDEST 17 ++ No 18
PM0714-1 pDEST 17 + No 100+
PM0714-2 pLIC-Nus + Yes 100+
PM0714-3 pLIC-Nus ++ Yes 150
PM0741 pDEST 17 + No 78
PM0786 pDEST 17 +++ No 35
PM0803 pDEST 17 + No 79
PM0892 pLIC-Nus +++ Yes 102
PM0903 pDEST 17 +++ No 40
PM0928 pDEST 17 +++ No 37
PM0966 pDEST 17 +++ No 15
PM0979 pDEST 17 ++ No 14
PM0998 pLIC-Nus ++++ Yes 87
PM1016 pDEST 17 +++ No 39
PM1025 pDEST 17 ++ No 19
PM1069 pLIC-Nus + Yes 103
PM1081 pLIC-Nus + Yes 140
PM1225 pDEST 17 ++ No 44
PM1238 pDEST 17 ++ No 34
PM1245 pLIC-Nus +++ Yes 89
PM1426 pLIC-Nus + Yes 90
PM1428 pBAD- ++ 100
DEST49
PM1451 pLIC-Nus ++ Yes 87
PM1501 pDEST 17 ++ No 24
PM1622 pDEST 17 + No 85
PM1717 pBAD- + 105
DEST49
PM1720 pDEST 17 +++ No 26
PM1730 pLIC-Nus + Yes 87
PM1809 pDEST 17 ++ No 59
PM1826 pLIC-Nus +++ yes 84
PM1886 pDEST 17 + No 14
PM1974 pDEST 17 +++ No 15
PM1980 pLIC-Nus ++ Yes 106
PM1992 pDEST 17 +++ No 79
PM1993 pDEST 17 +++ No 19
PM2008 pDEST 17 +++ No 18
PM0892 pLIC-Nus +++ yes 102
SOLUBLE HIS TAG
Gene Expression NuS
Name Vector Level A MW
PM0243 pLIC-Nus ++ 113
PM0368 pLIC-Nus ++ 84
PM0659 pDEST 17 + 190
PM0778 pLIC-Nus + 100
PM1050 pLIC-Nus ++ 93
PM1077 pLIC-Nus + 80
PM1578 pLIC-Nus ++ 93
PM1611 pDEST 17 ++ 17
PM1614 pLIC-Nus ++ 106
PM1670 pLIC-Nus + 80
PM1707 pLIC-Nus + 98
These expressed proteins were purified as insoluble inclusion bodies. Strains were grown to mid- exponential phase (OD600=0.5) and induced for 4 h by the addition of arabinose to a final concentration of 0.2%.
The induced cultures were chemically lysed by incubation of the culture with PopCulture (Novagen) , benzoase and lysozyrae for at least 15 rain at 2OC. ImI of the cell lysate was then added to a 96-well filter plate (Pall) and the solution drawn through the filter under vacuum. The insoluble inclusion bodies were retained, while soluble proteins passed through the filter. The retained inclusion bodes were washed once with Triton X-100 to remove any remaining soluble proteins, followed by two washes with phosphate buffer. The washed proteins were then denatured by the addition of 200 μl of 8M urea to each corresponding well, incubated for 16 h at 4C and then collected under vacuum.
Example 8 Generation of antibody in mice
Approximately 25 μg of each of a subset of the antigens prepared in Example 7, plus aluminium hydroxide (Sigma) as an adjuvant, was injected subcutaneousIy into 5 mice, followed by a booster injection also using aluminium hydroxide. The following antigens were used: PM0076, PM1064, PM1451, PM1578, PMl611, PM1614, PM1717, PM1746, PM1805, PM1809, PM1826, PM1827, PM1886, PM1897, PM1905, PM1980, PM1993 and PM2008. Each group of mice, including an unvaccinated control group, was then challenged intraperitoneally with 100 CFU of live virulent P. multocida X-73 in the BHI growth medium to assess the vaccine potential of the antigen. The mice were monitored for clinical symptoms, and euthanised in accordance to animal ethics requirements. The protective capacity of the antigen was assessed by the lack of clinical symptoms or a delay in onset of clinical symptoms in the vaccinated mice compared to unvaccinated controls.
Although an antibody response was generated against these antigens, no protective effect was observed in this experiment.
Example 9 Protection studies in chickens
Purified recombinant OMP is mixed with Alhydrogel (Sigma) 0.25 mg/ml . The birds are divided into groups with 4 to 10 birds per group. Test groups are injected intramuscularly with purified recombinant protein preparation up to 100 μg protein (0.5 ml) per bird. A positive control group 4 is injected intramuscularly with P. multocida X-73 bacterin prepared as described previously (Wang et al . , 1994a; Wang et al . , 1994b) . A negative control group is not vaccinated. The birds are vaccinated twice, at an interval of 2 to 3 weeks between vaccinations. Fourteen days after the second vaccination, a blood sample is taken from each bird and the birds are challenged with 100 CFU of P. multocida X-73. The birds are observed for 10-18 days after challenge, and mortalities are recorded.
Antibody titres in the blood samples are determined by enzyme-linked immunosorbent assay (ELISA) . Immunoplates (Nunc, VWR Scientific, Bridgeport, New Jersey) are coated at 40C overnight with 100 ng of the following antigens: recombinant OMP, and X-73 whole P. multocida cell lysate in carbonate buffer (pH 9.5). The plates are washed three times with 0.01 M PBS containing 0.05% Tween 20 (pH 7.2), followed by adding 200 μl of blocking buffer (PBS containing 1% bovine serum albumin) and incubated at room temperature for 30 minutes. After washing, 50 μl of antisera serially diluted with blocking buffer are added and incubated at room temperature for 30 minutes. After further washing, 50 μl of 1: 5000 diluted rabbit anti-chicken IgG conjugated to horseradish peroxidase (HRP) (Zymed Laboratories, Inc., San
Francisco, California) is added and incubated at room temperature for 1 hour. For colour development, 100 μl of 3,3', 5,5'- tetramethylbenzidine (TMB) substrate is added and incubated for 30 minutes, followed by addition of 0.25% 100 μl of hydrofluoric acid to stop the reaction.
Antibody levels in chicken blood may also be assessed by western blotting. Antigens consisting of
P. multocida whole cells, purified recombinant proteins or E. coli cells expressing the recombinant proteins are separated by ID SDS-PAGE as described above. Separated proteins are transblotted on to nitrocellulose membranes, pore size 0.45 μm (Schleicher and Scheuell, Dassel, Germany) using a BioRad transblot cell or equivalent apparatus at 75 V for 1 hour in transblot buffer consisting of 1.52 g Tris, 7.21 g glycine and 100 ml methanol made up to 1 litre with distilled water. Membranes are then blocked for 30 minutes at room temperature with 3% bovine serum albumin in TBS-Tween. Membranes are then incubated with dilutions of chicken serum from 1/50 to 1/10,000 for 1 hour to overnight at either room temperature or 37°C. Membranes are then washed four times for 5 minutes in TBS-Tween and then incubated at 370C for 2 hours with 1/100 to 1/10,000 dilutions in TBS-Tween of peroxidase-conjugated goat or rabbit anti-chicken immunoglobulins. Membranes are then washed four times for 5 minutes in TBS-Tween and once in TBS. Detection is achieved by incubating the membranes in the dark at room temperature in substrate solution consisting of 25ml TBS, 15 μl of 30% (vol/vol) hydrogen peroxide added to 5 ml methanol with 30 mg 4-chloro-l- naphthol until the desired colour level is obtained. Membranes are washed several times in distilled water and stored in the dark at room temperature .
Example 10 Identification of protective antigens This experiment was aimed at identifying vaccine antigens capable of protecting chickens from the devastating effects of P. multocida, the causative agent of fowl cholera. The objective was to identify which of the expressed recombinant proteins offers a degree of protection from the lethal effects of P. multocida. challenge. Sixty-seven candidate antigens were tested individually. Three multivalent vaccination groups were also tested, giving a total of 70 vaccinated groups.
The trial was performed using commercial layer
hens 12 weeks of age (288 birds) . The birds were randomly assigned to two rooms, each containing 12 pens with 12 birds in each pen. All birds were wing-tagged. Each treatment group consisted of four birds, so each pen housed three treatment groups, resulting in a total of 70 treatment groups (70 antigens) .
Prior to challenge, chickens were vaccinated subcutaneousIy with 0.5 ml of vaccine, containing 50 μg purified recombinant protein which was mixed with 0.5 ml Alhydrogel (Sigma) . The vaccination was repeated two weeks later. In each room each of 35 groups of birds received a unique vaccine. In each room a 36th group of birds acted as unvaccinated negative controls .
At 16 weeks of age all birds were challenged by intramuscular injection with 100 μl of bacterial culture containing 103 c.f.u. of P. multocida strain X-73 in BHI growth medium. All birds who developed signs of acute fowl cholera were euthanised.
At the end of the trial there were six intact groups of chickens (2 in room 1, 4 in room 2) , suggesting that six different recombinant proteins conferred a significant advantage in survival. These results are summarized in Table 6.
Table 6 Putative Vaccine Candidates
Room Protein Predicted function Survival
None 3 /4
(Control) PM0527 OMP ToIC efflux protein 4 /4
(confirmed by proteoraics) PM0680 OMP oligopeptidase 4 /4
None 0/4
(Control) PM1426 OMP phospholipase A 4/4
(confirmed by proteomics)
PM1428 iron-regulated OMP (binds 4/4 haemin)
PM1707 OMP bacterial kelch protein 4/4 PM1730 lipoprotein (confirmed by 4/4 proteomics)
In addition to the data regarding efficacy of the vaccine, sera were collected from the vaccinated groups prior to and after challenge, primarily in order to assess the response to each antigen, as well to obtain specific sera for each antigen as a resource for future functional studies . The sera were tested by Western blotting. The results, which are illustrated in Figure 5, show that antibodies specifically recognising four of the six putative vaccine candidates were elicited. Protective antibody responses were observed against the following putative immunogens :
PM0527
PM0680
PM1428 PM1426
PM1707
PM1730
For PM0680 and PM1426 we have not yet confirmed conclusively whether the reaction is specific for the antigen or for the solubility tag (NusA) . This is tested by recloning these proteins into a different expression vector.
To evaluate expression of antigens from P. multocida X-73 during infection in the chicken host, convalescent-phase sera from a number of chickens were also tested for reactivity against all the recombinant proteins prepared as described in Example 7, using
Western blot analysis. The results demonstrated that immune sera generated during experimental challenge with P. multocida recognised the following 16 recombinant proteins : PM0388, PM0442, PM0554, PM0659, PM0741, PM0786, PM0903, PM0966, PM0979, PM1050, PM1614, PM1614, PM1730, PM1979, PM1992, and PM1993, six of which, namely PM0442, PM0659, PM0979, PM1614, PM1979 and PM1993, have not previously been suggested to be associated with the outer membrane or to be immunogenic.
A further trial is carried out using 10 chickens per group in order to produce statistically significant results.
The amino acid sequences of the proteins used in this example are as follows:
PM0527 (SEQ ID NO: 1)
MLKRNPLTFLLLSTALVGCANLDDSYQLAKQDFQQYEEVTKQYSVQESWWALYHDTQ LNALITQGLDNNKNLAKAAINVNKALYQANLLGANLVPAFSGRVESSATRNIEHSQP SKIQHSGSINVSYTLDLWRRLADAASAGEWAYKASAQDLEAΆRLSLINSLIATYYQI AFLNDALQATEGTIKYYTQINTIMQNRFKLGVADSASSDQTQQAVLRARNQLITYQT QRKVAEQTLRNLLNLKPNEALNIKFPSILNVKTLGVNTNVPVSTIANRPDIKSAQYR LSSAFKDAKAVQKSWFPTITLGASLASAGAKVDTALDTPMASGLVSINLPFLSWNTV KWNVKISEANYELAKVSYEQTITTALNEIDTHYFSYQQSQANLANLQKADAYNKRIT
QYYKNRYDAGVSPLRDWLSAANTENDAKLAILNAKYQLIQQENTIYSAMAGYYSAK
PM0680 (SEQ ID NO: 2) MSNPLLSFEGLPPFSQIKPEHVQPAVENLIQACRDNIEQLLKQEQFTWDNFILPLTE
MGDRFSKAWSPVSHLNAVKNSPELRAAYQACLPLLSEYSTWVGQHKGLYQAYEKLKN SPEFAHYDLAQQKTIDNALRDFKLSGISLSAEKQKRYGEISARLSELSAQFSNNVLD
ATMGWDKVIENLEELKGLPESALAAAKQSAENKGLEGYRFTLEIPSYLPV]Y[TYCENR ALREEMYRAFVTRASDQGPNAGKWDNSAIMQEILNLRVELAHLLDFNCYTELSLATK MAEKPQQVLDFLDSLAKRSKTQGEKELAELLDFCQTQFGVNELEAWDIAFYSEKQKQ YLYSINDEELRPYFPENRVLAGLFELIQRIFNIRTVERFGIDTWHNDVRFFDLIDEN DNLRGSFYLDLYARENKRGGAWMDDCIGRRKKANGEIQKPVAYLTCNFNAPVGDKPA LFTHDEVTTLFHEFGHGIHHMLTEIDVADVAGISGVPWDAVELPSQFLENWCWEADA LDFISGHYETGEPLPKEKLAQLLKAKNFQAAMFVLRQLEFGLFDFRLHHHFDPTKAN QILDTLKAVKEEVAVIKGVEWARAPHSFSHIFAGGYAAGYYSYLWAEVLSADAFSRF EEEGIFNPETGKSFLAEILSRGGSEEPMTLFKRFRGREPQLDALLRHKGIAN
PM1426 (SEQ ID NO : 3)
VPLMVKLFTLVKEVIRMYKAKGINLYKKCLILAVLGVFVSHGTQANESDARPYKSKA EVLLTKSDAFIGLLGYEENYLMGTYSNRHFLKREKTQKDEIKFKISLALPLWRGILG NNSVLAASYTQKSWFQLSNVDDSSPFRETNYEPQLFLAWKTQYSLPFGWTLQDVETG INHQSNGRDDAEKLSRSWNRLYVRASAIKQNWTVEIKPWWRIPEKAKNDDNPDITKY RGHFDVALGYYYHDHQFKLSGHYNPISNKGGLEASYSYPITKNIRFYTQYYNGYGES LIDYQQRIQRIGIGISLNNVF
PM1428 (SEQ ID NO: 4)
MISRGCKVNKFFAVLMMCCIPQWWANTEKKQIVFLDEISVESKGAAFRSDPLSGLP KQNDILVSKQKLKTGSSTLGNALAGELSVHSNQFGGGSSAPWRGQEGVRLKILQNG SDVIDMSQLSPDHAIGVDTLLAEQVEIVRGASTLL YANASPAGVINWDKRIPTQLP
KKGYEVDFNTRYNTNSHEKLVTAALTFGLGKHIALRVEELLRGSNNYHVPAFKLDKT LNYVPDTQNKTKSGNYGVAFIGERGYVGFAYNLRREKYGLPGHNHKLDSCAAHIWGG NVRNDYYLGLYPHLMHDTDLVNTHFHCGSNHDMDGKHSHNHPYGHDHDHSIAGPLID SYAKRYDIRAEVKQPMKAIEKIKLSYSETRYKHDEKDGNIAVNLFKNNGYNLRVEIF HTPIAGLSGVIGAQYQTQTSSANIPRIAPCSNNASDPCHKKKQRDPSKITKGDRKSW
ALIENTQSQMSFFAIEQLRWQDFLFEIGVRTEKQRIDIEYDRAWLFKVKRKLEGCDP NSFFYSPSGCRQGSYPAPDFASYHDRATSYSGAISWNMTPDYTLSLTYSHNERHPTP MELYYHGKHLATVSFEHGNRNLKKEVSDNWEVGLAYLGDKLSYKVNVYYNDFKNRIF NQTLNKSGNLSLNRYNQSKAKYYGVEGRIDYALTPELHMGLFGDYVRGKLYDLPPTY RVDHVANSLEPVTQPDQDAPRVPPMRLGFRVNMEMTESLTSSLEYTYVYQQKKVAPL
ENQTAAYSLLNIGVDYSRQIAGVNYQLFVQANNVLNRKVYSHTSFLPFVPQMGRNVT
LGLNIHF
PM1707 (SEQ ID NO: 5)
MKFTKTALFTVLAATAFAAQAGQYPDLPEGIKAGAGALIGDTVYVGLGGTGTTKFYS LNLKDPKEWKEIAEFPGGKRNQPVAAGVNGKLYVFGGFQDTDVAKNQIINDAYEYNP ADNTWTKLSTRSPRSTSVGASVAADGGKIYFVGGVNHEIWNGLFQDVKAAGGDKEKE KAIFDPYFNLRAQDFFFSPEIISYEPANNVWRNEGYFPYSGRAGAAVAIKDGKLLW NGEVKAGLRSPGTALGTIGKDGVTWKKLGDLPAPTGYDKQDGIAGGMGGYTNGHYIV
TGGANFPGALANYEKGIMDAHRTGGLKKTYHKAVYALDGKTGNWKIVGELPATIGYG LAVSYNNKVLLIGGETDGGKPLSAVQTMSYDGKKLTVE
PM1730 (SEQ ID NO : 6)
MKLTKLFG]-ATLVSAVALAGCKDDKPAAAAAPQEPAARKLTVGVMTGAEAQVTEVAA KIAKEKYNIDVKLVEFTEYTQPNDALTKGDLDANAFQHKPYMDKEVEQRGYKLAIVG NTFVFPIAAYSKKIKNVSELQDGATVAVPNNPSNLGRALLLLEKQGLIKLKDPSNLF STS IDVI ENPKNLQ I KEVEGSLLPRMLDDVDFAI INNNYAVQQGLTAEKDGI FVEDK DSPYVNLWSREDNKDNEAIKDFVKAFQTEEVYQEALKHFQGGWKGW
PM0442 (SEQ ID NO : 7 )
MKKSVLAALVLGASLSVTGCFDKESKAGQEVEKAKASWETKEAWNAANEVKNSAV EAAKEAKETVATKVEEVKETTAAKVEEVKAATAAKVEEMKETTAAKVEEMKEASAAK MEEVKAATATKMEEMKAAVADAKNDVAEKAAEVKDAAAAKAEEAKAAVAEKSAEMKD AAAAKVEDAKVASSEAKEMVTEKATEMKDAMKAEVNKAADAVSEKTEEVKEVIVPKA Q PM0659 (SEQ ID NO : 8)
MNKQYFLSLFSTLAVALTLSGCWDKKQDEANAIQFNVNPIEITNYDETPKEVYPLVI SFSGPAAPITSVNKELTQGISIEPALKGKWVWNSDTLLSFKPETDWPTGQDYRVKID KKILNPQLHYTQKLNEPWFKTPEFKATLVEQYFHQDPTQAQVRHAIFKLSFTHPVD RQKFEKALQVNLVRKNNDNTQNILSPLKFNVRYGEKDLVAWVNSDNVALAQSDNQYI EVKIDKNLTALLGNNSLETDIISSVKVPTKYSLDFSTGILIAQNEKNEAEQVLHLNF THSIKGNELEKHISAYLLPEFTPENHPHWRYNLISRDVLQHAVAVPLQRLATETTYA NQQSFKLDIPEKRCLYIEVQNKITALGGYEMKGALGDLACAPDYPKYVGFVGKGSIL SSIGERKVTIATRNFTKVKLEIGRIQEEQLRHLIALNQGNFQNPDLGQLKIDNIADF FTKNYTLNNKKPQETTYLGIDLEKIVKQAEPAMGIYWLKVTGDSDNPNSTLRDTSQH
MDWRNDASNQFSDYRLIVISDLGVIAKKAVDGTQSVFVQSISRGEPVEGATVSVISR NGSIIKSDYTNEQGWNFSSLAHFKQELAPVMYLVSTQESLSFLPIDKYDRNLDYSR FDVGGIYASENAASLKAYLFNDRGIYRPNETLHTGIITKAQDWQLALNNIPLQFNLY SPSGMLMHKQTIRLEKSGLNSVSFTLPETAETGEWFAELLVTEKNNQTEIGSMTFQV QEFQPDNLKIKTTFNQAHAEGWVAPQDLVATVQLANLFGTPAQNRKVQANLTLQPLL
PKFSQYADYRFFDNQRNKSAILYETELNEQVTDKEGKAHFPIDLTQYAENTAQMLYF TADGFENDSGRAVSTVKSVMVSAQPWLIGYQTKNDLAYLKRNTPAVVNFIAVNPKLE KVAVEHLKATLLERKYVSVLTQQASGAYKYESKLIENEIEQTTLQINATGTDFTLNT GKSGDYVLVLSNEHDQEVNRIHYAVIGNQNVSVAMDKNTELKLRLNKKQFKPHEEIE IAIHAPYAGTGLITIESDRVYAHKWFKATTNSSVQRIQLPENFEGTGYVNVQFSRDI
HSDDIFTSPLSYGWPFTVNVDNRRLKLQLDSPKKVKSGETVEFKLSSDKPSKALIY AVNEGILQVAGYQFTDPLSYFFPKYALQVQTAQILDLILPEFSKVMQFAQTGGDADM NMELAMKMAMANMNPFKRKTDKPVAYWSGIVDIHGEKTVSYQIPEEFNGNLKVMAIA LSHDGKHLGHVATETLVRNDLILSPTVPLTLTPGDESEINWIANNTNKAQRVNLKA TLEPQLSFIGEAEKVIDIAPMSESRADFVIKATQELGSSTIRFIASYEDAQQQKVDA
VRHVTLSVRPIMPKQFATQIQKVAAGKTVTSPLPMTLFPQHRQQSALFSAAPLALAQ GVSTYLTHYDNYCTEQMISAAMPMVLFSKNPAYQPLLTALSRKAPQNVGSTGTHDTL EKAFKLLPSRQTEYGNYGIWNNVEEGNLFVTAYVAHFLIEARERHLVLPKAWFGQHG LFNNTISALEEQSVPQEGDSLATLRQRAYSAYLLTRLAKVPSNALLSIRTQLEQQFS AEEWQKDTVSAWLAAAYHMLKQDNEANKLIEPVINQLVAARPAQWTYDAYSDPLIKD
STMLYVIARHFPAQLSKVSDSVLERIVQDLNQQRYNTLSSSMVLLALDAYAQQHQSE LANLQIQHQGKEISQSTPLFRFADLADTQMDISFVNNSQQPAWFALSQVGYPQNAAQ QALSQGLEVDRSYTDKEGKPIRQVKIGDVIYVTVKIRASTDYVSDVIITDLYPAGFE VLWQQGAEDDFEDSWLAQHTELREDRLLSYLDAEKEMKVLKYQLKAVNIGTFQIPPI YAESMYDRAIKAYSASEGQIKVRK
PM0979 ( SEQ ID NO : 9 )
MKLTQLFAS LMVAGALTACAQNGADMKKAMEMKSSEPTFETAAYFCDVKGKKNQWS ATYTFVNGKADSATVTINRQWGHEMKLDSTYQDGVRFVEGNKVWSLDNGFAASTVG TTAAVMFTDNNKILAKNCTNAK
PM1614 ( SEQ ID NO : 10 ) MKKSFLLLPISVAVLAACSSNTPAPVESADGSLSPGMMQPVDASSGGTWEPQIQQQN TMPAGMDQSVYSPSTSQPSLPVSHQPTPPTSSSFDIPRKPVTGEPDYSKIARGSYQG ESYTVRKGDSMYLISYISGLSIKEIAALNNLSEPYTLATGQVLKLSNKVSTTSTMSP STAVGEVGTNVKPTTQHFEIPRNPADNRPDYSKIDKGFYKGETYTVRKGDTMYLIAY ISGLDVKELASLNNMSEPYRLSVGQTLRVSNGRVASTSSQPVTQPVTVPVSQPKSSE VTYTPGPHGTQYGSDGTIIGPIKSGVSSAPVPVQPEPWKPVESTSVPVPSTSSKHM VSNVTWQWPTKGNIVQGFSTADGGNKGIDIAGSRGQAVNAAAAGRWYAGNALRGYG NLIIIKHNDDYLSAYAHNESILVKDQQEVRAGQQIAKMGSSGTNSVKLHFEIRYKGK SVDPTRYLPKR PM1979 (SEQ ID NO: 11)
MLIEKLHGMTNSWVSKFLLGLIAVAFVLSGITGYVFTRVDTSAVKINGEEISQQTFY QRYESESERLRQQLGAQFAALSGSPEFVAGLRQSVLNNLINQELLRQYADELKIGIS DERVKQEIVTSQFFQQEGKFDNALYQRMLQLNGLTPDAYANIVREGLRLEQLQTGLA ESEFIVPAQQAQLTELFFQARTVRLAPFSLDQVLEKQTISDEEVSAYYEANKGAFLV
PELAKVQYMTLTRADVEKHIQVSDVEIAQYYQDNKALYVSQGQQRLSHIQVATEAEA KEIYQALQDGANFAGLASARSLDKISAENGGDLSWASAGTFPKAFEEAANALQVGQF SQPVKVDDQFHIILVTERKEPSTLPLEWKTQIADQIRQNLVNNQYFSIEKQLAEKA FEHPEGLEKAAEVAGLTIQETDFFSANDVPAALNYPNVISAIFHSDISQGGVNSEPM NVGEQHAVLVRVIANKPEGTRSLEEAKADIISYLKRQKAEEIVLAEANQAAQRLNDN
ASSTLPEGVQFGSAEKWVFAENRDAALNNVIFAMSLTDNKPSYIASKASNGEWLVE LSHIEQGALSAAESELFTKQLAQARQVALQNTLLQALRAKAKIEVNEKFFQQNEEQ
PM1993 (SEQ ID NO: 12)
MKKAVKVTALSLALAFTSSLAMATENIAFISGDYLFQNHPDRKMVAEKLESEFKARV EKLTANKKSIDEKIAASQKKVEAKVAALQKDAPKLRSADIKKREEEINKLGNSEQEA INKLVTAHDEEVSKYQDDYAKREREETAKLVDSIQNAVNTVAREKNYTLVLNEGAW FAADAKNITEDVLKVIPATQAK
DISCUSSION
A total of 35 OMPs was identified; of these, 12 were identified by both methods, six only by the 2-DGE MALDI-TOF MS and 17 only by the 1-D LC MS/MS. Standard 2-DGE protocols are generally biased against very large and hydrophobic proteins, due to solubilization problems, and against very basic or acidic proteins (Ong & Pandey,
2001; Bunai & Yamane, 2005) . In our hands the 2-DGE method showed only a minor bias against very basic or acidic proteins, as two of the four lowest pH (pH<5.2) and two of the five highest pH (pH>9.3) proteins were identified by this method. However, our standard 2-DGE protocols appeared to be significantly biased against large proteins, with only one of the nine largest proteins (>60 KDa) and none of the proteins larger than 100 KDa being identified by this method. Of the six proteins not identified by the 1-D
LC MS/MS method, one (TufA) was able to be identified in the in vivo-grown sample, in which the protein was expressed at much higher levels, one (PmO612) was the smallest protein (11 KDa) and may have run off the 1-D gel, and three of the other four proteins were lipoproteins. It is not clear why there may be a bias against lipoproteins for the 1-D LC MS/MS method. As the 1-D LC MS/MS method identified 16 more proteins than the 2-DGE, it appears that this is a more complete and sensitive method. However, for a comprehensive analysis of the proteome the use of both methods appears warranted. In addition, the use of 2-DGE allows for relative quantification of protein expression under different growth conditions. Thus 2-DGE formed the basis of our analyses of protein expression changes during in vivo and iron-limited growth.
All of the seven previously characterized P. multocida OMPs (OmpH_l, (Luo et al, 1997) P6-like protein (0mpl6, PmO966) (Kasten et al, 1995) , PIpB (Cooney & Lo, 1993), GIpQ (Lo et al, 2004), Lpp (Lo et al, 2004) , OmpA (PmO786) (Gatto et al, 2002) and Oma87 (Pml992) (Ruffolo & Adler, 1996)) were identified in the sarcosine-insoluble membrane fraction of in vitro-grown bacteria. Indeed, with the exception of GIpQ, which was only identified by the 2-DGE MALDI-TOF MS, each of these proteins was identified by both methods. For the other 28 proteins, 15 were predicted to be outer membrane or secreted proteins by at least one of the two subcellular
localisation programs PSORTB or Proteome Analyst (Table 3) . Two proteins were predicted to be periplasmic, but both of these were predicted to be lipoproteins (LipoP; (Juncker et al, 2003)), and may be anchored to the outer membrane but oriented towards the periplasmic side; this is likely also to be the case for GIpQ (Lo et al, 2004) . The other 11 proteins were predicted to be either cytoplasmic (five) , inner membrane (four) , either cytoplasmic or inner membrane (one) , or not predicted for any location by either algorithm (one) .
Orthologues of four of the predicted cytoplasmic proteins (ParC, PepP, TrpB and TorD) are well characterized in other bacterial species, and are likely to be true cytoplasmic contaminants. However, although tufA and tufB, which both encode elongation factor-Tu, are clearly normally located in the cytoplasm, they may be targeted to the outer membrane at certain times (Sedgwick & Bragg, 1986; Otto et al, 2001; Dallo et al, 2002; Berrier et al, 2000; and Marques et al, 1998) . Ef- Tu in Mycoplasma pneumoniae has been shown to be surface- located and involved in binding host fibronectin (Dallo et al, 2002) . Thus it is likely that TufA and TufB are legitimate components of the outer membrane . Two of the four predicted inner membrane proteins (RpS2 and MgIC) have well-characterised orthologues, and are likely to be inner membrane contaminants present in the sarcosine- insoluble membrane preparation, but PmO442 and PmlO21 have no well-characterised orthologues, and may be completely novel OMPs. PmlO21 has the following sequence:
MSFLFTPEQLTGKARTHLVALPCPFSVHHFLHQDCLVAFQCLQQSAAKHGFNLQPAS SFRDFQRQQAIWNAKFYGERKVHDDQGNPLDLSTLSDWEKVQAILRWSALPGGSRHH WGTEIDVFDPHLLPPHQTLQLEPWEYEQGGYFFELSDWLQQNLAHFDFALPFTQLSQ DKEIGYEPWHISYLPIAQQAQQQFNADILCEAWLQEEIAGKΆCLLANLAQIFCRFFI (SEQ ID NO. 13) .
All of the six proteins likely to be inner membrane or cytoplasmic contaminants (ParC, PepP, TrpB,
TorD, Rps2 and MgIC) were identified solely by the 1-D LC MS/MS method, indicating that they may have been present at low levels in the sarcosine-insoluble membrane fraction. Indeed, an important advantage of the use of 2-DGE is the ability to measure relative protein expression levels easily. This allows for the identification of the proteins which are present at lowest concentration, and which are therefore less likely to be legitimate components of the particular sub- cellular fraction.
So far we have identified thirty proteins which are likely to be true components of the outer membrane of P. multocida. Although the majority of these proteins have not been functionally characterised in P. multocida itself, approximately half are predicted on the basis of the characteristics of orthologues in other organisms to be involved in transport of molecules across the outer membrane. Ten of these proteins, OmpH_l, 0mpH_2, PfhR, Pm0300, PmO336, PmO337, Pm0803, PmlO69, PmlδOO and Pml992, have been predicted to be porins on the basis of the superfamily database (Madera et al, 2004) , and five of these, PfhR, Pm0300, PmO336, PmO337 and Pm0803, are likely to be involved in iron uptake, although only PmO803 appeared to be expressed more highly under iron- depleted conditions or during in vivo growth. Another three proteins, PIpB, Pml578 and Pml720, are probably involved in transport of nutrients (methionine, aliphatic sulphonates and an unknown substrate respectively) . Additionally, we predict that PmO527 is part of an efflux system involved in resistance to heavy metals.
Three of the identified proteins are probably involved in the synthesis and structural stability of the outer membrane. Pml426 has significant sequence identity with E. coli phospholipase A (Cronan & Rock, 1996) , so it is probably involved in phospholipid turnover in the P. multocida outer membrane. PmO786 is the major P. multocida OMP, and has significant sequence identity to E. coli OmpA, which is involved in outer membrane
stability and also has porin properties (Nikaido 2003) . PmO998 has significant sequence identity to E. coli MipA, which is involved in the structure and synthesis of the murein sacculus (Vollmer et al, 1999) . Est and GIpQ may also play a role in outer membrane synthesis, as Est is predicted to be involved in lipid metabolism, while GIpQ is involved in salvage of the glycerol portion of 'phospholipids after breakdown. The other outer membrane proteins have no identity to characterised proteins, so their function in P. multocida is presently unknown.
Bioinformatics analyses of the P. multocida genome sequence by either of the algorithms PSORTB or Proteome Analyst predicted that a combined set of 63 proteins was localized in the outer membrane. We identified 23 of these proteins, i.e. more than 1/3 of the predicted OMPs, in the sarcosine-insoluble membrane fraction. We also identified 10 of the 18 P. multocida porins identified in the superfamily database (Madera et al, 2004) , although two of these (PfhR and Pm0803) were identified only under in vivo or iron-limited growth conditions. Clearly some OMPs will not be expressed under the conditions which we have tested so far, but will be expressed under other conditions. Furthermore, it is possible that some of the OMPs predicted by bioinformatics are indeed pseudogenes, and will not be expressed at all under any environmental conditions. Thus it is likely that we have been able to identify significantly more than 1/3 of the OMPs truly expressed under the conditions analysed. Analysis of the sarcosine-insoluble membrane fraction from P. multocida grown under iron-depleted and iron-replete conditions indicated that one protein (Pm0803) was up-regulated in response to low iron concentrations, while one protein (OmpW) was down- regulated. Previous DNA microarray analysis (Paustian et al, 2001) showed that PmO803 was up-regulated nearly 5- fold and ompW down-regulated nearly 7-fold in response to low iron concentration, a finding consistent with the
proteomics data presented here. Both Pm0300 and PmO336 were identified as up-regulated in response to low iron conditions by DNA microarrays, but these proteins were never identified by the 2-DGE method, probably because of their large size (>100 kDa) . Thus although our sample size is small, there appears to be good agreement between the DNA microarray and proteomics data.
The proteins Pm0803, TufA and TufB were identified as up-regulated in response to the in vivo host environment by the 2-DGE proteomic analysis. The transcriptional response of P. multocida to growth in vivo in chickens has been analysed previously using DNA microarrays (Boyce et al, 2002; Boyce et al, 2004) . In those studies the pm0803 gene was up-regulated during growth in the host chicken in five of six infections, again indicating agreement between the microarray and proteomics data. However, tufA and tufB were not measured as up-regulated in vivo by the DNA microarrays. In E. coli TufA and TufB have been shown to be preferentially targeted to the periplasm under stress conditions (Berrier et al, 2000) , and therefore the increased levels measured in the outer membrane of P. multocida appear to be due to differential targeting and not to an increased level of transcription. In summary, we have identified 30 proteins which we postulate to be components of the P. multocida outer membrane. These proteins include numerous predicted porins and specific transporters, including those predicted to be involved in the transport of iron- containing compounds, amino acids, lipids and carbohydrates . We also identified a putative iron- regulated porin (Pm0803) which was highly up-regulated under both in vivo and iron-limited growth conditions. The gene encoding this protein has also been shown to be up-regulated by DNA microarray analysis under similar growth conditions (Paustian et al, 2001; Boyce et al, 2004) . This analysis increases the number of experimentally identified P. multocida OMPs by more than
four-fold, and will form the basis for a comprehensive search for P. multocida surface antigens which can stimulate protective immunity to heterologous P. multocida strains.
It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.
References cited herein are listed on the following pages, and are incorporated herein by this reference.
REFERENCES
Adelman et al . , DNA, 1983 2, 183
Adler, B., Bulach, D., Chung, J., Doughty, S., Hunt, M., Rajakumar, K., Serrano, M., van Zanden, A., Zhang, Y., Ruffolo, C, J. Biotechnol. 1999, 73, 83-90.
Baik, S. C, Kim, K. M., Song, S.M., Kim, D. S., Jun, J. S., Lee, S. G., Song, J. Y., Park, J. U. , Kang, H. L., Lee, W. K.,
Cho, M.J., Youn, H. S., Ko, G. H. , Rhee, K. H., J Bacteriol
2004, 186, 949-55.
Bavaay and Merrifield, "The Peptides," eds . E. Gross and F. Meienhofer, Vol. 2 Academic Press, 1980 pp.3-285.
Berrier, C, Garrigues, A., Richarme, G., Ghazi, A., J Bacteriol 2000, 182, 248-51.
Blanco-Viera, F. J., Trigo, F. J., Jaramillo-Meza, L. and Aguilar-Romero, F. 1995, Rev Latinoam Microbiol 37:121-6.
Botzler, R. G., Ann N. Y. Acad Sci 2002, 969, 224-8.
Boucher, D.J., Adler, B., Boyce, J. D., J. Bacteriol.
2005, 187, 2278-2285.
Boyce, J. D., Adler, B., Infect. Immun. 2001, 69, 1943-6.
Boyce, J. D., Wilkie, I., Harper, M., Paustian, M. L.,
Kapur, V., Adler, B., Infect. Immun. 2002, 70, 6871-9.
Boyce, J. D., Lo, R. Y. C, Wilkie, I., Adler, B. 2004. Pasteurella and Mannheimia, p. 385-96. In C. Gyles, C. Thoen, J. Prescott, and G. Songer (ed.), Pathogenesis of bacterial infections of animals. Blackwell Publishing, Iowa, USA.
Brennan et al . , Science 1985 229:81.
Bruggermann et al . , Year in Immunol., 7:33 (1993).
Bunai, K., Yamane, K., J Chromatogr B Analyt Technol Biomed Life Sci 2005, 815, 227-36.
Cabrita L. D., Dai W., Bottomley SP. BMC Biotechnol . 2006, 6, 12.
Carter, G. R., Adv. Vet. Sci. 1967, 11, 321-79.
Carter et al . , Proc . Natl. Acad. Sci. USA, 1992 89:4285.
Chothia and Lesk J. MoI. Biol. 1987 196:901-917
Chung, J. Y., Zhang, Y. M. , Adler, B., FEMS Microbiol. Lett. 1998, 166, 289-96.
Clackson et al . , Nature 1991 352:624-628.
Cooney, B.J., Lo, R. Y., Infect Immun 1993,61,4682-8.
Crea et al . , Proc. Natl. Acad. Sci. U.S.A., 1978 5765.
Cronan, J.E.J. , Rock, CE. 1996. Biosynthesis of membrane lipids, p. 612-36.
Cullen, P. A., Cordwell, S.J., Bulach, D. M., Haake, D.A., Adler, B., Infect. Immun. 2002, 70, 2311-8.
Dallo, S. F., Kannan, T. R., Blaylock, M. W., Baseman, J. B., MoI Microbiol 2002, 46, 1041-51.
Davies, R. L., Wall, R.A. , Borriello, S. P., J Immunol Methods 1990, 134, 215-25.
Davies et al Proc. Natl. Acad. Sci. 2005, 102, 547-552
Drews, 0., Reil, G., Parlar, H., Gorg, A., Proteomics 2004, 4, 1293-304.
Duchosal et al . Nature 1992 355:258.
El Tayeb, A. B., Morishita, T. Y., and Angrick, E.J. 2004, J Vet Diagn Invest 16:121-5.
Gardy, J. L., Spencer, C, Wang, K., Ester, M., Tusnady,
G. E., Simon, I., Hua, S., deFays, K., Lambert, C, Nakai, K., Brinkman, F. S., Nucleic Acids Res 2003, 31, 3613-7.
Gatto, N. T., Dabo, S. M., Hancock, R. E., Confer, A. W., Vet. Microbiol. 2002, 87, 221-35.
Goeddel et al . , Nucleic Acids Res. 1980 8,4057.
Gorg, A., Weiss, W., Dunn, M.J., Proteomics 2004, 4, 3665-85.
Heddleston, K. L., Gallagher, J. E., Rebers, P. A., Avian Dis. 1972, 16, 925-36.
Homchampa, P., Strugnell, R.A. , Adler, B., Vaccine 1997, 15, 203-8.
Ibrahim, R. S., Sawada, T., Shahata, M., Ibrahim, A., J. Comp. Pathol. 2000, 123, 278-84.
Jacques, M., Belanger, M., Diarra, M.S., Dargis, M., Malouin, F., Microbiol. 1994, 140, 263-70.
Jakobovits et al . , Proc . Natl. Acad. Sci. USA, 1993 90:2551.
Jakobovits et al . , Nature 1993 362:255-258.
Jameson et al, Nature, 1994 368.744.
Juncker, A. S., Willenbrock, H., Von Heijne, G., Brunak, S., Nielsen, H., Krogh, A., Protein Sci 2003, 12, 1652- 62.
Kasten, R. W., Hansen, L. M. , Hinojoza, J., Bieber, D., Ruehl, W. W., Hirsh, D. C, Infect. Immun. 1995, 63, 989- 93.
Kohler et al . , Nature 1975 256:495.
Laeramli, U.K., Nature 1970 227, 680-5.
Langer, Science 1990 249: 1527
Lawn et al . , Nucleic Acids Res. 1981 9, 6103.
Lo, M., Boyce, J. D., Wilkie, I. W., Adler, B., Microbes Infect 2004, 6, 58-67.
Lu, Z., Szafron, D., Greiner, R., Lu, P., Wishart, D. S., Poulin, B., Anvik, J., Macdonell, C, Eisner, R., Bioinformatics 2004, 20, 547-56.
Luo, Y. G., Glisson, J. R. , Jackwood, M.W. , Hancock, R. E. W., Bains, M., Cheng, I.H.N. , Wang, CL. , J. Bacteriol . 1997, 179, 7856-64.
Madera, M., Vogel, C, Kummerfeld, S. K., Chothia, C, Gough, J., Nucleic Acids Res 2004, 32 Database issue, D235-9.
Marks et al., J. MoI. Biol. 1991 222:581-597.
Marks et al . , Bio/Technology 1992 10:779-783.
Marques, M.A. , Chitale, S., Brennan, P.J., Pessolani,
M. C, Infect Immun 1998, 66, 2625-31.
May, B.J., Zhang, Q., Li, L. L., Paustian, M. L., Whittarn, T. S., Kapur, V., Proc . Natl. Acad. Sci . USA 2001, 98, 3460-5.
McCafferty et al., Nature 1990 348:552-554.
Merrifield, J. Am. Chem. Soc. 1963 85 2149
Millstein et al . , Nature 1983 305:537-539.
Molloy, M. P., Herbert, B. R., Slade, M. B., Rabilloud, T., Nouwens, A. S., Williams, K. L., Gooley, A.A. , Eur. J. Biochem. 2000, 267, 2871-81.
Morimoto et al . , Journal of Biochemical and Biophysical Methods 1992 24:107-117
Morrison et al . , Proc. Natl. Acad. Sci. USA 1984 81:6851- 6855.
Morton, R.J., Simons, K. R., Confer, A. W. , Vet Microbiol 1996, 51, 319-30.
Neidhardt, F. C, Curtiss 3rd, R., Ingraham, J. L., Lin, E. C. C, Low, K. B., Magasanik, B., Reznikoff, W. S. M., Riley, Schaechter, M., and Umbarger H. E. (ed.), Escherichia coli and Salmonella: Cellular and molecular biology, vol. 1. ASM Press, Washington.
Nikaido, H., Microbiol MoI Biol Rev 2003, 67, 593-656.
Ong, S. E., Pandey, A., Biomol Eng 2001, 18, 195-205.
Otto, K., Norbeck, J., Larsson, T., Karlsson, K.A. , Hermansson, M., J Bacterid 2001, 183, 2445-53.
Ozkanca, R., Flint, K. P., Lett Appl Microbiol 2002, 35, 533-7.
Paustian, M. L. , May, B.J., Kapur, V., Infect. Iramun. 2001, 69, 4109-15.
Pizza et al Science 2000, 287, 1816 - 1820
Presta et al . , J. Immunol. 1993 151:2623.
Ravaoarinoro, M., Ciurli, C, Toma, E., Morisset, R., Electrophoresis 1994, 15, 594-6.
Rimler, R. B., Rebers, P. A., Rhoades, K. R., Avian Dis. 1979, 23, 730-41.
Rimler, R. B., Rhoades, K. R., J. Clin. Microbiol. 1987, 25, 615-8.
Rimler, R. B., Avian Dis. 1987, 31, 884-7.
Rimler, R. B., Avian Dis. 38: 778-789.1994.
Ruffolo, CG. , Adler, B., Infect. Immun. 1996, 64,3161-7.
Schlink, G. T. and L. D. Olson, Avian Dis, 1987, 31, 22-8.
Sedgwick, E.G., Bragg, P. D., Biochim Biophys Acta 1986, 856, 50-8.
Sims et al . , J. Immunol. 1993 151:2296.
Snipes, K. P., Hirsh, D. C, Kasten, R. W. , Hansen, L. M. , Hird, D. W., Carpenter, T. E. and McCapes, R. H.. Journal of Clinical Microbiology 1989, 27: 1847-1853. [erratum appears in J Clin Microbiol 1989 Nov;27(ll) :2626.] .
Stewart et al . , Solid Phase Peptide Synthesis, W. H.
Freeman Co., San Francisco (1969);
Tabatabai, L. B., and Zehr, E. S. 2004. Infect Iramun 72: 1195-8.
Takahashi, S., Sato, H., Yaraada, T., Takenouchi, T., Sawada, T., Nakano, K. and Saito, H. 1996. J Vet Med Sci 58:269-72.
Tatusov, R. L., Koonin, E. V., Lipman, D.J., Science 1997, 278, 631-7.
Traunecker et al . , EMBO J. 1991 10:3655-3659.
Viera et al . , Meth. Enzymol. 1987 1-52,3.
Vollmer, W., von Rechenberg, M., Holtje, J. V., J Biol Chem 1999, 274, 6726-34.
Waltman, W.D., and A.M. Home. 1993. Avian Dis 37:616-21.
Wang, C. and J. R. Glisson, 1994a Avian Diseases, 1994, 38, 334-340.
Wang et al . , and J. R. Glisson, 1994b, Avian Dis . 38:506- 514.1994.
Waterhouse et al . , Nuc . Acids. Res. 1993 21:2265-2266.
Wilkins, M. R., Williams, K. L., J Theor Biol 1997, 186, 7- 15.
Zhang, H. W., A.J. Ainsworth, and R. D. Montgomery- Veterinary Immunology & Immunopathology, 1994, 41, 89- 100.
Zhao, G. S., Pijoan, C, Choi, K. W. , Maheswaran, S. K., Trigo, E., Can. J. Vet. Res. 1995, 59, 46-50.
Claims
1. An isolated immunogenic P. multocida surface polypeptide or a biologically active fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH, P6-like protein (Omplδ, PmO966) , PIpB, GIpQ, Lpp, OmpA (PmO786) , or Oma87 (Pml992) .
2. A polypeptide according to claim 1, which is an outer membrane protein.
3. A polypeptide according to claim 1 or claim 2, which comprises an extracellular domain.
4. A polypeptide according to claim 2, in which the extracellular domain is from loop 2.
5. A polypeptide according to any one of claims 1 to 4, which is from P. multocida serotype A:l, A: 3, A: 4, or B : 2.
6. A polypeptide according to claim 5, selected from the group consisting of the proteins listed in Table 3.
7. A polypeptide according to any one of claims 1 to 6, which is selected from the group consisting of: a) a protein involved in transport of molecules across a P. multocida outer membrane; b) a protein involved in iron uptake; c) a protein involved in transport of nutrients; d) a protein involved in resistance of P. multocida to heavy metals; and e) a protein involved in synthesis or structural stability of the outer membrane.
8. A polypeptide according to any one of claims 1 to 7, which is expressed more strongly when the bacterium is grown a) in vitro under iron-depleted, anaerobic or amino acid-depleted conditions, or b) in vivo.
9. A polypeptide according to claim 8, which is expressed more strongly when the bacterium is grown in vivo.
10. A polypeptide according to any one of claims 1 to 5, which is selected from the group consisting of est, mglC, ompH_2, ompW, parC, pepP, pfhR, PM0300, PM0336, PM0337, PM0442, PM0527, PM0612, PM0803, PM0979, PM0998, PMl021, PM1064, PM1069, PM1426, PM1578, PM1600, PM1720, PM1809, rpS2, torD, trpB, tufA, tufB and vacJ.
11. A polypeptide according to claim 1, which is selected from the group consisting of PM0388, PM0442, PM0554, PM0659, PM0741, PM0786, PM0903, PM0966, PM0979, PM1050, PM1614, PM1614, PM1730, PM1979, PM1992, and PM1993.
12. A polypeptide according to claim 1, which is selected from the group consisting of PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730.
13. A polypeptide according to any one of claims 1 to 12, which is fused to a heterologous polypeptide.
14. A polypeptide according to claim 13, in which the heterologous polypeptide is an immunogenic carrier polypeptide .
15. An antibody which specifically binds to a polypeptide according to any one of claims 1 to 12, or to a biologically-active fragment, derivative, or variant thereof .
16. An antibody according to claim 15, which is an avian, bovine, swine or rabbit antibody.
17. An antibody according to claim 15, which is a monoclonal antibody.
18. A composition comprising a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant thereof, together with a physiologically-acceptable carrier .
19. A vector comprising a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14.
20. A vector according to claim 19 which is an expression cassette.
21. A host cell comprising a vector according to claim 19 or claim 20.
22. A method of treating or preventing a disease or condition caused by P. multocida, comprising the step of administering a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these, to a subject suffering from, suspected to be suffering from or at risk of such a disease or condition.
23. A method of diagnosing a disease or condition caused by P. multocida, comprising the step of detecting a polypeptide according to any one of claims 1 to 12, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12, or a biologically-active fragment, derivative, or variant of any of these, in a biological sample from a subject suffering from, suspected to be suffering from, or at risk of such a disease or condition.
24. Use of a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these, in the treatment or prevention of a disease or condition caused by P. multocida.
25. Use of a polypeptide, antibody and/or nucleic acid molecule a polypeptide according to any one of claims 1 to 12, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12, or a biologically-active fragment, derivative, or variant of any of these, in the diagnosis of a disease or condition caused by P. multocida.
26. A composition comprising a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14 , or a biologically-active fragment, derivative, or variant of any of these, together with a pharmaceutically- or veterinarily- acceptable carrier.
27. A composition according to claim 26, comprising a polypeptide according to any one of claims 1 to 14.
28. A composition according to claim 27, in which the polypeptide is selected from the group consisting of
PM0388, PM0442, PM0554, PM0659, PM0741, PM0786, PM0903, PM0966, PM0979, PM1050, PM1614, PMl614, PM1730, PM1979, PM1992, and PM1993.
29. A composition according to claim 27, in which the polypeptide is selected from the group consisting of
PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730.
30. A composition according to any one of claims 27 to 29, further comprising an adjuvant.
31. A composition according to any one of claims 27 to 29, which elicits an immune response which is protective against infection with P. multocida.
32. A composition according to any one of claims 27 to 31, which provides protection against at least two different serotypes of P. multocida.
33. A composition according to any one of claims 27 to 31, which elicits antibodies which bind specifically to a P. multocida surface polypeptide.
34. A kit comprising one or more of a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these.
35. A kit according to claim 34 for detecting the presence of DNA associated with P. multocida in a sample, in which the kit comprises : a) a known amount of a first oligonucleotide which consists of at least about 7 to about 50 nucleotides, in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12; b) a known amount of a second oligonucleotide, in which the second oligonucleotide consists of at least about 7 to about 50 nucleotides, and in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleotide sequence which is complementary to a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12 and optionally c) reagents for nucleic acid amplification.
36. A kit according to claim 35, comprising two or more pairs of first and second oligonucleotides.
37. A method for detecting a nucleic acid molecule encoding a surface polypeptide of P. multocida, comprising the step of contacting a nucleic acid obtained from a biological sample of a subject with at least two oligonucleotides, under conditions effective to amplify the nucleic acid so as to yield an amount of amplified nucleic acid, in which a) at least one of the oligonucleotides is specific for a nucleic acid encoding a' surface polypeptide according to any one of claims 1 to 12, and b) the biological sample comprises cells suspected of containing a nucleic acid molecule encoding the immunogenic polypeptide .
38. A library of candidate immunogenic P. multocida outer membrane proteins, prepared by a method comprising the steps of a) subjecting the genomic DNA sequence of
P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins ; e) cloning and expressing open reading frames identified in step(d); and f) isolating the expressed proteins.
39. A method of preparing a plurality of nucleic acid molecules encoding candidate P. multocida surface proteins, comprising: a) identifying P. multocida nucleic acid sequences, and b) cloning the nucleic acid sequences of a) , in which the identification is by one or more of: i) predicted cellular location of the encoded protein; ii) similarity of the encoded protein to a protein with a putative or confirmed role in infection and immunity; and iii) subtractive hybridisation of a nucleic acid sequence specific to a virulent P. multocida strain.
40. A method of identifying an immunogenic P. multocida outer membrane protein, comprising the steps of a) subjecting the genomic DNA sequence of
P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing proteins encoded by the open reading frames identified in step(d); f) isolating the expressed proteins; and g) testing the isolated proteins for ability to protect a test animal from challenge with virulent P. multocida.
41. A method according to claim 39 or claim 40, in which the virulent P. multocida strain is from chickens, swine or cattle .
42. A method according to any one of claims 39 to
41, in which the nucleic acid is specific to a strain from chickens .
43. A plurality of nucleic acid molecules prepared by a method according to any one of claims 39 to 42.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005903721 | 2005-07-13 | ||
AU2005903721A AU2005903721A0 (en) | 2005-07-13 | Bacterial proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007006101A1 true WO2007006101A1 (en) | 2007-01-18 |
Family
ID=37636674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2006/000990 WO2007006101A1 (en) | 2005-07-13 | 2006-07-13 | Surface proteins of pasteurella multocida |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007006101A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018148586A1 (en) * | 2017-02-10 | 2018-08-16 | Epitopix, Llc. | Proteins and immunizing compositions containing pasteurella proteins and methods of use |
CN111638329A (en) * | 2020-06-09 | 2020-09-08 | 南方医科大学 | ELISPOT detection kit for detecting brucellosis and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029724A2 (en) * | 1997-12-08 | 1999-06-17 | University Of Georgia Research Foundation, Inc. | Dna encoding pasteurella multocida outer membrane protein |
-
2006
- 2006-07-13 WO PCT/AU2006/000990 patent/WO2007006101A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029724A2 (en) * | 1997-12-08 | 1999-06-17 | University Of Georgia Research Foundation, Inc. | Dna encoding pasteurella multocida outer membrane protein |
Non-Patent Citations (2)
Title |
---|
DATABASE PROTEIN [online] XP003006250, accession no. NCBI Database accession no. (Q9CKB7) * |
MAY B.J. ET AL.: "Complete genomic sequence of Pasteurella multocida, Pm70", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 6, 2001, pages 3460 - 3465, XP002202785 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018148586A1 (en) * | 2017-02-10 | 2018-08-16 | Epitopix, Llc. | Proteins and immunizing compositions containing pasteurella proteins and methods of use |
JP2020511426A (en) * | 2017-02-10 | 2020-04-16 | エピトピックス, エルエルシー | Protein and immunization composition containing Pasteurella protein and method of use |
US10967056B2 (en) | 2017-02-10 | 2021-04-06 | Epitopix, Llc | Proteins and immunizing compositions containing pasteurella proteins and methods of use |
JP7183168B2 (en) | 2017-02-10 | 2022-12-05 | エピトピックス, エルエルシー | Proteins and Immunizing Compositions Containing Pasteurella Proteins and Methods of Use |
US11696945B2 (en) | 2017-02-10 | 2023-07-11 | Epitopix, Llc | Proteins and immunizing compositions containing Pasteurella proteins and methods of use |
CN111638329A (en) * | 2020-06-09 | 2020-09-08 | 南方医科大学 | ELISPOT detection kit for detecting brucellosis and application thereof |
CN111638329B (en) * | 2020-06-09 | 2021-06-01 | 南方医科大学 | ELISPOT detection kit for detecting brucellosis and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boyce et al. | Analysis of the Pasteurella multocida outer membrane sub‐proteome and its response to the in vivo environment of the natural host | |
Shivachandra et al. | A review of hemorrhagic septicemia in cattle and buffalo | |
van den Bosch et al. | Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs | |
Selke et al. | Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine | |
US20060018920A1 (en) | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | |
AU2018253506A1 (en) | Enzyme-linked immunosorbent assay (ELISA) for the detection of anti-mycoplasma hyorhinis IgG in swine serum | |
US20060159707A1 (en) | Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses | |
EP2262828B1 (en) | Compositions, methods and kits | |
WO2007006101A1 (en) | Surface proteins of pasteurella multocida | |
US7052697B1 (en) | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | |
EP1177212A1 (en) | Lawsonia derived gene and related sodc polypeptides, peptides and proteins and their uses | |
US20100068214A1 (en) | Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus | |
EP1332154A1 (en) | Novel therapeutic compositions for treating infection by lawsonia spp | |
US10166280B2 (en) | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use | |
MX2010009516A (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof. | |
WO2000069904A1 (en) | LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | |
AU2004224903A1 (en) | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses | |
US6495661B1 (en) | DNA encoding the outer membrane protein of Pasteurella multocida | |
US6846487B2 (en) | Therapeutic compositions for treating infection by Lawsonia spp. | |
US20090068218A1 (en) | Antigens for Vaccination Against and Detection of Mycoplasma Suis | |
US7029683B1 (en) | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses | |
JP2006025659A (en) | New polypeptide having prevention activity against erysipelothrix rhusiopathiae infection derived from serum type 18 being another strain of erysipelothrix, gene thereof and method for producing the same | |
WO2014066162A1 (en) | Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection | |
Ahmed | Molecular Characterization of Pasteurella multocida Vaccine Strains | |
AU1481002A (en) | Novel therapeutic compositions for treating infection by lawsonia SPP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06760852 Country of ref document: EP Kind code of ref document: A1 |